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GENERAL INTRODUCTION 
Hearing impairment is today’s most common sensory disorder and as such 
presents a major social and economic burden. Approximately one in 1000 
newborns is deaf, one in 300 is affected with congenital hearing impairment of a 
lesser degree and an additional one in 1000 becomes profoundly hearing 
impaired before adulthood.1 An additional large part of the population experiences 
progressive hearing impairment by the age of 65 years.1 Hearing impairment can 
be caused by genetic defects, environmental factors, or a combination of both. 
Approximately 25% of childhood deafness is caused by environmental factors 
such as prematurity, infection and ototoxic drug exposure. In contrast, it is 
estimated that 50% to 75% of childhood deafness is due to genetic defects. In 
most cases of late-onset hearing impairment a combination of both genetic as well 
as environmental factors is involved.2 In approximately 30% of hereditary hearing 
impairment cases other clinical features in addition to the hearing loss are 
encountered (syndromic hearing impairment), whereas in 70% no additional 
clinical abnormalities are present (non-syndromic hearing impairment). Non-
syndromic hearing impairment is transmitted in approximately 77% as an 
autosomal recessive trait, in 22% as an autosomal dominant trait, and is X-linked 
in 1% or mitochondrial in less than 1%.1  
 
Historical note on hereditary hearing impairment 
Documentation of awareness that inheritance is important in hearing impairment 
can be traced back to the sixteenth century. According to Goldstein 3, the earliest 
known author to have recognized that some forms of deafness may be hereditary 
was Johannes Schenck (1531-1598). He noted a family in which several children 
were born deaf. Stephens 4 includes a pedigree drawing of a sixteenth century 
family of the Spanish aristocracy in which members in three generations were 
documented as being deaf. In 1621 the papal physician Paolus Zacchias (1584-
1659) recommended that the deaf abstain from marriage because of evidence 
that their children will also be deaf indicating his conviction that heredity is 
important in deafness.5 Sir William Wilde (1815-1876) succeeded in adding a 
questionnaire on familial deafness to the Irish census in 1841 and was the first to 
describe direct (later called autosomal dominant) inheritance in hearing 
impairment.6 Later on, Arthur Hartmann (1849-1931), otologist in Berlin, presented 
evidence for indirect (autosomal recessive) inheritance based on extensive 
studies in schools for the deaf in Germany.7 Adam Politzer (1853-1920), by many 
considered to be the founder of contemporary otology, endorsed both Wilde’s and 
Hartmann’s views on modes of inheritance and emphasized in the second edition 
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of his manual of otology ‘Lehrbuch der Ohrenheilkunde’ that inheritance is an 
important cause of deafness.8 
The original work of Gregor Mendel (1822-1884) was re-appreciated in 1900 and 
provided insight into various patterns of inheritance.9 In the first half of the 
twentieth century scientific research on hereditary hearing impairment focused on 
hearing impairment as part of syndromes. The introduction of the audiometer in 
the 1930s paved the way for more detailed descriptions of hearing impairment 
resulting in numerous reports on both syndromic as well as non-syndromic genetic 
hearing impairment. 
The discovery of the structure of DNA in 1953 by Watson and Crick marked the 
beginning of a new era and led to the development of molecular biology.10 It was 
not until 1992, however, that Léon et al. reported linkage to the first autosomal 
dominant hearing impairment locus on chromosome 5q31 (DFNA1).11 
 
Genetic description 
Hearing impairment loci are called DFN (DeaFNess) and are numbered in 
chronological order of discovery. According to the mode of inheritance a locus is 
designated DFNA (autosomal dominant), DFNB (autosomal recessive), DFN (X-
linked) or DFNY (Y-linked). Additionally, modifier loci (DFNM) and a locus for 
auditory neuropathy (AUNA) have been documented. Otosclerosis loci are 
designated OTSC. For an up-to-date overview of known hearing impairment loci 
see “Hereditary Hearing Loss Homepage” at http://webh01.ua.ac.be/hhh/.12 
Currently, 54 loci for autosomal dominant, 67 loci for autosomal recessive and 7 
loci for X-linked hearing impairment have been identified. Of these 21, 23 and 1 
genes have been cloned, respectively.12 Based on their function in the inner ear, 
genes involved in non-syndromic hearing impairment disorders can be divided into 
different classes including those encoding for cytoskeletal components (DIAPH1, 
MYO1A, MYO3A, MYO6, MYO7A, MYO15, MYH9, STRC), for extracellular matrix 
components (TECTA, COL11A2, OTOA, COCH), for molecules involved in 
maintaining ion homeostasis (GJB2, GJB3, GJB6, GJA1, KCNQ4, CLDN14, 
SLC26A4, Pres), for transcription factors (POU3F4, POU4F3, EYA4, TFCP2L3), 
for molecules belonging to the cadherin superfamily (CDH23) and genes with an 
unknown function (TMPRSS3, USH1C, OTOF, TMIE, DFNA5, TMC1, WFS1).13 
 
Clinical description 
For the clinical description of genetic hearing impairment it has been 
recommended to assess the characteristics as outlined in table 1.14 
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This thesis focuses on phenotype descriptions of the non-syndromic autosomal 
dominant hearing impairment disorders DFNA9, DFNA15 and autosomal 
dominantly inherited otosclerosis (OTSC5 and OTSC7). An overview of these 
hearing impairment disorders is given below. 
Most genetic cases present with sensorineural hearing impairment, but a 
conductive type is also encountered (for example otosclerosis, see below). 
Generally, autosomal dominant types of hearing impairment are post-lingual and 
progressive, whereas autosomal recessive types are pre-lingual and stable at 
profoundly poor hearing levels. 
 
 
Table 1. Characteristics for an adequate clinical description of genetic hearing 
impairment.14 
 
Characteristic Subdivision Explanation 
Conductive 
related to disease or deformity of outer/middle ear. Audiometrically 
there are normal bone-conduction thresholds (<20 decibels hearing 
level (dB HL)) and an air-bone gap >15 dB HL averaged over 0.5, 1 
and 2 kHz. 
Sensorineural related to disease/deformity of the inner ear/cochlear nerve with an air/bone gap < 15 dB HL averaged over 0.5, 1 and 2 kHz. 
Type of hearing 
impairment 
Mixed 
related to combined involvement of the outer/middle ear and the 
inner ear/cochlear nerve. Audiometrically >20 dB HL in the bone 
conduction threshold together with >15 dB HL air-bone gap 
averaged over 0.5, 1 and 2 kHz. 
Mild 20-40 dB HL 
moderate 41-70 dB HL 
severe 71-95 dB HL 
Severity of 
 hearing 
impairment 
profound > 95 dB HL 
Low frequency 
ascending 
>15 dB HL difference between the poorer low frequency thresholds 
and the higher frequencies. 
Mid frequency 
U-shaped 
>15 dB HL difference between the poorest thresholds in the mid-
frequencies, and those at higher and lower frequencies. 
gently sloping: 15-29 dB HL difference between the mean of 0.5 and 
1 kHz and the mean of 4 and 8 kHz. High frequency 
steeply sloping: >30 dB HL difference between the above 
frequencies. 
Audiometric 
configuration 
Flat <15 dB HL difference between the mean of 0.25, 0.5 kHz thresholds, the mean of 1 and 2 kHz and the mean of 4 and 8 kHz. 
Low frequencies < 0.5 kHz 
mid frequencies >0.5 kHz < 2 kHz 
high frequencies 2 kHz < 8 kHz 
Frequency ranges 
extended high 
frequencies > 8 kHz 
Age of onset  Congenital, birth to 10 years, 11 to 30 years, 31 to 50 years, >50 
years, uncertain 
Progression  Deterioration of >15 dB HL in the average over the frequencies of 
0.5, 1, and 2 kHz within a 10 year period 
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Huygen et al. have presented an overview of hereditary types of non-syndromic 
hearing impairment classified according to audiometric profile, thereby integrating 
genetic and audiometric information (chapter 1.2).15 
 
 
DFNA9 
The autosomal dominant non-syndromic hearing impairment disorder DFNA9 is 
characterized by progressive high-frequency sensorineural hearing impairment 
with midlife onset. Hearing deteriorates severely over a few decades of life, with 
annual threshold deterioration (ATD) values of 2-7 dB eventually leading to 
residual hearing or (sub)residual hearing threshold levels.16-18 Speech recognition 
is relatively poor, showing features similar to presbyacusis that, however, occur at 
a younger-than-usual age. 
The first clinical description of a DFNA9 family dates from 1988 16, 8 years before 
genetic linkage analysis mapped the DFNA9 locus on chromosome 14q12-13.19 
The original report described a Dutch family in which affected individuals 
developed high-frequency sensorineural hearing impairment and vestibular 
areflexia after the age of 40 years.16  
In the Dutch and Flemish populations, the P51S mutation in the COCH gene is 
most frequently encountered, and is considered a founder mutation.20 Recently, 
Kemperman et al.21 reported on a Dutch DFNA9 family with the G88E mutation, 
previously reported to occur in a family originating from the United States of 
America.22-24 The third and fourth DFNA9 causing COCH mutations that were 
found in The Netherlands are the G87W and I109T mutations. Clinical 
characteristics of patients with these two mutations will be presented in this thesis 
(chapters 2.1 and 2.2) 
Apart from DFNA11, DFNA9 is the only DFNA type known to exhibit substantial 
concomitant vestibular impairment. Vestibular dysfunction develops gradually and 
may eventually lead to vestibular areflexia.25 Head movement-dependent oscillop-
sia and unsteadiness of gait when visual fixation is excluded are characteristic 
symptoms of vestibular areflexia. Furthermore, these individuals may exhibit a 
broad-based gait, have difficulty riding a bicycle on a narrow track and loose their 
course while riding and attempting to look backwards over their shoulder. In 
addition, vestibular areflexia results in compensatory enhancement of the cervico-
ocular and optokinetic nystagmus reflexes.26,27 In case of mild vestibular 
impairment, it may be difficult to detect dysfunction without using instrumental 
methods. Ménière-like vertigo is not an unusual feature of DFNA9.28,29 
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Recently, ophthalmologic examination in 3 Dutch DFNA9 families revealed a 
peculiar pattern of vertical corneal striae, which in general was a sub-clinical 
feature.30 Two of these families harbor the P51S COCH mutation and the third 
carries the G88E mutation. In a fourth DFNA9 family with the G87W mutation 
vertical corneal striae were observed only in one patient.30 A significant 
association between the vertical corneal striae and midlife-onset cochleovestibular 
impairment was found for the DFNA9 families with a P51S and G88E mutation in 
COCH.30 
 
In 1994 the COCH gene was isolated using a human fetal cochlear cDNA library 
31 and was considered a positional candidate gene for the familial progressive 
cochleovestibular disorder DFNA9.32 DFNA9 was linked to chromosome 14q12-13 
in 1996.19  
Three different departments involved in genetic hearing loss research reported on 
COCH mutations causing DFNA9; in 1998 Robertson et al. identified the V66G, 
G88E and the W117R mutations 24 and in 1999 de Kok et al. and Fransen et al. 
reported on the P51S mutation.18,33 To date, ten different mutations in COCH have 
been identified: P51S, V66G, G87W, G88E, V104del, I109N, I109T, W117R, 
A119T and C542F 24 (Table 2; Figure 1). 
 
 
Table 2. Summary of reported data of the DFNA9-causing mutations in the COCH gene. 
 
Mutation Origin Age of onset Genetic reference Phenotype reference 
P51S The Netherlands/ 
Belgium 
4th – 5th decade De Kok et al. (1999)18 Fransen et al. (1999) 33;  
Bom et al. (2003) 34;  
Bischoff et al. (2005) 25 
V66G USA 2nd– 3rd decade Manolis et al (1996) 19; 
Robertson et al. (1998) 24 
Manolis et al (1996) 19 
G87W The Netherlands 4th – 5th decade Collin et al. (2006) 35 Pauw et al. (2007) 36 
G88E USA 
The Netherlands 
5th decade 
5th decade 
Robertson et al. (1998) 24 
Kemperman et al (2005) 21
Khetarpal et al (1991)23 
Kemperman et al (2005) 21 
V104del Hungaria 43 years * Nagy et al. (2004) 37 Not available 
I109N Australia 4th – 5th decade Kamarinos et al. (2001) 38 This thesis 
I109T The Netherlands 4th – 5th decade Pauw et al., in press 39 Pauw et al., in press 39 
W117R USA 5th decade Robertson et al. (1998) 24 Not available 
A119T Japan 35 years * Usami et al. (2003) 40 Not available 
C542F USA 2nd decade Street et al. (2005) 41 Street et al. (2005) 41 
* Genotyping only performed in one individual. Onset age relates to subjective (reported) onset 
age. 
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Figure 1. A) Schematic representation of the human cochlin protein. Shown are a signal 
peptide (SP), the LCCL domain and two von Willebrand factor A (vWFA) domains. Arrows 
indicate the positions of the amino acids that are substituted in reported cases of DFNA9. 
B) Sequence comparison of the LCCL domains of several mammalian and non-
mammalian cochlin proteins. Identical residues in all sequences are white on a black 
background, whereas amino acid residues that are conserved in three or more species 
are white on a gray background. Similar amino acids are black on a greyish background. 
Amino acids previously reported to be mutated in DFNA9 are marked with an asterisk. 
 
The COCH gene has 12 exons that encode a protein called cochlin, which is a 
major constituent of the inner ear extracellular matrix.42 Cochlin contains a signal 
peptide, an LCCL domain and two von Willebrand factor A-like domains (vWFA1 
and vWFA2) (Figure 1). Nine of the 10 presently known mutations are located in 
the LCCL domain and 1 recently identified mutation occurs in the vWFA2 
domain.41 Liepinsh et al. showed that, except for W117R, all the other then known 
mutations (P51S, V66G, G88E, I109N, W117R) in the LCCL domain disrupt its 
normal structure and lead to protein misfolding of this domain.43 
 
Interestingly, histopathological examination of temporal bone sections, as was 
reported already before the identification of the DFNA9 locus, revealed the 
presence of eosinophilic glycosaminoglycan deposits in the cochlea, macula and 
crista of DFNA9 patients.22,23 These acidophilic acellular deposits were localized 
to the spiral ligament, limbus, osseous spiral lamina, stria vascularis, and stroma 
of the maculae and cristae.23 Recently, Robertson et al. showed in post-mortem 
temporal bone of a patient with a P51S mutation that the eosinophilic acellular 
deposits in mesodermal structures of cochlea and vestibulum indeed contain 
cochlin.44 As cochlin deposits occur in areas surrounding neurons and their 
processes, but not in the neuronal cell bodies or processes themselves, neuronal 
and axonal damage may be secondary and caused by strangulation of these 
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structures, resulting in hearing impairment and vestibular dysfunction. Disruption 
of ion homeostasis in endolymph has also been suggested to play a role in the 
pathogenesis of this disorder.20,44 
 
 
DFNA15 
The autosomal dominant hearing impairment disorder DFNA15 is characterized 
by bilateral progressive, adult-onset sensorineural hearing impairment.45-47 
Worldwide, three DFNA15 families have been identified. To date, only one has 
been reported.45,46 As part of this PhD study, a second large DFNA15 family has 
been studied.47 A third DFNA15 family study is still in progress and will be 
completed soon (de Heer et al., personal communication 2007). 
The first description was for an Israeli family.45 Hearing impairment in this family 
appeared to be moderate to severe and audiometric configuration varied between 
flat and down sloping. Age of onset was between 18 and 30 years.45,46 Annual 
threshold deterioration (ATD, expressed in dB/year) was 1.1 dB/year at 0.25 – 1 
kHz and 2.1 dB/year at 2 – 8 kHz.  Speech recognition scores were fairly good in 
relation to age and level of hearing impairment.46,48 
Linkage analysis was performed on 12 affected and 11 unaffected family 
members older than age 40. Initially, linkage to the DFNA1 locus at chromosome 
5q31 was found. However, after subsequent genotyping of markers in the 5q31 
region it became apparent that the Israeli family linked to a region telomeric to the 
DFNA1 locus. Because large regions of homology between human and mouse 
chromosomes exist, the homologous region on chromosome 18 in the mouse was 
examined and a candidate gene was identified. This gene, Pou4f3 (also known as 
Brn3c or Brn3.1), encodes a transcription factor and regulates target gene 
expression by binding to DNA. It is strongly expressed in mouse cochlear and 
vestibular hair cells and has been shown to be essential for the differentiation and 
survival of these cells.49,50 Targeted deletion of Pou4f3 results in profound hearing 
loss and impaired balance due to complete loss of auditory and vestibular hair 
cells in mice homozygous for the deletion.51,52 
Subsequently, the human POU4F3 gene was cloned and an 8 base-pair (bp) 
deletion in POU4F3 (884del8) was identified in DNA from affected family 
members. This deletion results in a frame shift that causes premature termination 
of the POU4F3 protein.45  
The second family that was linked to DFNA15 is a large family of Dutch origin and 
is part of this PhD study.47 (Collin et al, unpublished data) A novel missense 
mutation in POU4F3 was identified resulting in p.L289F. The clinical picture was 
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largely consistent with the report on the original Israeli family. An early adult to 
mid-life onset of hearing impairment applies to the present family. Most often, a 
high-frequency type of hearing impairment is observed with a downsloping 
audiometric configuration. However, mid-frequency as well as flat audiometric 
configurations also occurred. ATD was 0.8 dB/year at 0.25-2 kHz and 1.4 dB/year 
at 4-8 kHz. Similar to the original Israeli family speech recognition scores 
remained fairly good with advancing age and with progression of hearing 
impairment. Two affected individuals reported vestibular symptoms and under-
went vestibular function tests. These tests showed hypofunction of the vestibular 
labyrinth in both of them. For this reason, the study on vestibular function in this 
DFNA15 family has been extended. An additional subset of mutation carriers of 
the present DFNA15 family takes part in vestibular function tests to assess 
whether DFNA15 represents a cochleovestibular disorder such as DFNA9 21,25,36 
and DFNA11 53 and as has been demonstrated in mice with a targeted deletion of 
Pou4f3.51,52 
 
 
Otosclerosis 
Otosclerosis is a primary disorder of bone metabolism which is known to only 
occur in the human temporal bone.54 It is characterized by focal inappropriate 
resorption and formation of otic capsular endochondral bone, leading to the 
development of newly formed bone of greater density, cellularity and vascularity 
and eventually to the inactive end-stage of thick sclerotic bone.  
A predilection site for otosclerotic foci is a region anterior to the oval window, 
referred to as the fissula ante fenestram. Otosclerotic foci in this region may cause 
fixation of the stapedial footplate, thereby leading to conductive hearing loss due 
to reduced mobility of the ossicular chain. Sensorineural hearing loss, which 
occurs in about 10% of patients with otosclerosis, is thought to be caused by the 
development of cochlear otosclerosis.55 
Otosclerosis can be divided into a histological and a clinical type. In histological 
otosclerosis clinical symptoms or manifestations are absent and it is only 
discovered in histological temporal bone sections. Early reports on the prevalence 
of histological otosclerosis specify figures ranging from 8.3 56 to 11.4% 57, where-
as a more recent report estimates the prevalence to be 3.4% in Caucasians.58 In 
70-80% of patients the disease is bilateral.59 The prevalence of clinical oto-
sclerosis varies greatly between various ethnic populations; it is rare in Africans, 
Asians and American Indians and more common in Caucasians.60 Clinical 
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otosclerosis has a lower prevalence (0.3-0.4%) than the histological type and 
leads to conductive and/or sensorineural hearing loss.55,59 
 
Historical note 
Stapes fixation was first described by Antonio Maria Valsalva in 1704.61 Toynbee 
was the first to link stapes fixation to hearing impairment.62 Politzer coined the 
term otosclerosis in 1894 63 and described it as a primary disease of the bony 
labyrinthine capsule, in which neoplastic bone gradually replaces normal bone, 
and produces ankylosis of the stapes. The first known photographs of otosclerosis 
were published in the second edition of Politzer’s Lehrbuch der Ohrenheilkunde 
für praktische Ärzte und Studierende in 1887 (Figure 2).8 
 
 
Figure 2. The first available photograph of otosclerosis from the 2nd edition of Politzer’s 
Lehrbuch der Ohrenheilkunde für praktische Ärzte und Studierende.8 
 
 
Surgery for otosclerosis 
The earliest reports of improved hearing in patients with otosclerosis were 
anecdotal cases of patients who experienced hearing improvement after head 
trauma. Kessel, in 1878 reported on one such case.  He examined the temporal 
bones of a patient who had improved hearing after falling off a wagon and found 
that he had a fracture through the horizontal canal. At this time, surgical 
treatments were considered unfeasible, and in Bacon’s Manual of Otology in 1898 
he recommends that operations on the stapes “should not be considered for a 
moment”.64 However, Holmgren had noted the findings of Kessel, and began 
Chapter 1.1 
 
22 
treating a number of patients with otosclerosis by creating a horizontal canal 
fenestration and covering it with mucoperiost.  He is now well known as the father 
of fenestration surgery. Holmgren’s student, Sourdille, later reported a satisfactory 
result in 64% of cases for the three-staged operation: (1) mastoidectomy, (2) 
external ear canal skin flap and (3) horizontal canal fenestration covered by the 
skin flap.  Single stage horizontal canal fenestration was popularized by Lempert 
in the 1940s and further refined thereafter by others including John House who 
described the double blue line technique to avoid drilling directly over the 
fenestration. 
Despite the wide acceptance of the fenestration technique, it was rarely 
successful in completely closing the air-bone-gap (ABG) and had a > 2% risk of 
profound sensorineural hearing loss. Therefore, alternative methods were 
explored. In the 1950s, with initial criticism, Samuel Rosen proposed mobilization 
of the stapes. This had the advantage of achieving immediate hearing 
improvement and complete closure of the ABG in most instances. It was soon 
realized that re-fixation of the stapes was the rule rather than the exception in 
these cases. In 1956 John Shea performed the first stapedectomy. He covered 
the oval window with a vein graft from the hand and used an artificial nylon stapes 
attached to the incus. This technique gained wide acceptance and has been 
improved since its introduction. In the 1970s, Myers conducted stapedotomy using 
a piston prosthesis. In the early 1980s, Perkins began using the laser for stapedo-
tomy in a procedure in which a small hole is made in the footplate, as opposed to 
complete or subtotal removal. 
Many of the techniques developed by the above mentioned pioneers of stapes 
surgery still persist today. Variations in technique and style such as grafting 
material and prosthesis choice, performing stapedotomy instead of stapedectomy, 
and use of laser or microdrill instead of sharp instrumentation have arisen with 
similar success rates. The basic principle of re-establishing a mobile connection 
between the tympanic membrane and vestibule has remained the goal of surgery 
for patients with otosclerosis. 
Cochlear implantation in patients with retrofenestral otosclerosis has been 
successfully performed.65 
 
Histology 
Histologically, otosclerosis is divided in two main forms: an early active or 
spongiotic phase and a late inactive or sclerotic phase. The early phase is 
characterized by multiple active cell groups including osteocytes, osteoblasts, and 
histiocytes. A spongy appearance develops as a result of vascular dilation 
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secondary to osteocyte resorption of bone surrounding blood vessels. This phase 
is referred to as otospongiosis, a term introduced by Siebenmann in 1912.66 In the 
late inactive sclerotic phase, dense sclerotic bone forms in the areas of previous 
resorption.  Both the sclerotic and spongiotic as well as intermediate phases may 
be present simultaneously. 
 
Radiology 
Otospongiotic foci can be detected with computed tomography (CT) imaging, on 
which these foci show lesions with decreased density compared to normal bone. 
With the development of high-resolution CT imaging, it has become possible to 
detect sub-millimeter otospongiotic foci and the use of this technique in the 
diagnostic workup has increased over the past years. The use of CT in the 
diagnosis of otosclerosis, however, remains a subject of debate, in part due to the 
fact that mature otosclerotic foci can be missed, because these foci tend to have 
the same density as normal bone on CT images. Detection rates of otosclerotic/ 
otospongiotic foci in known otosclerosis patients of up to 91% have been 
reported.67,68 Apart from that, pre-operative CT images can be particularly useful 
in case of a dehiscent facial nerve (canal), a dehiscent superior semicircular canal 
69, a widened vestibular/cochlear aqueduct or a widened lateral part of the internal 
acoustic canal, of which the latter two findings carry an increased risk of stapes 
gusher.70-72 A clinically relevant classification of otospongiotic foci on CT images 
was proposed by Naumann et al. (Table 3) 73, in which fenestral and cochlear 
otosclerotic foci are distinguished and classified according to relative size. 
 
Table 3. Classification of otospongiosis based on CT imaging as proposed by Naumann 
et al.73 
 
Group 1 Otospongiosis limited to the fissula ante fenestram 
Group 2 Otospongiosis extends to at least half the diameter of the 
oval window niche and/or the cochleariform process 
Fenestral 
otospongiosis 
Group 3 Otospongiosis extending over the entire diameter of the 
oval window niche 
Group 1 Otospongiosis not exceeding the diameter of one cochlear 
turn 
Group 2 Between Group 1 and 3 
Cochlear 
otospongiosis 
Group 3 Spongiotic involvement of the entire otic capsule 
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Etiology 
Despite extensive research, the etiology of otosclerosis is poorly understood and 
environmental as well as genetic factors have been implicated. Epidemiologic 
studies suggest autosomal dominant inheritance with reduced (25-40%) 
penetrance.74 Strong support for a genetic cause of otosclerosis is provided by 
studies on monozygotic twins in which concordance for clinical otosclerosis has 
been found in nearly all cases.75 In addition, other factors, such as measles viral 
infection 76 or autoimmunity may play a role as well.77 
 
Genetic linkage 
In 1998 Tomek et al.78 were the first to report a locus for otosclerosis on 
chromosome 15q25-26. At present 8 different loci for otosclerosis have been 
identified (Table 4) 12, of which 6 have been publicly reported.78-83 None of the 
corresponding genes have yet been cloned. The number of loci reflects the 
genetic heterogeneity of this disorder. Given this heterogeneity, a thorough 
genotype-phenotype correlation study on each otosclerotic locus could be in place 
to help distinguishing possible differences in clinical behavior. Insight into the 
clinical characteristics may contribute to understanding gene function once the 
corresponding genes have been identified. 
 
Table 4. Loci for otosclerosis derived from the Hereditary Hearing Loss Homepage, 
accessed February 2007 (http://webhost.ua.ac.be/hhh/).12 
 
Locus Location Origin Gene Clinical reference Genetic reference 
OTSC 1 15q26.1-qter India Unknown
Tomek et al., 1998 78 
(limited data available) 
Tomek et al.,1998 
78 
OTSC 2 7q34-q36 Belgium Unknown Declau et al., 2007 84 Van den Bogaert et al., 2001 79 
OTSC 3 6p21.3-22.3 Cyprus Unknown Not available Chen et al., 2002 
80 
OTSC 4 16q21-23.2 Israel Unknown
Brownstein et al., 
2006 81 
Brownstein et al., 
2006 81 
OTSC 5 3q22-q24 The Netherlands Unknown Pauw et al., 2006 85 Van den Bogaert et al., 2004 82 
OTSC 6 Reserved 
OTSC 7 6q13-16.1 Greece The Netherlands Unknown
Iliadou et al., 2005 86 
Pauw et al., submitted Thys et al., 2007 
83 
OTSC 8 Reserved 
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Aims and outline of this thesis 
The general aim of this thesis was to provide further insight into the phenotype of 
autosomal dominant non-syndromic types of hearing impairment. This thesis 
focuses on genotype-phenotype studies in DFNA9 (chapter 2), DFNA15 (chapter 
3) and otosclerosis (chapter 4) and the following objectives were set: 
• To outline the DFNA9 phenotype in families with novel COCH mutations by 
detailed descriptions of history, physical examination, audiograms, statistical 
analyses of audiometric data and vestibular tests. 
• To compare the DFNA9 phenotype in families with novel COCH mutations to 
previously reported phenotypes in DFNA9 families with different COCH 
mutations. 
• To evaluate the phenotype in a DFNA15 family with a novel POU4F3 
mutation and to compare the data to those obtained in the original DFNA15 
family. 
• To describe the audiometric characteristics of two otosclerosis families in 
which linkage of the disease to novel OTSC loci was found and to 
radiographically evaluate selected individuals using high resolution spiral 
computed tomography images. 
 
Following this general introduction, a comprehensive review of all currently known 
forms of hereditary non-syndromic hearing impairment in relation to their 
audiometric profile is presented in chapter 1.2. Based on audiometric 
configuration hearing impairment loci were classified into the following types: 
residual hearing, high-frequency downsloping, flat-to-gently downsloping, mid-
frequency or U-shaped and low-frequency audiometric configuration. This review 
may facilitate the differential diagnosis of (novel) genetic hearing impairment traits. 
 
Chapter 2 provides detailed phenotype analyses of the cochleovestibular 
impairment typical for DFNA9. Two Dutch families with a novel mutation in the 
COCH gene (G87W and I109T) and the Australian family with a known mutation 
in the COCH gene (I109N) are described in chapters 2.1, 2.2 and 2.3, 
respectively. Results from cross-sectional as well as longitudinal analyses of 
audiometric and vestibular data are presented and compared to those obtained in 
previously identified COCH mutation carriers with different COCH mutations.  
 
In chapter 3, the clinical characteristics of a large Dutch DFNA15 family with a 
novel mutation in the POU4F3 gene are presented. This is the second DFNA15 
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family that has been identified worldwide and clinical data are compared to those 
of the first DFNA15 family. 
 
Otosclerosis is the subject of chapter 4. A detailed analysis of audiometric as well 
as radiological data from a Dutch otosclerosis family linked to OTSC5 are 
presented in chapter 4.1. A Dutch otosclerosis family with suggestive linkage to 
OTSC7 was clinically investigated and is the subject of chapter 4.2. Detailed 
analyses of audiometric and radiological data of this family are presented. 
 
Chapter 5 presents a general discussion. A summary of this thesis is provided in 
chapter 6. This chapter includes a summary in Dutch as well. 
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ABSTRACT 
Non-syndromic hearing impairment disorders were classified according to pheno-
type with regard to audiometric configuration. The following categories of pheno-
type were distinguished: residual hearing, high-frequency (steeply) downsloping, 
flat to gently downsloping, mid-frequency or U-shaped and low-frequency audio-
metric configuration. Audioprofiles were derived and are graphically presented for 
the autosomal dominant traits linked to the chromosomal loci DFNA1, DFNA2, 
DFNA3, DFNA4, DFNA5, DFNA6/14, DFNA7, DFNA8/12, DFNA9, DFNA10, 
DFNA11, DFNA13, DFNA15, DFNA16, DFNA17, DFNA18, DFNA20/26, DFNA21, 
DFNA25, DFNA28, DFNA31 and DFNA36, the autosomal recessive traits linked 
to DFNB1, DFNB4, DFNB21 and DFNB30, and the X-linked traits linked to DFN2, 
DFN3 and DFN6. Most of the traits linked to the other loci presently defined for 
non-syndromic hearing impairment, which includes most of the autosomal 
recessive DFNB loci, show residual hearing. Audioprofiles can be used for the 
differential diagnosis of non-syndromic hearing impairment disorders, for 
counseling purposes, especially for focusing on treatment options, and for guiding 
genotyping efforts involving newly identified non-syndromic hearing impairment 
traits. 
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INTRODUCTION 
A useful phenotypic classification of genetic non-syndromic hearing impairment 
disorders comprises the various types of audiometric configurations. Apart from 
conductive or mixed hearing impairment, Konigsmark and Gorlin (1976) 1 and 
Toriello, Reardon and Gorlin (2004) 2 distinguished several types of non-
syndromic sensorineural hearing impairment (SNHI): (downsloping) high-
frequency SNHI, mid-frequency SNHI with a U-shaped audiometric configuration, 
(upsloping) low-frequency SNHI and SNHI with a residual hearing type of 
audiogram, i.e. measurable thresholds only in the low frequency range. Additional 
distinctive features are related to progression (stable/progressive), age of onset 
(congenital, early, late onset) and severity (mild, moderate, severe, profound), see 
next section. 
 
Using such a classification, this review gives a survey of those genetic non-
syndromic hearing impairment disorders that have already been linked to human 
chromosomal loci, following the specifications of the Hereditary Hearing Loss 
Homepage (here called HHH).3 The autosomal dominant (AD) loci for “deafness” 
include DFNA1-5, DFNA6/14/38, DFNA7, DFNA8/12, DFNA9-11,DFNA13, 
DFNA15-18, DFNA20/26, DFNA21-25, DFNA28, DFNA30-31, DFNA36, DFNA41-
44 and DFNA47-50. The autosomal recessive (AR) loci include DFNB1-6, 
DFNB7/11, DFNB8/10, DFNB9, DFNB12-18, DFNB20-23, DFNB26-27, DFNB29-
33, DFNB35-40, DFNB42, DFNB44, DFNB46 and DFNB48-49. The X-linked loci 
include DFN2-4 and DFN6. In addition, a recently identified Y-linked locus (not on 
the HHH) is also included. Otosclerosis is only briefly mentioned, because, on the 
one hand, the audiometric phenotype of “otosclerosis”, which must be a mixed 
bag of loci yet to be identified, is sufficiently well known, whereas, on the other 
hand, the phenotypes pertaining to the newly identified loci for otosclerosis, such 
as OTSC2 and OTSC5, have only just begun to become outlined. As regards 
hereditary auditory neuropathy, the AR type caused by OTOF mutations (DFNB9) 
is not specifically mentioned here because it fits in with the vast majority of AR 
SNHI disorders showing residual hearing. The first locus that has been identified 
for AD auditory neuropathy (AUNA1, not on the HHH), is included. Obviously, 
syndromic hearing impairment is not included in this review. However, considering 
that the Pendred syndrome (PDS) overlaps with DFNB4, that the differential 
diagnosis between PDS and DFNB4 can be notoriously difficult and that the 
hearing impairment phenotypes of the two disorders may be very similar because 
the underlying cause associated with the inner ear malformation, i.e. the large 
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endolymphatic duct and sac, is common to these disorders, it is reasonable to 
include the PDS.  
 
The purposes of this review are to facilitate: (1), the differential diagnosis of 
genetic hearing impairment phenotypes; (2), the consideration of treatment 
opportunities; (3), counseling; (4), guidance for genotyping efforts of newly defined 
non-syndromic hearing impairment traits. Illustrative examples are given as much 
as possible in figures based on previously reported data, our own original data or 
original data communicated to us. In previous related (review) papers, we only 
dealt with non-syndromic AD SNHI.4-9 The present review not only updates and 
extends these reviews regarding AD SNHI disorders (linked to DFNA loci), but 
also covers AR SNHI (DFNB loci) and X-linked SNHI disorders (DFN loci), as well 
as a newly identified Y-linked disorder. 
 
 
METHODS 
We adopted the classification by Koningsmark and Gorlin 1 with some minor 
modifications, most of which are in line with the GENDEAF recommendations 
reported by Mazzoli et al..10 These include 2 subcategories of high-frequency 
configuration: steeply (down)sloping, here designated “high frequency”, and flat to 
gently (down)sloping, the latter of which is a combination of the GENDEAF 
categories “flat” and “gently sloping”. The categories of frequency range are the 
recommended categories: low frequencies, 0.25-0.5 kHz; mid frequencies, 1-2 
kHz; high frequencies, 4-8 kHz. We invoked previously classified onset categories 
which, however, appeared to be difficult to apply to many published reports. We 
therefore preferred to stay as close as possible to the original descriptions and 
just relay this information about onset age. The recommended categories of 
severity were applied: mild (20-40 dB HL), moderate (41-70 dB), severe (71-95 
dB) and profound (> 95 dB), the latter of which was supposed by us to be similar 
to the category of residual hearing. The GENDEAF recommendations call hearing 
impairment progressive if the annual threshold deterioration (ATD) for the pure 
tone average (PTA) at 0.5, 1 and 2 kHz, i.e. PTA(0.5,1,2 kHz), exceeds 1.5 dB; 
instead, we specify progression, including the ATD where possible, and then also 
specify whether progression is or is not significant. Progression is called 
significant when the threshold at the appropriate frequencies increases 
significantly with increasing age. Progression beyond presbyacusis is specified if 
the thresholds are still significantly progressive following correction for median 
(P50) presbyacusis according to ISO 7029.11 
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What we call “audiometric profile” comprises either an example audiogram for a 
“typical” case as a minimum, a “mean audiogram” if hearing impairment does not 
change appreciably with increasing, but not too advanced, age, or age-related 
typical audiograms (ARTA). ARTA were constructed where possible using the 
method previously reported.7 The threshold data used to derive ARTA were our 
own original data, original data obtained from others by personal communication 
where specified, or data obtained from published papers, using table entries or 
plotted data points. 
 
 
PHENOTYPE BY AUDIOMETRIC PROFILE 
Residual hearing configuration (Figures 1-3) 
DFNA loci 
Virtually none of the AD hearing impairment disorders associated with DFNA loci 
has residual hearing as a key distinctive feature. One exception is the 
(sub)residual hearing audiometric configuration shown by a MYO6-based SNHI 
trait linked to locus DFNA22.12 However, residual hearing can certainly be the 
endstage of any progressive AD hearing impairment phenotype. This includes 
obliterative otosclerosis, where, eventually, the air bone gap (ABG) can be hardly 
discernible. Rapid progression to residual hearing is typical of the recently 
identified AD type of auditory neuropathy linked to the AUNA1 locus.13 Patients 
with auditory neuropathy have SNHI with intact otoacoustic emissions combined 
with poor speech recognition even at subresidual hearing levels and they may not 
benefit from using hearing aids. However, recent reports suggest there may be a 
place for cochlear implantation in auditory neuropathy.14-16 
 
DFNB loci 
The AR hearing impairment disorders associated with the DFNB loci generally 
show residual hearing, i.e. prelingual severe to profound SNHI.17-20 This category 
includes “rapid progression to residual hearing”. This feature has been noticed in 
a study on a DFNB8/10 trait showing childhood onset with progression to a 
residual hearing configuration 21 and a study on a preligual DFNB13 trait showing 
progression starting from a flat to gently downsloping configuration with moderate 
threshold levels at young ages.22 However, most importantly and most 
impressively, the feature of  early, rapid progression leading to residual hearing is 
shown (Figure 1) by DFNB4 and/or the (possibly overlapping) PDS.23,24  
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Figure 1. Age related audiograms (ARTA) for the Pendred syndrome (PDS) and/or 
DFNB4 caused by a mutation in the SLC26A4 gene showing rapid progression to residual 
hearing. Age in years (italics). 
 
 
And such progression can be accompanied by substantial threshold 
fluctuations.25-30 There is no doubt that fluctuations in inner-ear function of this 
kind, which not only include hearing ability but also vestibular function, are 
associated with the feature of large endolymphatic duct and sac, which can be 
identified by magnetic resonance imaging, or the related feature of a large 
vestibular aqueduct designated in the days that computer tomography was the 
main imaging method and widening of the bony contours of the endolymphatic 
duct was identified as a key feature in PDS 31 and as an associated feature in 
some other syndromic hearing impairment disorders, such as the BOR syndrome. 
 
It has been stated in some reports that a minority of the DFNB1 patients with the 
35delG/35delG genotype may show progression.32,33 However, we found no 
indications of progression in cross-sectional analyses in a recent multicentre study 
(Snoeckx et al., unpublished data) or in individual longitudinal analyses.34 One 
report demonstrates progression of genotypes involving a large deletion in GJB6 
35, another report, however, shows a lack of significant progression in longitudinal 
analyses of such cases.36 Santos et al. also described the longitudinal analysis of 
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a patient with the GJB2 H100P/S139N genotype (H100P is a novel mutation) who 
showed significant progression in SNHI in both ears, with ATD values of 1-2 dB.34 
It should again be emphasized that most of the studies on DFNB1 and other 
DFNB loci indicate the usual residual-hearing configuration, with few exceptions 
(see below). The most important exception is that patients with DFNB1 may show 
variable degrees of SNHI. DFNB1 is a fine example that our genotype-phenotype 
correlation studies are now becoming more sophisticated at the mutational level. 
DFNB1 is particularly suitable for such type of studies, because it is, by far, the 
most prevalent cause of congenital genetic SNHI, which is mainly based on GJB2 
mutations 33, however, refinement of this type of analyses requires large numbers 
of data and therefore depends on multicentre research projects. Part of the 
variability in the SNHI associated with DNFB1 can be explained by recent findings 
indicating that biallelic compound heterozygous GJB2 mutation combinations of 
the type X/Y can show a residual hearing configuration if both X and Y are some 
type of truncating mutation, or subresidual or even better hearing levels with a 
relatively flat audiometric configuration at mild to severe threshold levels if X 
and/or Y are some type of non-truncating mutation 37 (Figure 2).  
 
 
Figure 2. The 50th, 10th and 90th percentiles (P50, P10 and P90, respectively) of the 
threshold distribution, not related to age, for DFNB1/GJB2 with biallelic, i.e. homozygous, 
combinations of the truncating 35delG mutation (left) and (right) biallelic combinations of 
several different  non-truncating mutations, i.e. the missense mutations V37I and L90P, 
as well as the splice site mutation IVS1+1G>A. Multicentre threshold data underlying the 
report by Cryns et al.37; the symbol # indicates the number of patients. 
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The most important truncating mutations are 35delG 37, 233delC or 235delC 38,39, 
167delT 40, W24X 41, as well as a large deletion in the GJB6 gene (indicated as 
del(GJB6)) located in the vicinity of the GJB2 gene responsible for DFNB1 42. At 
the moment, the most important GJB2 mutations in this respect seem to be the 
non-truncating mutations M34T 43-49, V37I 37,39,44,48,49 and L90P 37,44,46,48,50, as well 
as the splice site mutation IVS1+1G>A (Figure 2).37 
Many authors, especially Cohn and Kelley 19, Murgia et al. 51, Tóth et al. 52 and 
Cryns et al.37,  have emphasized the wide spectrum of threshold variability shown 
by 35delG/35delG homozygotes. One possible explanation is that modifying 
genes are involved; further research into such a possibility certainly requires 
additional large-scale efforts. 
 
 
 
 
Figure 3. Thresholds for various ages in decade steps for air conduction (AC, i.e. ARTA), 
bone conduction (BC) and air bone gap (ABG) in DFN3 (stapes gusher). Note that ABG is 
stationary throughout life (0-70 years). Modified from Cremers et al.64 
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DFN loci 
The majority of the X-linked types of SNHI, i.e. DFN2 53-55, DFN3 56,57 and DFN4 
54,55,58-60 have congenital onset and show a residual hearing type of configuration. 
In many instances progression to a residual hearing type has been specified: for 
DFN2 61, as well as for DFN3.55,62-68 
It should be realised that DFN3 patients with a subresidual AC threshold may 
show a low-frequency audiometric configuration on the basis of their ABG 
configuration, which, quite remarkably, is stationary throughout life (Figure 3). 
DFN3 is also associated with vestibular failure.56,57,63,66,67  
Exceptional X-linked traits linked to DFN2 and DFN6 having different audiometric 
configurations that are not compatible with residual hearing are specified in the 
following sections. 
 
High-frequency downsloping audiometric configuration (Figure 4) 
This category includes stable as well as progressive high-frequency downsloping 
configurations. Progression is the rule for AD traits.18 Exceptions are some traits 
linked to DFNA3 that have been presumed to show stable SNHI and the traits for 
which linkage to DFNA23 or DFNA24 was reported. The latter were specified as 
being non-progressive. However, threshold data collected by F Häfner (personal 
communication to P.H. 1999) did show age-related progression in the trait linked 
to DFNA24 that may be compatible with presbyacusis (data not shown). Stability 
is the rule for AR traits. Some high-frequency downsloping audiometric 
configurations can be also interpreted as representing a milder variant of the 
residual hearing type.  
 
DFNA2 (Figure 4) 
DFNA2 traits typically show a progressive high-frequency audiometric 
configuration (Figure 4) with, presumably, congenital onset and ATD in the range 
of 0.7-1 dB, no matter whether they are caused by KCNQ4 mutations in the 
channel pore region 4,69-77, GJB3 mutations 78 or mutations in as yet unidentified 
genes at the DFNA2 locus.4,79-81 The traits with genes that have not yet been 
identified have reported onset ages in the first or second decade of life. 
A different phenotype was found in a Belgian DFNA2/KCNQ4 trait with a 
truncating frame shift mutation (Fs71) affecting the first intracellular domain of the 
KCNQ4-related voltage-gated K+ channel: only the thresholds for the high 
frequencies (> 1 kHz) were increased, which produced a much steeper down-
sloping configuration than in the other DFNA2/KCNQ4 traits (see De Leenheer et 
al.75 for more detailed data). 
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Figure 4. High-frequency progressive phenotypes of DFNA2/KCNQ4 (only mutations 
involving the channel pore region, see De Leenheer et al. and Topsakal et al.75,77 and text 
for data sources), DFNA3/GJB2 84, DFNA5 88, DFNA7 (modified from Pennings et al. 
2003 8, see that reference and present text for original data sources), DFNA9 96, DFNA15 
101, DFNA16 and DFNA17 (modified from Pennings et al. 2003 8, DFNA20/26 (sources 
specified in text), DFNA36 112, DFNB30 120 and DFN6.121 The symbol # followed by a 
number labels mean ARTA covering the specified number of different traits or families. 
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In the present type of progressive SNHI the lower and the speech frequencies can 
be relatively spared for many years (Figure 4) and therefore even congenital or 
early-childhood onset does not necessarily interfere with the normal development 
of speech and language skills. Bom et al.82 found remarkably good speech 
recognition scores in DFNA2 patients, anyway, even at advanced ages and levels 
of hearing impairment. 
 
DFNA3 (Figure 4) 
The report by Grifa et al.83 only hints to variable audiometric configurations in a 
GJB6-linked SNHI trait. Denoyelle et al. 84,85 indicated a high-frequency to a fairly 
flat configuration (Fig. 4) with stable hearing; onset was at age < 4 years or in the 
second decade of life, depending on the GJB2 mutation (W44C or C202F). 
 
DFNA5 (Figure 4) 
The DFNA5 traits identified sofar show a progressive high-frequency audiometric 
configuration (Figure 4) with early-childhood to early-adolescent onset and most 
rapid progression in the first or second decade of life. The review by Kunst et al.4 
reproduces audioprofiles typical of the original Dutch family (see their refs). Part of 
this family was re-analysed by De Leenheer et al.86 Speech recognition remained 
relatively good.87 A second Dutch family was identified by Bischoff et al.88 These 
authors found that speech recognition in the second family was somewhat better 
than in the original family, which perhaps related to the slightly more favourable 
hearing thresholds. A third, Chinese family was recently identified with fairly 
similar features.89 
 
DFNA7 (Figure 4) 
A SNHI trait with a progressive high-frequency configuration (Figure 4) and post-
lingual (first-decade) onset was described by Fagerheim et al.90 and Elverland et 
al.91 and reviewed by Tranebjærg et al.92 
 
DFNA8/12 (1 trait) 
Alloisio et al.93 described a trait with prelingual onset and a progressive high-
frequency configuration at mild to moderate threshold levels. The ATD was 0.7 dB 
at 0.5-4 kHz, which presumably indicates some progression beyond presbyacusis. 
A mutation was found in the zonadhesin-like domain of TECTA. 
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DFNA9 (Figure 4) 
All the reported traits show progressive high-frequency SNHI (Figure 4) with 
midlife onset or, in one American family, onset in the second to third decade of 
life.94,95 Vestibular dysfunction also develops gradually 96 and eventually leads to 
vestibular areflexia. Hearing deteriorates over a few decades, with maximum ATD 
values of 2-7 dB 97 or even higher in some individual cases, eventually leading to 
residual hearing or (sub)residual hearing threshold levels.98,99 The ARTA shown in 
Fig. 4 are compatible with an average ATD of 2-3 dB. Speech recognition is 
relatively poor 95, showing features similar to presbyacusis that already occur at a 
younger-than-usual age.82 
 
DFNA15-17 (Figure 4) 
The DFNA15 trait described by Frydman et al.100 showed a progressive high-
frequency pattern (Figure 4) with postlingual onset. Progression beyond presby-
acusis occurred with ATD values of between 1.1 dB at 0.25-1 kHz and 2.1 dB at 
2-4 kHz 101; the onset age was estimated at 15-25 years using fitting methods in 
cross-sectional data analysis. Speech recognition continued to be relatively good 
even at the higher threshold levels.100 Fukushima et al.102 described a DFNA16 
trait with early onset and a high-frequency pattern with rapid progression (Figure 
4) in the first decades of life. A distinctive feature was that large threshold 
fluctuations occurred that appeared to respond favourably to steroid treatment. 
Lalwani et al. 103,104 reported on a DFNA17 trait with early onset that showed 
progressive high-frequency features (Figure 4). Individual longitudinal analyses 
revealed ATD values of up to about 3 dB. Speech recognition scores were 
relatively good, also in members of the family having substantial SNHI. 
 
DFNA20/26 (Figure 4) 
DFNA20/26 traits show progressive high-frequency audiometric configurations 
(Figure 4) with postlingual onset varying between childhood and late 
adolescence.105-109 Teig 110 described a trait of which linkage to the DFNA20/26 
locus was recently confirmed and an ACTG1 mutation was identified (L 
Tranebjærg, personal communication to P.H. at the GENDEAF final meeting in 
Caserta, March 2005). Kemperman et al.109 reported relatively good speech 
recognition scores at sound levels of < 100 dB HL. 
 
Next DFNA loci (Figure 4) 
SNHI traits with postlingual onset showing progressive high-frequency 
configurations have been reported with linkage to DFNA30 111 in a trait whose 
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onset age was relatively late (10-40 years) and to DFNA36 for a trait that showed 
SNHI with postlingual onset in the first decade and a high degree of progression 
(Fig.4 ) with ATD values in the range of 5-8 dB at increasing audio frequencies.112 
It should be noted that these high ATD values related to the initial stage of 
deterioration. Subsequently, the rate of deterioration decreased. The ARTA based 
on the last-visit threshold data (Fig. 4) reflect much lower ATD values of around 1 
dB. Traits linked to DFNA42 113, DFNA47 114 and DFNA48 115 also showed 
postlingual onset in the first to third decade of life and similar audiometric profiles; 
progression was fairly slow in the reported DFNA48 trait. Presumably “non-
progressive” types of SNHI, i.e. SNHI that did not appear to show progression 
beyond presbyacucis, were reported for DFNA23 116 in a trait also showing 
conductive loss and for DFNA24.117 The latter two traits showed prelingual onset. 
 
DFNB loci (Figure 4) 
Houseman et al.45 described 2 sibs with an M34T/M34T GJB2 genotype (DFNB1) 
with a high-frequency audiometric configuration with moderate to severe threshold 
levels. We presume that this type of SNHI is stable. Ahmed et al.118 reported on a 
DFNB8/10 trait with congenital SNHI and a stable high-frequency audiometric 
configuration. Villamar et al.119 reported on a DFNB16 trait with early childhood 
onset showing a high-frequency configuration with stable thresholds at moderate 
to severe levels. Walsh et al.120 described a DFNB30 trait (Figure 4) with post-
lingual (fairly late and variable) onset SNHI showing a progressive gently to more 
steeply downsloping audiometric configuration (Figure 4). Substantial progression 
in SNHI is exceptional for AR hearing impairment disorders. We estimated the 
ATD to be approximately 1.2 dB at 0.5-8 kHz. Progression was certainly beyond 
presbyacusis at the low frequencies. 
 
DFN6 (Figure 4) 
One reported DFN6 trait showed SNHI with postlingual onset in the first decade of 
life and a progressive high-frequency type of audiometric configuration (Figure 
4).121 We estimated an ATD of about 1 dB from the 2 audiograms depicted by del 
Castillo et al.121 
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Flat to gently downsloping audiometric configuration (Figure 5) 
This category includes stable as well as progressive flat to gently downsloping 
phenotypes. In the following, the majority of the traits show a progessive pheno-
type. A stable audiometric configuration is shown by the exceptionally mild DFNB1 
phenotypes encountered in some patients having DFNB1 with biallelic non-
truncating mutations in GJB2 (see above). 
 
DFNA loci (Figure 5) 
DFNA4 traits have postlingual progressive flat to gently downsloping audiometric 
configurations as shown in Figure 5.122,123 Pusch et al.124 reported thresholds at 
moderate to severe levels (mean 75 dB) and an ATD of approximately 0.5 dB, 
which is presumably compatible with normal presbyacusis (Figure 5). Although 
one of the patients described by McGuirt et al.123 was measured twice and the 
ATD that can be derived from these data is 3-4 dB, the ensemble of available 
threshold data suggests only limited progression given the corresponding ages 
(Figure 5). The DFNA8/12 trait described by Pfister et al.125 is exceptional among 
traits linked to locus DFNA8/12 because it showed a flat to gently downsloping 
rather than a mid-frequency configuration and was progressive with an ATD of 
about 0.4 dB, which seems to be compatible with presbyacusis. The reported 
DFNA10 traits show postlingual, variable onset within the first 4 decades of life 
and a  progressive flat to gently downsloping configuration (Figure 5) with an ATD 
of approximately 0.8 dB (pooled frequencies) 126,127 to 1.1 dB (0.5-4 kHz).128 
McGuirt et al.123 showed an example of one member of the original DFNA10 
family whose ATD may have been as high as 4 dB in the higher frequency range. 
Speech recognition was relatively good in the American family according to the 
phoneme scores analysed by De Leenheer et al.126 
 
Fairly similar phenotypes (Figure 5) with postlingual onset in the first 2 decades of 
life have been reported for DFNA11 129-133, DFNA18 134, DFNA21 135, DFNA25 136, 
DFNA28 137, the DFNA31 trait that initially had been linked to DFNA13 (Fig. 5) 138, 
see Snoeckx et al.139, DFNA41 140,  DFNA43 141 and DFNA50.142  
It can be appreciated from Fig. 5 that some traits, for example, those linked to 
DFNA25 and DFNA43, showed high-frequency characteristics (only) at relatively 
young ages. Other SNHI traits, such as those linked to DFNA10, DFNA18, 
DFNA28 and DFNA41, tended to develop more high-frequency characteristics at 
increasing age. Progression produced ATD values of between  0.6 dB for 
DFNA11 129,130 and DFNA28 137 and 1.1-1.5 dB for DFNA31 138 and DFNA50.142 In 
DFNA21 (Fig. 5), the ATD is 0.7-1.1 dB from the low to the high frequencies.135 
Chapter 1.2 
 
46 
Subjective onset age was reported to be in the second decade of life for DFNA41 
and DFNA50. For the DFNA21 trait studied by Kunst et al. 135 the subjective onset 
age that was reported by the affected family members varied between childhood 
and late adolescence or even later. However, the available threshold data allowed 
for backward extrapolation in linear regression analyses, which produced 
consistent estimates of onset age at about 3-5 years for all frequencies.  
 
 
Figure 5. Phenotypes showing a flat to gently downsloping audiometric configuration. For 
DFNA4, two different traits are covered by different panels (top): trait 1, data from Chen et 
al.122 and McGuirt et al.123; trait 2, Pusch et al.124; asterisk marks longitudinal data 
(indicating ATD 3-4 dB). Other data or modified figures from: (DFNA10), Smith and 
Huygen 9; (DFNA11), Tamagawa et al.129, Luijendijk et al.131, Street et al.132 and Bischoff 
et al.133 ; (DFNA18), Bönsch et al.134; (DFNA21), Kunst et al.135; (DFNA25), Thirlwall et 
al.136; (DFNA28), Peters et al.137; (DFNA31), Ensink et al.138; (DFNA41), Blanton et al.140; 
(DFNA43), Flex et al.141; (DFNA50), Modamio-Høybjør et al.142. 
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Backward extrapolation in cross-sectional linear regression analysis produced 
estimates of onset ages for the DFNA31 trait between 5 years (0.25-0.5 kHz) and 
12 years (2-8 kHz).138 Such apparently discrepant findings may be typical of slow 
postnatal progression in SNHI. A distinctive feature of DFNA11 is progressive 
vestibular dysfunction, eventually leading to vestibular areflexia.129-131 
 
OTSC2, 5 
At the GENDEAF final meeting in Caserta, March 2005, F Declau presented a 
paper specifying a fairly flat audiometric configuration for OTSC2, including the 
ABG. In an OTSC5 trait we recently obtained fairly similar findings.143 Given the 
natural history of otosclerosis, the clinical picture must include progression during 
at least a number of years prior to surgery. 
 
DFNB loci 
Several of  the DFNB1 genotypes with relatively mild SNHI show thresholds at 
moderate to severe levels with a relatively flat audiometric configuration (Figure 
2). One study on a DFNB13 trait specified a relatively flat configuration with 
moderate threshold levels at young ages, probably preceding progression.22 
 
Y-linked locus 
A SNHI trait in a Chinese family showed Y-linked inheritance with onset in 
childhood to late adolescence and a progressive flat to gently downsloping 
audiometric configuration. Threshold levels were mild to severe, but there was no 
residual hearing.144 There was no significant age-related increase in threshold 
between 9 and 71 years of age.  The binaural mean PTA (all frequencies) was 71 
dB; the audiometric configuration was not clearly described. 
 
Mid-frequency or U-shaped audiometric configuration (Figure 6) 
This category includes stable as well as progressive mid-frequency configurations. 
This phenotype is only encountered among AD traits, although one exceptional X-
linked trait has been described to show mid-frequency-like features. In some of 
the AD traits, progression may be compatible with presbyacusis, but there are 
also traits that show genuine progression beyond presbyacusis.  
 
DFNA loci (Figure 6) 
The majority of the TECTA-based traits linked to DFNA8/12 show prelingual onset 
of SNHI with a stable mid-frequency (sometimes more low-frequency) audiometric 
configuration (Figure 6).145-148 Almost all of the other AD traits with the mid-
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frequency configuration show progression. This includes the DFNA8/12 trait 
described by Moreno-Pelayo et al.149 with an ATD of 0.4 dB at 0.5- 2 kHz, the 
reported DFNA13 traits (Figure 6) 123,150-152, the DFNA44 trait described by 
Modamio-Høybjør et al. (Figure 6) 153 and the DFNA49 trait described by Moreno-
Pelayo et al.154 that may also have shown some low-frequency characteristics.  
 
 
 
Figure 6. Mid-frequency phenotypes. Loci relating to TECTA in top row. Data or modified 
figures from: (DFNA8/12), Kirschhofer et al.147, Govaerts et al.145 and Iwasaki et al.186; 
(DFNB21), Naz et al.156; (DFNA13), Kunst et al.150 and De Leenheer et al.151,152; 
(DFNA44), Modamio-Høybjør et al.153. Top row panels show mean ±1 intertrait SD.The 
dotted line in the panel for DFNA44 highlights the fact that this threshold line mainly 
relates to one, possibly exceptional, patient who showed a remarkably unfavourable 
threshold at an advanced age and therefore should be regarded with reservation. 
 
Some traits showed substantial progression beyond presbyacusis: the DFNA44 
trait had an ATD of 1.1-1.2 dB and the DFNA49 trait had an ATD of 0.7 dB at all 
frequencies. However, the DFNA13 trait underlying the report by McGuirt et al.123 
did not show significant progression beyond presbyacusis. Given the special 
threshold configuration and limited degree of SNHI, the normal development of 
speech and language skills in patients having SNHI linked to DFNA13 does not 
 
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
10
20
30
40
50
60
70
             Frequency
   
   
   
   
   
   
   
 T
hr
es
ho
ld 0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
20
40
10
30
50
60
DFNA8/12/TECTA #3 DFNB21/TECTA #2
DFNA13/COL11A2 #2 DFNA44
 Audiopropiles in genetic non-syndromal hearing impairment 
 
49 
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
0
10
20
30-
             Frequency
   
   
   
   
   
   
   
 T
hr
e s
ho
ld 0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
 0 10
20
50
60
70
30
40
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
DFNA1/DIAPH1 DFNA6/14/38/WFS1 #7 DFNA54
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
12
DFN2
exclude the possibility of prelingual or congenital onset. One DFNA13 trait was 
studied by De Leenheer et al.155 using special audiolological tests, which showed 
that DFNA13 represents a special type of intracochlear conductive hearing 
impairment; speech recognition was found to be relatively good. The latter finding 
was also reported for DFNA8/12 by Kirschhofer et al.147 
 
DFNB21 (Figure 6) 
The study by Naz et al. (Figure 6) 156 indicates a stable flat to gently downsloping 
configuration of prelingual SNHI at moderate to severe levels for a DFNB21 trait 
(Figure 6). Although the audiometric configuration could be classified as flat to 
gently downsloping, this SNHI trait is classified here with the mid-frequency traits 
DFNA8/12 that are caused by TECTA mutations as well. Minor differences 
between these TECTA-based traits seem to relate to the degree of hearing 
impairment, especially at the high frequencies (Figure 6).  
 
DFN2? (Figure 7) 
Manolis et al. (Figure 7) 157 described an exceptional trait with presumable linkage 
to DFN2 that showed congenital SNHI with a progressive low-frequency to mid-
frequency type of audiometric configuration. 
 
Low-frequency audiometric configuration (Figure 7) 
This category includes stable and progressive low-frequency, i.e. upsloping, 
configurations. This phenotype is almost exclusively encountered among AD 
traits. Some of the traits have stable hearing and in those showing progression, 
this may be compatible with presbyacusis in some instances. 
 
Figure 7. Low-frequency progressive phenotypes. Data or modified figures from: 
(DFNA1), Smith and Huygen 9; (DFNA6/14/38), see text; (DFNA54), Gürtler et al.173; 
subject and age not specified; (DFN2), Manolis et al.157 
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DFNA loci (Figure 7) 
The only trait linked to DFNA1 showed early onset of SNHI with a low-frequency 
configuration with rapid progression.158-160 The ARTA shown in Fig. 7 are 
compatible with an ATD of 3-5 dB. Part of the traits linked to the DFNA6/14/38 
locus showed an apparently stable low-frequency configuration 161, see ARTA in 
Kunst et al. 1998 4, i.e. with progression presumably not beyond presbyacusis.18, 
162-165 This may also apply to the two traits reported very recently by Gürtler et al. 
166 The other DFNA6/14/38 traits (Figure 7), however, showed substantial 
progression beyond presbyacusis.167-170 The traits described by Bom et al.171 
showed ATD values of 0.5-1.3 dB at increasing frequencies. The trait (family A) 
described by Bille et al.167 showed a median ATD of 1.1 dB at 2-4 kHz in their 
individual longitudinal analyses. One of the two traits described by Pennings et 
al.172 did not show significant progression; the other showed a pooled ATD of 1 
dB. The latter study also demonstrated relatively good speech recognition scores. 
Onset in all these traits varied between possibly congenital or somewhere in early 
childhood and somewhere in the first 3 decades of life. The DFNA54 trait 
described by Gürtler et al. (Figure 7) 173 represents the third locus for AD SNHI 
that is associated with a low-frequency configuration; it showed relatively late 
onset (5-40 years) and progression beyond presbyacusis. 
 
DFN2? (Figure 7) 
The exceptional (presumable) DFN2 trait reported on by Manolis et al. (Figure 7) 
157 can be also mentioned in this category because of its low-frequency-like 
features. 
 
 
DISCUSSION 
The purposes of this review 
Facilitating the differential diagnosis, counseling and guidance for genotyping 
efforts 
As regards the differential diagnosis, it needs emphasis that different genotypes 
may show fairly similar phenotypes. The classification of phenotypes by audio-
metric configuration seemed to do reasonably well at first sight. From Figures 4-7 
it would seem that the differences in audioprofile between these figures are 
greater than within these figures. Maximum downward slopes in the audiogram 
are > 10 dB/octave in high-frequency downsloping configurations (Figure 4) and < 
10 dB/octave with few exceptions in flat to gently downsloping configurations 
(Figure 5). The exceptions in Figure 5 are found in the panels for DFNA41 and 
DFNA43. Although the average slope in the decade threshold lines is < 10 
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dB/octave, “local” slopes of >> 10 dB/octave can be seen in the high frequencies 
at advanced ages in DFNA41 and in DFNA43 in the mid frequencies in midlife. 
Accentuated local slope in the audiogram configuration is also found in high-
frequency downsloping configurations (Fig. 4). The feature of steepest slope in the 
mid-frequency range is also found in DFNA5 in late adolescence and in DFNA15 
at advanced ages. A midlife-associated steepest slope in the audiogram is found 
in DFNA9 in the  2-4  kHz range. The steepest slopes are found in the low-
frequency range in DFNA36 throughout life and in DFNA20/26 at advanced ages 
(Figure 4). 
 
Despite this type of detailed observations, which can be made regarding possibly 
distinctive features, the differential diagnosis of phenotypes is often quite 
problematic. We used the threshold features array (TFA) as previously defined 7 in 
an attempt to find out the apparent similarities or dissimilarities of those traits for 
which sufficient reliable ARTA data were available in a quantified, objective way. It 
appeared that regrouping of phenotypes within and between the 4 main classes 
pertaining to Figures 4-7 is certainly possible (see sections on TFA below). 
 
The onset age does not generally contribute to the differential diagnosis, apart 
from the differential diagnosis between DFNA5 (onset in early childhood to early 
adolescence) and DFNA9 (midlife onset). Early onset with rapid progression may 
be a useful distinctive feature (see DFNB4/PDS in Figure 1, DFNA1 in Figure 7, 
and DFNA16, DFNA17, DFNA36 and DFN6 in Figure 4). Progression by itself can 
be an important item. Extremely rapid deterioration, showing up in the ARTA as a 
great distance between consecutive (decade) threshold lines, can be seen in 
DFNA1 (Figure 7). Rapid initial deterioration with a gradually decreasing rate of 
deterioration, i.e. nonlinear progression that is associated with non-equidistant 
(decade) threshold lines in the ARTA, can be noted in traits linked to DFNB4/PDS 
(Figure 1), DFNA5 and DFNA9 (Figure 4) and DFNA10 (Figure 5). 
The occurrence of substantial fluctuations in threshold (DFNB4/PDS and 
DFNA16) is another distinctive feature of importance. This also holds for 
vestibular failure (DFNB4/PDS, DFNA9/COCH, DFNA11/MYO7A and DFN3/ 
POU3F4). 
 
As regards the possible value that careful phenotyping may have for the guidance 
of genotyping efforts, we and others have already had favourable experiences 
with some of the more remarkable traits. Congenital residual hearing on a possibly 
autosomal recessive basis should be always tested for DFNB1. DFNA2-linked 
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traits are fairly easy to recognize (Figure 4). Although, as stipulated here, there 
are several traits with fairly similar phenotypes, the relatively high prevalence of 
DFNA2-linked traits favours guidance in this case.77 This also applies to traits with 
SNHI caused by WFS1 mutations whose phenotype is even more easily 
recognized (DFNA6/14/38, see Figure 7 and the editorial by Smith and Huygen 
2003 9). The combination of the features of midlife onset and progressive 
deterioration in hearing and vestibular function is so typical that DFNA9/COCH 
can be easily recognized 97; in The Netherlands and Belgium (Flanders) the 
relative prevalence of traits linked to DFNA9 is relatively high. For other traits, 
especially the less typical or prevalent traits, the probably best strategy for guided 
phenotyping is to screen all the loci that are associated with possibly similar 
phenotypes and extend the list of loci to be checked, anyway, if the first search is 
negative.  
So it would seem that, in general, phenotyping does not contribute very much to 
genotyping efforts in terms of guidance, anyway. Genotyping will always remain to 
be necessary. Sometimes, however, careful phenotyping does contribute to the 
guidance of genotyping to the effect that the latter can be limited and lots of time, 
efforts and costs can be saved (see last section below). 
 
Facilitating the consideration of treatment opportunities 
It is important to realise in which types of genetic hearing impairment disorder the 
affected subjects are likely to have residual hearing. In that case, cochlear 
implantation is a treatment option. In other types of hearing impairment, i.e. those 
not associated with residual hearing, fitting a (multiband) hearing aid may be a 
reasonable option. Given the sometimes remarkably mild types of hearing 
impairment of DFNB1 phenotypes involving non-truncating GJB2 mutations 
(Figure 2), it is important to recognize the relatively good opportunities for fitting 
hearing aids in such cases, where a typical residual hearing type of SNHI might 
have been expected to develop. The most important distinctive feature of DFN3 is 
the ABG and it is important to recognize this phenotype feature because stapes 
surgery should be avoided because of the risk of perilymphatic gusher. The bone 
conduction level may allow for effective amplification (Figure 3). An important item 
for counseling in the slowly progressive types of hearing impairment is that 
auditory communication will become more difficult from around midlife onwards. 
Although in such cases the degree of hearing impairment may still be limited at 
more advanced ages (Figure 5) and aided hearing certainly is a realistic option, 
the choice of profession made decades before midlife can be critical. 
Updating and using the TFA 
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Using the previously described method 7 that bears on the threshold features 
array (TFA) we updated and extended the previously designed table with TFA 
data (Table I). We have outlined the purpose of such data and the attached 
method in the previous paper. Briefly, they can be used to test whether the ARTA 
and the derived TFA for a given novel trait are similar or dissimilar to previously 
reported ones.7,77 Testing between complete TFAs derived for the newly 
established ARTA shown in the present paper was performed as previously 
outlined using the chi-square test. Table 2 shows the result of these tests in the 
form of S values equalling the P values attached to the corresponding chi-square 
tests for pairwise comparisons. 
 
 
Table 1. Threshold features arrays a for suitable loci data that can be used in conventional 
chi-square tests. b 
 
Locus, # traits Cell a Cell b Cell c Cell d Cell e Cell f Cell g Cell h Cell I 
DFNA2 #8 9 3 1 7 11 8 0 2 7 
DFNA5 #2 9 6 3 7 6 5 0 4 8 
DFNA6/14/38 #7 1 6 10 15 10 6 0 0 0 
DFNA9 11 11 8 5 4 2 0 1 6 
DFNA10 #2 9 6 6 7 10 7 0 0 3 
DFNA11 #3 5 5 4 11 11 10 0 0 2 
DFNA13 #2 14 9 7 2 7 8 0 0 1 
DFNA15 12 10 8 4 5 4 0 1 4 
DFNA18 10 5  6 11  0 0  
DFNA20/26 #6 7 5 3 8 4 4 1 7 9 
DFNA21 12 10 9 4 6 6 0 0 1 
DFNA25   10   6   0  
DFNA28 12 8 7 4 8 9 0 0 0 
DFNA31 15 11 10 1 5 6 0 0 0 
DFNA36 5   4   7 10 12 
DFNA41 3 2 3 12 11 7 1 3 6 
DFNA43 12 8 6 4 7 6 0 1 4 
DFNA50 7 5 5 7 9 7 2 2 4 
 
a Cell count for cells a-i as defined by Huygen et al. 7 
b Cells a,b,c pertain to 0-39 dB and 0.25-0.5 Khz, 1-2 kHz and 4-8 kHz, respectively; cells d,e,f 
pertain to 40-79 dB and these grouped frequencies; cells g,h,i pertain to 80 dB and over and these 
grouped frequencies. Averages (bold) pertain to norm (multi-trait) values. It should be noted that a 
conventional chi-square test can be used for testing across separate arrays (single trait or 
average), but that a chi-square test for goodness of fit should be used if (average) norm values are 
applied as representing expected values for comparison with a single trait. Prior to performing a 
conventional chi-square test on a given contingency table that can be constructed by combining 
any arrays, cells should be combined where necessary according to general rules described for 
chi-square tests in most textbooks on statistics. 
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We replaced the symbol P, for probability, by the symbol S for similarity, because 
the TFAs do not cover real sampled data. The consecutively sampled values 
predicted by regression do not pertain directly to the original data points and are 
unlikely to be stochastically independent. S=1 indicates complete similarity 
(=identity), whereas S=0 indicates no similarity at all. All of the present traits 
whose audioprofiles are shown in Figures 4-7 for which sufficient testable ARTA 
data could be obtained are included in this table with disregard of their tentave 
classification into the corresponding main phenotypes. 
As the S values in Table 2 were intended to assist in visual pairwise comparison 
between the (complete) ARTA of different loci, we performed such a visual 
comparison for all complete ARTA included in Figures 4-7 in descending order of 
the corresponding S value. Starting from the highest S value involving a given 
locus, we looked at the successive other loci. For DFNA11 (ARTA in Figure 5), for 
example, the highest S value in Table 2 is 0.66, which is attached to the 
comparison with DFNA10 (Figure 5); the next S value involving DFNA11 is 0.35, 
attached to the comparison with DFNA50 (Figure 5). Looking at the ARTA of the 
corresponding pairs of loci, we concluded that the ARTA of DFNA11 and DFNA10 
might be visually confused, but the ARTA of DFNA11 and DFNA50 would not 
seem likely to be confused. After having made all the visual comparisons by all 
the available complete ARTA, we concluded that loci whose TFAs in pairwise 
comparison (chi-square test) produce an S value of 0.6 or higher would seem 
fairly likely to be visually confused. Remarkably, there are only 2 loci whose ARTA 
are unlikely to be visually confused with the ARTA for any other loci: DFNA6/14/38 
(Figure 7) and DFNA41 (Figure 5). There are 4 loci (DFNA2, DFNA9, DFNA11 
and DFNA20/26) whose ARTA can be fairly easily confused with the ARTA of 1 
different locus each (Table 2). The ARTA of 3 loci (DFNA5, DFNA28 and 
DFNA31) can be fairly easily confused with the ARTA of 2 different loci each, 
whereas the ARTA of 5 loci (DFNA10, DFNA13, DFNA15, DFNA43 and DFNA50) 
could be confused with the ARTA of 3 loci each. There is one locus, DFNA21 
(Figure 5), whose ARTA could be confused with the ARTA of 5 other loci 
(DFNA13 in Figure 6, DFNA15 in Figure 4, DFNA28, DFNA31 and DFNA43 in 
Figure 5). It shows that 8 of the 15 S values > 0.6 in Table 2 pertain to pairwise 
comparisons involving ARTA included in the same figure (Figures 4, 5 or 6) and 7 
S values > 0.6 pertain to comparisons involving ARTA included in different figures 
(Fig. 4, 5 or 6). This kind of observations demonstrates that our assignment of loci 
to the main tentative phenotypes for which Figures 4-7 were designed must have 
been fairly arbitrary. It is indeed possible to group fairly similar ARTA in a number 
of different clusters that might represent separate phenotypical entities. In order to 
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attempt forming tentative phenotype clusters, we started from the grouped loci 
specified above and checked whether the attached S value for the group (= P 
value in simultaneous chi-square test) was 0.6 or higher. This limiting value was 
chosen because we presume that a value of S = 0.6 attached to simultaneous 
comparison between TFAs (n > 2) also corresponds to ARTA that might be fairly 
easily confused on visual inspection. If the tentative cluster had S < 0.6, we 
searched for the locus or loci that could best be skipped from the cluster in order 
to obtain S > 0.6. If the tentative cluster had S > 0.6, it was checked whether the 
cluster could be extended with additional loci while maintaining the condition of S 
> 0.6. Small tentative clusters were neglected if they were found to form part of 
any larger tentative cluster(s). The clusters thus obtained were: (A), DFNA6/14/38; 
(B), DFNA41; (C), DFNA10 and 11; (D), DFNA5, 20/26 and 50; (E), DFNA10, 43 
and 50; (F), DFNA13, 21, 28 and 31; (G), DFNA2, 5, 10 and 50; (H), DFNA9, 10, 
13, 15, 21 and 43; (I), DFNA13, 15, 21, 28, 31 and 43. It is of note that DFNA11 
initially formed part of a former version of cluster E (with S = 0.47) that is formed 
by (Table 2) starting from DFNA10 but had to be skipped in order to obtain S > 0.6 
for the final cluster (S = 0.81). Cluster H was obtained by starting from DFNA15 by 
combining all the loci whose TFA in pairwise comparison with the TFA for 
DFNA15 had S > 0.6 (Table 2) and then also add the TFAs for DFNA10 and 
DFNA13 by trial and error to obtain S = 0.62 for the final cluster. 
 
Which loci should be tested for a given new trait? 
When a complete ARTA has been derived for a newly outlined SNHI trait, Figures 
4-7 should be scanned to see what it looks like. If it looks like any of the complete 
ARTA in these figures, the scheme indicated in Table 3 might be followed. 
This scheme has been obtained by looking up in which of the above described 
clusters the look-alike ARTA is included and then specify all the other loci included 
in these clusters. If a newly derived ARTA looks most similar to one of the 
incomplete ARTA included in Figures 4-7, the next most similar complete ARTA 
should be pinpointed to apply the scheme. Table 3 indicates that initial testing of a 
limited number of loci (n = 1-9) might be sufficient. If all the initial tests are 
negative, additional loci could be tested, even if the present paper indicates that 
they seem to be unlikely to be associated with fairly similar phenotypes. 
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ABSTRACT 
The present study aims to report audiological and vestibular characteristics of a 
Dutch DFNA9 family with a novel mutation, G87W, in the LCCL domain of COCH.  
From the family with the novel G87W COCH mutation audiometric data were 
collected and analyzed longitudinally. Results were compared with those obtained 
in previously identified P51S COCH mutation carriers (n = 74) and with those 
obtained in G88E mutation carriers. Special attention was also given to a 
comparison of age-related features, such as progressive hearing loss and 
vestibular impairment. 
A novel mutation (G87W) in COCH segregates with hearing impairment and 
vestibular dysfunction in the present family. Pure-tone thresholds, phoneme 
recognition scores, and vestibular responses of the G87W mutation carriers were 
essentially similar to those previously established in the P51S and G88E mutation 
carriers. Deterioration of hearing and vestibular function in the G87W mutation 
carriers started at age 43 years. Remarkably, similar to G88E mutation carriers, 
the proportion of patients over 40 years of age who developed complete vestibular 
areflexia was significantly lower for the G87W mutation carriers than for the P51S 
mutation carriers. 
In conclusion: the phenotype associated with the novel COCH (G87W) mutation is 
largely similar to that associated with the P51S and G88E mutation carriers. 
However, subtle differences in terms of onset age and rate of progression seem to 
exist. 
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INTRODUCTION 
At present 54 loci for autosomal dominant non-syndromic hearing impairment 
(DFNA1-54) have been described, of which the causative genes have been 
identified in 21 cases.1 A thorough phenotype description of each novel locus and 
mutation is needed to identify the clinical significance of all the new findings and, 
for counseling reasons, to gain insight into the natural course of the specific 
genetic disease. 
The autosomal dominant non-syndromic hearing disorder DFNA9 is characterized 
by progressive high-frequency sensorineural hearing impairment with midlife 
onset. Hearing deteriorates fully over a few decades of life, with annual threshold 
deterioration (ATD) values of 2-7 dB eventually leading to residual hearing or 
(sub)residual hearing threshold levels.2-4 Speech recognition is relatively poor, 
showing features similar to presbyacusis that, however, occur at a younger-than-
usual age. Apart from DFNA11, DFNA9 is the only DFNA locus known to exhibit 
substantial concomitant vestibular impairment. Vestibular dysfunction develops 
gradually and may eventually lead to vestibular areflexia.5 Meniere-like vertigo is 
not unusual.6,7 Interestingly, ophthalmologic examination in a large Dutch DFNA9 
family with the P51S mutation in COCH revealed a peculiar pattern of corneal 
striae, which in general was a sub-clinical feature.8 A subset of the present 
DFNA9 family participated in an ophthalmological study involving 4 different 
DFNA9 families.8 
DFNA9 was linked to chromosome 14q12-13 in 1996.9 Two different departments 
involved in genetic hearing loss research independently reported on COCH 
mutations causing DFNA9; in 1998 Robertson et al. identified the V66G, G88E 
and the W117R COCH mutations 10 and in 1999 de Kok et al. and Fransen et al. 
reported on the P51S COCH mutation.4,11 COCH has 12 exons that encode a 
protein called cochlin, which is a major constituent of the inner ear extracellular 
matrix.12 Cochlin contains a signal peptide, an LCCL domain and two von 
Willebrand factor A-like domains (vWFA1 and vWFA2). Including the novel G87W 
mutation, nine different mutations have been identified, of which eight occur in the 
LCCL domain (V66G, W117R, G88E, P51S, I109N, A119T, V104del, G87W 4,10,13-
16). A recent study by Street et al. reported on the first DFNA9 mutation in the 
vWFA2 domain (C542F).17  Liepinsh et al. showed that, except for W117R, all the 
other then known mutations (P51S, V66G, G88E, I109N, W117R) in the LCCL 
domain disrupt its normal structure and lead to protein misfolding of this domain.18 
Interestingly, histopathological examination of temporal bone sections revealed 
the presence of eosinophilic glycosaminoglycan deposits in the cochlea, macula 
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and crista of DFNA9 patients.19,20 Recently it was shown that these deposits 
contain cochlin.21 
In this report we describe the clinical characteristics of a DFNA9 family with a 
novel mutation in the COCH gene, resulting in an amino acid substitution G87W in 
the LCCL domain of cochlin. The identification of this novel mutation is reported in 
a separate genetic paper by Collin et al.15 
 
 
PATIENTS & METHODS 
Patients 
The proband of this family presented to our Otorhinolaryngology department for 
genetic counseling for his progressive sensorineural hearing impairment. Based 
on the family history and the clinical presentation, the diagnosis DFNA9 was 
suspected and confirmed by mutation analysis of the COCH gene. A novel 
mutation, G87W, was detected and is described in a separate report by Collin et 
al.15 After written informed consent had been obtained from the proband and other 
participating family members, a family investigation was performed and a pedigree 
was constructed (Figure 1). The study was approved by the local medical ethics 
committee. Medical history was taken from all participants, paying attention to 
hearing impairment, vestibular and ocular symptoms. Furthermore, concomitant 
disease, use of medication and any other possible cause of acquired deafness 
were ruled out. After micro-otoscopic examination, pure tone audiometry was 
performed. Clinically affected individuals also underwent speech audiometry. 
Vestibular function was tested in 16 family members (12 mutation carriers). Thirty 
family members (10 mutation carriers) underwent ocular examination as part of an 
ophthalmological research project in 4 DFNA9 families.8 Blood samples were 
collected from 17 affected family members, 25 presumably unaffected family 
members and 6 spouses for the purpose of mutation analyses. Previous medical 
records and audiograms, where available, were traced to enable individual 
longitudinal analysis. 
 
Audiometry and data analysis 
Audiometric examination comprised conventional pure-tone audiometry in a 
sound-treated room according to the International Organization for 
Standardization (ISO) standards 389 and 8253-1.22,23 The individual 95th 
percentile threshold values of presbyacusis in relation to the patient’s sex and age 
were derived for each frequency using the ISO 7029 method.24 Individuals were 
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considered affected if the best hearing ear showed thresholds beyond the 95th 
percentile threshold values for presbyacusis. 
Similar to the previously reported analysis of the P51S COCH mutation carriers 5, 
cross-sectional binaurally averaged threshold data (air-conduction level in 
decibels of hearing loss) were plotted against age for each frequency and 
analyzed using nonlinear regression analysis (threshold on age). An attempt was 
made to fit a sigmoidal response curve with a variable slope (Prism 3, GraphPad, 
San Diego, CA, U.S.A.) as previously described.25 The level of significance used 
in all tests was p = 0.05.  
Speech audiometry was performed under the above-mentioned conditions using 
phonetically balanced standard Dutch consonant-vocal-consonant word lists. The 
maximum phoneme recognition score (percentage correct, mean value for both 
ears) was obtained from monaural performance-intensity curves and was 
analyzed in relation to age and to pure-tone average (mean value for both ears) at 
the frequencies of 1, 2, and 4 kHz (PTA 1,2,4 kHz). Non-linear regression analysis 
was performed to fit individual longitudinal scores for the present G87W carriers. 
The age of onset and the onset level (i.e. X90) were defined at a recognition score 
of 90% in cross-sectional performance (Y) versus age or performance versus 
impairment (X) plots, respectively. For X90 > X > X60, a straight line was also fitted 
to simplify the results and to obtain an estimate of local average slope that was 
called deterioration rate in the score-against-age plot and deterioration gradient in 
the score-against-PTA1,2,4 kHz plot.26 A previously described group of subjects 
with only presbyacusis was used as a reference group.27 Only those subjects with 
presbyacusis who had either a matching age and/or degree of impairment by PTA 
1,2,4 kHz were used for comparison purposes. 
 
Vestibulo-ocular examination and data analysis 
A total of 16 family members underwent vestibular and ocular motor tests, 12 of 
which were mutation carriers. The tests included evaluation of the vestibulo-ocular 
reflex, using electronystagmography with computer analysis and saccadic, smooth 
pursuit, and optokinetic nystagmus responses. Vestibular stimulation comprised 
rotatory and caloric tests. Details and normal values have been previously 
described.28 The analysis of the vestibulo-ocular reflex focused on the dominant 
time constant (T, in seconds) derived from (90°/s) velocity-step test responses in 
either direction. Because this parameter shows a lognormal distribution 29, the 
geometric mean for both nystagmus directions was used for further evaluation; the 
90% (P5-P95) confidence interval for T was 13 to 23 seconds. An arbitrary zero (T 
= 0) was assigned to rotatory responses showing vestibular areflexia with no or 
 Phenotype of a novel DFNA9/COCH (G87W) mutation 
77 
just a few nystagmus beats. The above-mentioned procedure for fitting a 
sigmoidal curve was also applied to the T versus age data. 
 
 
RESULTS 
After written informed consent had been obtained from the proband and all 
participating family members, a pedigree was constructed (Figure 1). Twenty-five 
persons were affected by history, 17 of which are alive. Blood samples were 
obtained from 47 individuals for genetic analysis. Audiometry was performed 
and/or audiograms could be retrieved from elsewhere in 48 individuals and 
revealed that 17 individuals were affected. An autosomal dominant pattern of 
inheritance is apparent. The case histories and physical examinations excluded 
syndromic involvement. Most clinically affected individuals reported bilateral, 
slowly progressive hearing loss with mean subjective onset age of 43 years 
(range 10 - 66 years). Varying vestibular symptoms were reported by 15 of them 
(individuals III:14, III:16, III:20, III:22, III:32, III:35, III:39, III:45, III:49, III:72, III:81, 
III:83, IV:18, IV:21, IV:27) including instability, especially in the dark, vertigo, and a 
tendency to fall. No Meniere-like symptoms were reported. Mean subjective onset 
age of vestibular symptoms was 51 years (range of 30 – 65 years) and in all 
patients vestibular symptoms occurred following symptoms of hearing impairment. 
 
 
Figure 1. Simplified pedigree of Family W05-196 with nonsyndromic autosomal dominant 
hearing loss and vestibular impairment. Square, male; circle, female; open symbol, 
clinically unaffected; solid symbol, clinically affected; slash, deceased individual. 
 
 
Recently, we showed that the observed phenotype is caused by a novel missense 
mutation in the COCH gene (G87W).15 The G87W mutation was present in all 
affected individuals but not in the non-affected individuals aged above 43 years. 
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Genetic analysis revealed a total of 28 mutation carriers, 17 of which were 
clinically affected. All clinically unaffected mutation carriers were under 43 years of 
age.  
 
Audiometry 
Pure tone thresholds related to age 
All threshold data measured for the G87W mutation carriers are plotted against 
age in Figure 2. Individual longitudinal measurements are combined with single 
snapshot measurements. Also, the last-visit measurement among the longitudinal 
data is represented as a snapshot measurement. Neither the cross-sectional nor 
the individual longitudinal threshold data permitted reliable fitting of sigmoidal 
curves, for which reason no curves pertaining to these data are shown in Figure 2. 
There was a lack of data in the middle ages. For this reason, the steeply sloping 
part of the sigmoidal curve, which pertains to the period of maximum progression 
in hearing impairment, could not be fitted in a reliable way. Most of the cross-
sectional data related to either young ages, where no tangible impairment was 
seen, or to advanced ages, where progression was decreasing or had almost 
stopped. Most of the longitudinal data had been obtained at these more advanced 
ages. 
For comparison, the sigmoidal curves previously fitted to the data of G88E and 
P51S mutation carriers 5,25 are included in Figure 2, showing that the development 
of hearing impairment in the present G87W mutation carriers resembles that in the 
G88E and P51S mutation carriers. For the G88E mutation carriers a distinct 
tendency to show later onset ages and/or relatively more limited impairment in the 
high frequency range at the more advanced ages can be noticed. 
 
Speech recognition scores 
Figure 3 shows the single snapshot measurements of the phoneme scores in the 
present G87W mutation carriers. Onset age X90 was 49 years, from which the 
recognition score deteriorated by 0.99% per year on average. The 90% 
recognition score was found at a PTA1,2,4 level of 51 dB and deteriorated by 
0.75% per year for X90 > X > X60. The G87W mutation carriers showed worse 
speech recognition scores than patients with only presbyacusis at similar ages 
(Figure 3, left panel). The scores of G87W mutation carriers tend to be better than 
those obtained for patients with a G88E or a P51S mutation carriers, whose data 
were fitted with almost coinciding (dotted and dashed) curves (Figure 3).  
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Figure 2. Mixed single snapshot (open circles) and longitudinal individual (binaural mean 
air-conduction threshold) measurements (small symbols, different ones for each G87W 
mutation carrier, with connection lines) are shown for the present family without any fitted 
curve, together with sigmoidal lines that are identical with the curves presented for the 
G88E mutation carriers (dotted line) and the measurements for the P51S mutation 
carriers (dashed lines) included in the report by Kemperman et al.25 There are two dashed 
curves for P51S carriers, the uppermost one fitted to the original threshold data, the 
lowermost fitted to the same data corrected for zero offset threshold at age zero. 
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Figure 3. Single snapshot measurements for the G87W mutation carriers (open circles) of 
binaural mean phoneme recognition scores against age (left) and against binaural mean 
pure-tone average at 1, 2 and 4 kHz (right). The solid line is a sigmoidal curve fitted to 
these measurements as previously described.26 The dotted and dashed curves are 
identical to similarly fitted curves previously established for G88E and P51S mutation 
carriers, respectively.5,25 The asterisks represent single snapshot measurements for those 
patients with only presbyacusis 27 who had matching ages and levels of hearing 
impairment. 
 
As related to the level of hearing impairment, the scores for patients with the 
G87W mutation appear to be better at similar levels of impairment than those with 
a G88E or P51S mutation. The scores of P51S carriers clustered with those of 
patients with only presbyacusis (Figure 3, right panel). 
 
Vestibulo-ocular examination 
Figure 4 illustrates the comparison of vestibulo-ocular reflex data between carriers 
of the different mutations as reflected by the decrease in dominant time constant 
with advancing age. Reliable values for onset level and age at onset of 
deterioration could not be established, because of a lack of data obtained from 
G87W mutation carriers (open circles) who had just started to show deterioration 
in vestibular function. However, the conclusion seems justified that the data for 
G87W showed a tendency to cluster with the data for G88E rather than with the 
data for P51S. This implies that, similar to patients with G88E, G87W carriers with 
vestibular areflexia are found at relatively advanced ages, compared to P51S 
patients. Fisher’s exact test detected a significant difference in relative frequency 
of vestibular areflexia between the patients with G87W and the previously 
described patients with P51S.25 At the age of 40 years and higher, 52 of 64 P51S 
mutation carriers showed complete vestibular areflexia, whereas only 2 of the 
present 10 G87W mutation carriers showed this feature (p=0.00026). The relative 
frequency of vestibular areflexia in the present patients (2 of 10) was similar to 
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that (2 of 8) of the previously described G88E mutation carriers for the same age 
group.25 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Mean vestibulo-ocular reflex time constant T plotted against age for the G87W 
mutation carriers (open circles and solid curve). The dotted and dashed curves are 
identical to similarly fitted curves previously established for G88E and P51S mutation 
carriers, respectively.5,25 
 
 
DISCUSSION 
Many reports on the clinical characteristics of DFNA9 as well as on more 
fundamental aspects of the COCH gene and its protein cochlin have contributed 
to our knowledge of this progressive cochleovestibular disorder. 
Generally, hearing impairment in DFNA9 has a mid-life onset and first affects the 
high frequencies, followed by the middle and low frequencies, resulting in 
progressive loss in the low to middle frequencies coupled with a high frequency 
slope.30 
In the Dutch and Flemish population, the P51S mutation in the COCH gene is 
most frequently encountered, and is considered a founder mutation.31 Progression 
of hearing impairment starts from about 40 years of age onwards and vestibular 
deterioration appears to start about 9 years earlier and progresses more rapidly 
than hearing impairment.5 Recently, Kemperman et al.25 reported on a Dutch 
DFNA9 family with the G88E mutation, previously reported to occur in a family 
originating from the United States of America.10,19,20 Similar to its American 
counterpart, the Dutch DFNA9 family with the G88E COCH mutation showed a 
subjective onset age of hearing impairment in the fifth and sixth decades of life 
and vestibular dysfunction followed hearing impairment. 
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The present family with the G87W mutation in COCH shows similar characteristics 
of cochleovestibular impairment as other families with different mutations in the 
COCH gene. Reported onset age is around 43 years and sensorineural hearing 
impairment always starts at the high frequencies. Later on, progression also 
involves the lower and mid frequencies. The longitudinal data in figure 2 show 
more variability at the low frequencies than at the high frequencies. This might 
reflect the existence of relatively slow and/or late starters. Of 28 mutation carriers 
11 did not show the DFNA9 phenotype. Their ages range between 22 and 43 
years, which is below the onset age of hearing impairment in this family. 
Therefore, these figures presumably do not represent true non-penetrance, but 
more likely reflect the late onset age of clinical symptoms, characteristic for 
DFNA9. This is corroborated by the finding that penetrance is 100% in mutation 
carriers over 43 years of age. 
The available audiometric data clustered in the young and more advanced age 
groups. We were therefore unable to reliably fit the steeply sloping part of the 
sigmoidal curve to the threshold-on-age data for each frequency. This steep part 
of the sigmoidal curve corresponds to the rapid progression of hearing impairment 
that has been shown to occur in mid-age P51S and G88E mutation carriers.5,25 In 
figure 2 the sigmoidal curves fitted to audiometric data of several P51S families 5 
and of a Dutch G88E 25 family are added for comparison to the present G87W 
family. Although the progression of hearing impairment with advancing age was 
fairly similar for all three mutations, G87W mutation carriers seemed to be more 
similar to P51S mutation carriers in terms of onset age and level of progression, 
especially in the high frequencies. However, the curves at these frequencies 
showed a downward bias consequential to the exclusion of out-of-scale 
thresholds.25 
When comparing the vestibulo-ocular time constant values, the data from the 
present G87W family seem more similar to those of the G88E family than to those 
of the P51S families. The relative frequency of complete vestibular areflexia at 
age 40 years or older differed significantly between the present G87W mutation 
carriers and the previously described P51S mutation carriers, whereas no 
difference was found between G87W and G88E mutation carriers.5,25 
Although all the presently identified allelic variants of DFNA9 generally show 
comparable clinical characteristics, when taking a closer look to the results of 
audiometric and vestibular tests, differences in terms of onset-age and rate and/or 
degree of progression are observed. Based on our current knowledge on DFNA9, 
the COCH gene and its protein cochlin, we do not have an explanation for such 
differences. All known mutations except one - C542F 17 - occur in the LCCL 
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domain of the COCH gene, and, in the case of G88E and G87W, the mutation 
occurs in the neighboring amino acid. Several COCH mutations, including G88E 
and P51S, have been shown to result in misfolding of the protein 18 and this is 
likely to be true for the present G87W mutation.15 
The acidophilic acellular deposits found in temporal bones of DFNA9 patients 
were localized to the spiral ligament, limbus, osseous spiral lamina, stria 
vascularis, and stroma of the maculae and cristae.20 Recently, Robertson et al. 
showed in post-mortem temporal bone of a patient with a P51S mutation that the 
eosinophilic acellular deposits in mesodermal structures of cochlea and 
vestibulum indeed contain cochlin.21 Since cochlin deposits occur in areas 
surrounding neurons and their processes, but not in the neuronal cell bodies or 
processes themselves, neuronal and axonal damage may be secondary and 
caused by strangulation of these structures, resulting in hearing impairment and 
vestibular dysfunction. Disruption of ion homeostasis in endolymph has also been 
suggested to play a role in the pathogenesis of this disorder.21 Progression of 
hearing impairment and vestibular dysfunction may be explained by ongoing 
precipitation of mutant cochlin, suggesting that the development and progression 
of these clinical entities is a cumulative process. The difference in onset age and 
rate of progression between the different mutations in the COCH gene might be 
explained by the fact that different mutations cause different rates, and perhaps 
also different extents, of precipitation of cochlin.   
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ABSTRACT 
This paper aims to report audiological and vestibular characteristics of a Dutch 
DFNA9 family with a novel mutation, I109T, in the LCCL domain of COCH.  
From the Dutch family with the novel I109T COCH mutation audiometric data 
were collected and analyzed longitudinally. Results were compared to those 
obtained in previously identified P51S, G88E and G87W COCH mutation carriers. 
Special attention was also given to a comparison of age-related features, such as 
progressive hearing loss and vestibular impairment. 
A novel mutation (I109T) in COCH segregates with hearing impairment and 
vestibular dysfunction in the present family. Pure-tone thresholds, phoneme 
recognition scores, and vestibular responses of the I109T mutation carriers were 
essentially similar to those previously established in the P51S, G87W and G88E 
mutation carriers. Deterioration of hearing in the I109T mutation carriers started at 
age 43 years and vestibular function started to deteriorate at least 7 years later.  
From these data it can be concluded that the phenotype associated with the novel 
COCH (I109T) mutation is largely similar to that associated with the P51S and 
G88E mutation carriers. However, subtle differences in terms of onset age and 
rate of progression seem to exist. 
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INTRODUCTION 
The autosomal dominant non-syndromic hearing disorder DFNA9 is characterized 
by progressive high-frequency sensorineural hearing impairment with midlife 
onset. Hearing deteriorates completely over a few decades of life, with annual 
threshold deterioration (ATD) values of 2-7 dB eventually leading to residual 
hearing or (sub)residual hearing threshold levels.1-3 Speech recognition is 
relatively poor, showing features similar to presbycusis. Apart from DFNA11, 
DFNA9 is the only locus for autosomal dominant non-syndromic hearing 
impairment known to exhibit substantial concomitant vestibular impairment. 
Vestibular dysfunction develops gradually and may eventually lead to vestibular 
areflexia.4 Ménière-like features are not unusual.5,6 
DFNA9 was linked to chromosome 14q12-13 in 1996 7 and mutations in the 
COCH gene were found to be responsible for the development of the disorder.3,8,9 
COCH has 12 exons that encode a protein called cochlin, which is a major 
constituent of the inner ear extracellular matrix.10 To date, nine different mutations 
in COCH have been identified (V66G, W117R, G88E, P51S, I109N, A119T, 
V104del, G87W, C542F.8,11-15  Liepinsh et al. showed that, except for W117R, all 
the other then-known mutations (P51S, V66G, G88E, I109N, W117R) disrupt the 
normal structure of the protein and lead to protein misfolding.16 Interestingly, 
histopathological examination of temporal bone sections revealed the presence of 
eosinophilic glycosaminoglycan deposits in the cochlea, maculae and cristae of 
DFNA9 patients.17,18 Recently it was shown that these deposits contain cochlin.19 
Recently, ophthalmologic examination in a large Dutch DFNA9 family with the 
P51S mutation in COCH revealed a peculiar pattern of vertical corneal striae.20 A 
group of family members of the current DFNA9 family was therefore subjected to 
detailed ophthalmologic examination. 
Here we report on a novel mutation in the LCCL domain of COCH, I109T, found in 
a Dutch DFNA9 family. Both genetic and clinical characteristics will be presented. 
The audiological and vestibular characteristics will be analysed in detail and 
compared to those previously described for P51S, G87W and G88E mutation 
carriers.  
 
 
PATIENTS & METHODS 
Patients 
Based on the clinical presentation in combination with the family history, the 
diagnosis DFNA9 was suspected for the proband. This was confirmed by mutation 
analysis of the COCH gene. A novel mutation in the LCCL domain of COCH, 
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I109T, was found (see below) and a family study was initiated. After written 
informed consent had been obtained from all 14 participating family members, a 
family investigation was performed and a pedigree was constructed (Figure 1). 
The study was approved by the local medical ethics committee. Medical history 
was taken from all participants, paying attention to hearing impairment, vestibular 
and ocular symptoms. Furthermore, concomitant disease, use of medication and 
any other possible cause of acquired deafness were ruled out. After micro-
otoscopic examination, pure tone audiometry was performed. Clinically affected 
individuals also underwent speech audiometry. Vestibular function was tested in 7 
affected family members. Blood samples were collected from 11 affected family 
members, 2 presumably unaffected family members and 1 spouse for the purpose 
of mutation analysis. Available previous medical records and audiograms were 
traced to enable individual longitudinal analysis. 
 
Mutation analysis  
Exons 4 and 5 including intron-exon boundaries of the COCH gene were 
amplified, using forward primer 5’-CTTAAATCTCACACTGTAGTC-3’ and reverse 
primer 5’-AAAGGAAATAATCACGTCTGC-3’ for exon 4, and forward primer 5’-
TCTTTAGATGACTTCCCTGATGAG-3’ and reverse primer 5’-
TCACAGGTTTTTCCATCAAGGTTA-3’ for exon 5 under standard PCR 
conditions. Subsequently, PCR fragments were purified using QiaQuick spin 
columns (Qiagen) and completely sequenced using the corresponding forward 
primers with the ABI PRISM Big Dye Terminator cycle sequencing V2.0 ready 
reaction kit and an ABI PRISM 3730 DNA analyzer (Applied Biosystems).  
 
Audiometry and data analysis 
Audiometric examination comprised conventional pure-tone audiometry in a 
sound-treated room. The individual 95th percentile threshold values of presbycusis 
in relation to the patient’s sex and age were derived for each frequency using the 
ISO 7029 method.21 Individuals were considered affected if the best hearing ear 
showed thresholds beyond the 95th percentile threshold values for presbycusis. 
Cross-sectional binaurally averaged threshold data (air-conduction level in 
decibels hearing level) were plotted against age for each frequency and analyzed 
using linear regression analysis (threshold on age). The regression coefficient 
(slope) was called annual threshold deterioration (ATD), expressed in dB per year. 
Progression was significant if the 95% confidence interval of the ATD did not 
include zero. If significant progression was present, age-related typical audio-
grams (ARTA) were constructed following a method previously described 
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elsewhere.22 Individual longitudinal analysis of threshold values on age was only 
performed in clinically affected persons with three or more consecutive 
measurements and an overall follow-up period of at least 3 years. The level of 
significance used in all tests was p=0.05.  
Speech audiometry was performed using phonetically balanced standard Dutch 
consonant-vocal-consonant word lists. The maximum phoneme recognition score 
(percentage correct, mean value for both ears) was obtained from monaural 
performance-intensity curves and was analyzed in relation to age and to pure-tone 
average (mean value for both ears) at the frequencies of 1, 2, and 4 kHz (PTA 1,2,4 
kHz). Non-linear regression analysis was performed using a dose-response curve 
with variable slope to fit individual longitudinal scores for the I109T carriers.23 The 
age of onset and the onset level (i.e. X90) were defined at a recognition score of 
90% in cross-sectional performance (Y) versus age or performance versus 
impairment (X) plots, respectively. Between the scores of 90% and 40%, a straight 
line was also fitted to simplify the results and to obtain an estimate of local 
average slope that was called deterioration rate in the score-against-age plot and 
deterioration gradient in the score-against-PTA1,2,4 kHz plot.23  
A previously described group of subjects with only presbycusis was used as a 
reference group.24 
 
Vestibulo-ocular examination and data analysis 
Seven mutation carriers (III:5, III:7, III:9, III:11, IV:3, IV:5 and IV:6) underwent 
vestibular and ocular motor tests. The tests included evaluation of the vestibulo-
ocular reflex, using electronystagmography with computer analysis and saccadic, 
smooth pursuit, and optokinetic nystagmus responses. Vestibular stimulation 
comprised rotatory and caloric tests. Details and normal values have been 
previously described.25 The analysis of the vestibulo-ocular reflex focused on the 
dominant time constant (T, in seconds) derived from (90°/s) velocity-step test 
responses in either direction. Because this parameter shows a lognormal 
distribution 26, the geometric mean for both nystagmus directions was used for 
further evaluation; the 90% (P5-P95) confidence interval for T is 13 to 23 seconds. 
An arbitrary zero (T = 0) was assigned to rotatory responses showing vestibular 
areflexia with no or just a few nystagmus beats. The above-mentioned procedure 
for fitting a dose-response curve with a variable slope was also applied to the T 
versus age data. 
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Ophthalmologic examination 
Four mutation carriers were subjected to a detailed ophthalmologic examination 
(III:5, III:11, IV:2 and IV:5) Slit-lamp examination was performed with and without 
fluorescein paper strips, using the slit-lamp microscope with a broad beam and a 
cobalt blue filter. Corneas were photographed by tangential illumination of the 
limbus with white light and after application of fluorescein. Fluorescein was 
instilled in the lower fornix of the eyes. The patient was asked to blink several 
times. Rubbing the eyes was avoided. The corneal surface curvature was 
measured using the Javal keratometer. For testing intraocular pressure, 
Goldmann applanation tonometry (normal value: 12-20 mmHg) was used. The 
visual acuity was assessed and the Schirmer test was used to evaluate tear 
production (normal value: >15 mm per 5 min). 
 
 
RESULTS 
After written informed consent had been obtained from all participating family 
members, a pedigree was constructed (Figure 1). Thirteen persons were affected 
by history, 11 of which were alive at the time of the study. Blood samples were 
obtained from 14 individuals for genetic analysis. Audiometry was performed 
and/or audiograms could be retrieved from elsewhere in 13 individuals and 
revealed that 11 individuals were affected. An autosomal dominant pattern of 
inheritance is apparent. The case histories and physical examinations excluded 
syndromic involvement. 
 
 
Figure 1. Simplified pedigrees of the Dutch DFNA9 family W05-427 with the I109T 
mutation in COCH. Square, male; circle, female; open symbol, clinically unaffected; solid 
symbol, clinically affected; slash, deceased individual;  plus, mutation carrier. 
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Most clinically affected individuals reported bilateral, progressive hearing loss with 
a mean subjective onset age of 43 years (range 35-52 years). Varying vestibular 
symptoms were reported by 5 of them (individuals III:1, III:4, III:5, III:7, III:11) 
including instability, especially in the dark, vertigo, and a tendency to fall. No 
Ménière-like symptoms were reported. Mean subjective onset age of vestibular 
symptoms was 65 years (range of 58-73 years) and in all patients vestibular 
symptoms occurred following symptoms of hearing impairment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Partial sequence of the COCH gene in an affected individual, carrying the 
heterozygous c.326C>T  nucleotide substitution, and in a non-affected family member. 
The resulting amino acid substitution (I109T) in the affected individuals is indicated above 
the sequence. 
 
 
Mutation analysis  
Results of audiometric analysis and vestibular function tests of the affected 
individuals in this study were consistent with previous reports on DFNA9-family 
studies.27 Therefore, we decided to analyze COCH as a candidate gene. Since 
the majority of mutations found in this gene are within the region encoding the 
LCCL domain, exons 4 and 5 (that encode this domain) were completely 
sequenced in one of the affected individuals. Our analysis revealed the presence 
of a heterozygous nucleotide substitution (c.326C>T) that is predicted to result in 
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the substitution of a threonine for an isoleucine (I109T) (Figure 2). Mutation 
analysis in the complete family showed that this nucleotide substitution was 
present in all affected individuals and not in the non-affected family members. The 
mutation was found not to be present in > 96 ethnically- and age-matched control 
individuals.  
 
The replacement of this particular isoleucine residue by an asparagine has 
previously been shown to cause DFNA9 in an Australian family.14 The highly 
conserved isoleucine residue at position 109 in the cochlin protein is an amino 
acid with a nonpolar side chain, while both an asparagine residue as well as a 
threonine residue have uncharged but polar side chains that are relatively 
hydrophilic. Therefore, the substitution of the isoleucine by either an asparagine or 
a threonine will probably have a similar effect on cochlin structure or function, and 
thus may cause a similar DFNA9 phenotype. 
 
Audiometry 
Pure tone thresholds related to age 
The audiograms that were included in the cross-sectional analysis are shown in 
figure 3. High-frequency hearing impairment had already started before the age of 
40 years, as evidenced by the downsloping audiograms in figure 3. From the late 
40s to the early 50s the low frequency threshold levels started to deteriorate 
resulting in low-frequency threshold levels in the order of 80 dB and high-
frequency threshold levels in the order of 100-120 dB. 
All threshold data measured for the I109T mutation carriers are plotted against 
age in figure 4, individual longitudinal measurements as well as single-snapshot 
measurements. Cross-sectional analysis only included the latter, as well as the 
last-visit measurement among the longitudinal (open circles). Neither the cross-
sectional nor the individual longitudinal threshold data permitted reliable fitting of 
sigmoidal curves, for which reason no curves pertaining to these data are shown 
in figure 4. The sigmoidal curves fitted to audiometric data of several P51S 
families 4 and of a Dutch G88E family 27 were added to figure 4 for comparison to 
the present I109T family. Although the progression of hearing impairment with 
advancing age was fairly similar for all three mutations, I109T mutation carriers 
seemed to be more similar to P51S mutation carriers in terms of onset age and 
level of progression, especially in the high frequencies. The data pertaining to the 
higher frequencies show less variability than those pertaining to the lower 
frequencies.  
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Figure 3. Individual audiograms of I109T mutation carriers from family W05-427, ordered 
by age (from top left to bottom right). Shown are AC threshold levels for the right (open 
circles) and for the left (crosses) ear. Above each audiogram the age in years (y) is given. 
The dotted line represents the 95th percentile AC threshold levels of presbycusis for a 
given age and sex according to ISO 7029.21 
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Figure 4. Mixed single-snapshot (open circles) and longitudinal individual measurements 
(small symbols with connection lines, different symbols for each I109T mutation carrier) 
are shown for each frequency separately. A dose-response curve with a variable slope 
could not be fitted to the data. Sigmoidal curves fitted to data pertaining to P51S (2 
dashed curves, one relating to an apparent congenital offset level) and G88E (dotted 
curve) mutation carriers are included for comparison. The number in the lower right-hand 
corner of each panel represents the average threshold deterioration value in dB/year 
derived from cross-sectional linear regression analysis. 
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Linear regression analysis was performed on cross-sectional threshold-on-age 
data (open circles in Figure 4) and showed significant progression with advancing 
age for each frequency. ATD values range from 1.0 to 2.8 dB/year with the 
highest values at the lower frequencies (Figure 4, italic numerals in lower right-
hand corner). Based on the results of cross-sectional linear regression analysis, 
ARTA were constructed as shown in figure 5 (left panel). The age range (40-70 
years) corresponds to the data that were available for cross-sectional analysis. 
From figures 4-5 it is clear that at 40 years of age deterioration of threshold levels 
in the higher frequencies had already occurred. The ARTA from G88E and P51S 
mutation carriers 27 were added for comparison. The ARTA from the I109T 
mutation carriers looks more similar to those from P51S than to those from G88E 
mutation carriers. 
 
 
Figure 5. Age-related typical audiograms (ARTA) derived from cross-sectional regression 
analysis of mean AC threshold levels for the present family W05-427 (left panel). For 
comparison the ARTA pertaining to the P51S (centre panel) and G88E (right panel) 
mutation carriers are shown. Italic numerals indicate age in years. 
 
 
Speech recognition scores 
Figure 6 shows the single-snapshot measurements of the phoneme scores in the 
I109T mutation carriers. 
Onset age X90 was 43 years, from which age the recognition score deteriorated by 
2.0% per year on average. The 90% recognition score was found at a PTA1,2,4 
level of 55dB and deteriorated by 1.3% per dB between the scores of 90% and 
40%. 
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The I109T mutation carriers showed similar speech recognition scores as patients 
with only presbacusis  (Figure 6, left panel). The scores of I109T mutation carriers 
tended to be worse at given ages than those obtained for patients with a G87W, 
G88E or P51S mutation (Figure 6). The data pertaining to G88E and P51S 
mutation carriers were fitted with almost coinciding (dotted and dashed) curves. 
As related to the level of hearing impairment, the scores for patients with the 
I109T mutation appeared to be better at similar levels of impairment than those 
with a G88E or P51S mutation and comparable to those with a G87W mutation. 
They seemed to be better than those for the presbacusis patients. 
 
 
Figure 6. Single-snapshot measurements for the I109T mutation carriers (open circles) of 
binaural mean phoneme recognition scores against age (left panel) and against binaural 
mean pure-tone average at 1, 2 and 4 kHz (right panel). The solid line is a sigmoidal 
curve fitted to these measurements as previously described.23 The dotted and dashed 
curves overlap and are identical to similarly fitted curves previously established for G88E 
and P51S mutation carriers, respectively.4,27 The dotted-and-dashed curve was previously 
established for G87W mutation carriers.28 The asterisks represent single-snapshot 
measurements for those patients with only presbacusis.24 
 
 
Vestibulo-ocular examination 
Figure 7 illustrates the comparison of vestibulo-ocular reflex deterioration between 
carriers of the different mutations as reflected by the decrease in dominant time 
constant with advancing age. Reliable values for onset level and age at onset of 
deterioration could not be established, because of a lack of data obtained from 
I109T mutation carriers (open circles). However, the conclusion seems justified 
that the data for I109T showed a tendency to cluster with the data for G88E and 
G87W rather than the data for P51S. This implies that, similar to patients with 
G88E and G87W, I109T carriers with vestibular areflexia are found at relatively 
advanced ages, compared to P51S patients. Fisher’s exact test detected a 
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significant difference in the relative frequency of vestibular areflexia between the 
patients with I109T and the previously described patients with P51S.27 At the age 
of 40 years and higher, 52 of 64 P51S mutation carriers showed complete 
vestibular areflexia, whereas only 1 of the 7 presently tested I109T mutation 
carriers showed this feature (p=0.0008). The relative frequency of vestibular 
areflexia in the present patients (1 of 7) was similar to that (2 of 8 and 2 of 10) of 
the previously described G88E and G87W mutation carriers for the same age 
group, respectively.27,28 
 
 
 
 
 
 
 
 
 
 
Figure 7. Mean vestibulo-ocular reflex time constant T plotted against age for the I109T 
mutation carriers (open circles and solid curve). The dotted, dashed and dotted-and-
dashed curves are identical to similar fitted curves previously established for G88E, P51S 
and G87W mutation carriers, respectively.4,27,28 The dotted horizontal lines delineate the 
90% confidence interval (13-23s) of the geometric mean of the time constant T for both 
nystagmus directions. 
 
 
Ophthalmologic examination 
In none of the 4 mutation carriers that underwent ophthalmological examination, 
the pattern of vertical corneal striae was detected. Intra-ocular pressure ranged 
between 12-16 mm Hg, which is within normal limits. Schirmer’s lacrimation test 
and Javal keratometry were also within normal limits (data not shown). 
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DISCUSSION 
The present family with the I109T mutation in COCH shows similar characteristics 
of hearing impairment as other families with different mutations in the COCH 
gene. Reported onset age is around 43 years and sensorineural hearing 
impairment always started at the high frequencies. At a more advanced age, 
progression also involves the lower and mid frequencies. Interestingly, the highest 
ATD values calculated from cross-sectional linear regression analysis occur in the 
lower frequencies. This finding is probably due to the fact that threshold 
deterioration in the higher frequencies had already started before the age of 42 
years (age of youngest patient in the present family). High ATD values for the 
higher frequencies presumably occur before this age. Also, the longitudinal data in 
figure 3 show more variability at the low frequencies than at the high frequencies. 
This might reflect variability in onset age at which mid and/or low frequency 
threshold deterioration starts. 
All I109T mutation carriers (42-73 years of age) showed the DFNA9 phenotype. 
So, 100% penetrance applies to this study sample. Age-dependant penetrance 
has been reported for the DFNA9 phenotype and reflects the relatively late onset 
age of the disorder.27,28  
In mid-life P51S and G88E mutation carriers a period of rapid deterioration of 
hearing threshold levels occurs.4,27 This period of rapid progression probably 
applies to the present family as well, as judged by the audiograms presented in 
figure 2, from which it can be appreciated that a large threshold increase occurs at 
ages between 48 and 56 years. In addition, the longitudinal data presented in 
figure 3 clearly show that, except for 8kHz, the relatively greatest individual 
progression occurred in the fifth and sixth decade of life. Although the progression 
of hearing impairment with advancing age was fairly similar for all three mutations, 
I109T mutation carriers seemed to be more similar to P51S mutation carriers in 
terms of onset age and level of progression, especially in the high frequencies. 
(figure 3)  
The ARTA from three DFNA9 families with different mutations in COCH (Figure 5) 
allow for easy comparison of audiometric characteristics between these families. 
The I109T mutation carriers compare better to the P51S mutation carriers than to 
G88E mutation carriers.  
The vestibular data from the present I109T family seem more similar to those from 
the G88E and G87W families than to those from the P51S families. The relative 
frequency of complete vestibular areflexia at age 40 years or older differed 
significantly between the present I109T mutation carriers and the previously 
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described P51S mutation carriers, whereas no difference was found between 
I109T and G88E and between I109T and G87W mutation carriers.4,27,28 
Bischoff et al. reported on a pattern of vertical corneal striae present in mutation 
carriers of two DFNA9 families with a P51S mutation and one DFNA9 family with 
a G88E mutation.20,27 This pattern was not found in mutation carriers of a family 
with a G87W mutation.20,28 In 4 mutation carriers of the present family this pattern 
of vertical corneal striae was not detected, so, this finding may be mutation 
specific. 
From these data it can be concluded that cochlear involvement in DFNA9 is 
similar across the different COCH mutations, but that penetrance and extent of 
vestibular involvement seem to vary between them. The latter may also apply for 
corneal involvement. These conclusions should however be treated with caution, 
because they are based on data of relatively small numbers of mutation carriers of 
each mutation except for the P51S mutation. The P51S mutation in COCH is 
relatively common in The Netherlands and Belgium so phenotype descriptions are 
more reliable as they are based on large amounts of data.  
Currently, we do not have an explanation for the apparent differences in clinical 
presentation of DFNA9 between the different COCH mutations. All known 
mutations except one - C542F 15 - occur in the LCCL domain of the COCH gene, 
and, in the case of G88E and G87W, the mutation occurs in the neighboring 
amino acid. Several COCH mutations, including G88E, P51S and I109N, have 
been shown to result in misfolding of the protein and this is likely to be true also 
for the present I109T mutation.16 It has recently been demonstrated that the 
acidophilic acellular deposits found in temporal bones of DFNA9 contain 
cochlin.18,19 These cochlin deposits occur in areas surrounding neurons and their 
processes, but not in the neuronal cell bodies or processes themselves. So it has 
been proposed that neuronal and axonal damage is secondary and caused by 
strangulation of these structures. Ongoing precipitation of mutant cochlin could 
result in progression of hearing impairment and vestibular dysfunction. Different 
COCH mutations may result in different rates, and perhaps also different extents, 
of cochlin precipitation, which would explain the observed variation in onset age 
and rate of progression between the different COCH mutations. 
It would be interesting to compare the phenotype of the Dutch I109T family to that 
of the Australian I109N family as reported by Kamarinos et al.14, because in both 
families the amino acid isoleucine at position 109 is changed resulting in a 
threonine or an asparagine, respectively. Kamarinos et al report that the observed 
phenotype is similar compared to other then-known DFNA9 families, however, the 
audiometric data presented in that report do not allow for quantitative analysis.14 
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Overall, more clinical data on DFNA9 families carrying different COCH mutations 
are needed to provide a reliable phenotype characterisation of each mutation. 
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ABSTRACT 
This study reports on the clinical characteristics of an Australian family with 
autosomal dominantly inherited sensorineural hearing impairment (DFNA9) 
caused by an I109N mutation in COCH.  
Audiometric data from 8 mutation carriers of an Australian DFNA9 family with the 
I109N COCH mutation were retrospectively analyzed and compared to those 
obtained in previously identified DFNA9 families with P51S, V66G, G87W, G88E, 
I109T and C542F COCH mutations.  
Cross-sectional analysis of hearing levels related to age revealed that 
deterioration of hearing in the I109N mutation carriers presumably started before 
the age of 40 years. The audiometric characteristics of the I109N mutation carriers 
are essentially similar to those previously established in I109T mutation carriers 
and to a lesser extent to P51S, G87W and G88E mutation carriers.  
Although subtle differences in terms of onset age and rate of progression seem to 
exist, it can be concluded that the phenotype associated with the I09N COCH 
mutation is largely similar to that associated with the I109T, P51S, G87W and 
G88E mutation carriers. 
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INTRODUCTION 
 The autosomal dominant non-syndromic hearing disorder DFNA9 is 
characterized by progressive high-frequency sensorineural hearing impairment 
with midlife onset. Hearing deteriorates fully over a few decades of life, with 
annual threshold deterioration (ATD) values of 2-7 dB eventually leading to 
residual hearing or (sub)residual hearing threshold levels.1-3 Speech recognition is 
relatively poor, showing features similar to presbycusis that, however, occur at a 
younger-than-usual age. Apart from DFNA11, DFNA9 is the only autosomal 
dominant hearing impairment disorder known to exhibit substantial concomitant 
vestibular impairment. Vestibular dysfunction develops gradually and may 
eventually lead to vestibular areflexia.4 Ménière-like features are not unusual.5,6 
DFNA9 was linked to chromosome 14q12-13 7 and mutations in the COCH gene 
were found to be responsible for the development of the disorder.3,8,9 To date, ten 
different mutations have been identified (P51S, V66G, G87W, G88E, V104del, 
I109N, I109T, W117R, A119T and C542F.3,8,10-14 Interestingly, histopathological 
examination of temporal bone sections revealed the presence of eosinophilic 
glycosaminoglycan deposits in the cochlea, macula and crista of DFNA9 
patients.15,16 Recently it was shown that these deposits contain cochlin, the 
protein encoded by COCH.17 
In 2001, Kamarinos et al. reported on an Australian DFNA9 family with an I109N 
mutation in COCH.12 No detailed phenotype analysis of this mutation has been 
presented. For this report we have retrieved and analyzed serial audiograms of 8 
proven mutation carriers of the original Australian DFNA9/I109N family. These 
data will be presented and compared to those previously described for other 
DFNA9 families. 
 
 
PATIENTS & METHODS 
Patients 
Clinical data and serial audiograms from 8 clinically affected I109N mutation 
carriers from the original Australian family 12 were retrospectively analysed. 
 
Audiometry and data analysis 
Pure tone audiometry 
The individual 95th percentile threshold values of presbycusis in relation to the 
patient’s sex and age were derived for each frequency using the ISO 7029 
method.18 Individuals were considered affected if the best hearing ear showed 
thresholds beyond the 95th percentile threshold values for presbycusis. 
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Cross-sectional binaurally averaged threshold data (air-conduction level in 
decibels hearing level) were plotted against age for each frequency and analyzed 
using linear regression analysis (threshold on age). The regression coefficient 
(slope) was called annual threshold deterioration (ATD), expressed in dB per year. 
Progression was significant if the 95% confidence interval of the ATD did not 
include zero. If significant progression was present, age-related typical audio-
grams (ARTA) were constructed following a previously described method.19 
Individual longitudinal analysis was only performed of threshold values on age in 
clinically affected persons with three or more consecutive measurements and an 
overall follow-up period of at least 3 years. The level of significance used in all 
tests was p=0.05.  
 
Speech audiometry 
In 6 patients, also results of speech audiometry were analyzed. The maximum 
phoneme recognition score (percentage correct, mean value for both ears) was 
obtained from monaural performance-intensity curves and was analyzed in 
relation to age and to pure-tone average (mean value for both ears) at the 
frequencies 1, 2, and 4 kHz (PTA 1,2,4 kHz). Non-linear regression analysis was 
performed using a dose-response curve with variable slope to fit individual 
longitudinal scores for the I109N carriers. The age of onset and the onset level 
(i.e. X90) were defined at a recognition score of 90% in cross-sectional 
performance (Y) versus age or performance versus impairment (X) plots, 
respectively. Between the scores of 90% and 40%, a straight line was also fitted 
to simplify the results and to obtain an estimate of local average slope that was 
called deterioration rate in the score-against-age plot and deterioration gradient in 
the score-against-PTA1,2,4 kHz plot.20 
 
 
RESULTS 
A simplified pedigree of the Australian DFNA9/I109N family is shown in figure 1 
and clinical and audiometric data from 8 proven I109N mutation carriers were 
retrospectively analyzed. 
All affected family members reported bilateral, progressive hearing loss with 
subjective onset age ranging between 30 and 43 years. Varying vestibular 
symptoms were reported by 5 of them (individuals IV:1, IV:2, IV:3, IV:5 and V:2) 
including instability, especially in the dark, vertigo, a tendency to fall and head 
movement dependent oscillopsia. No Ménière-like symptoms were reported. If 
present, vestibular symptoms appeared to occur after symptoms of hearing 
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impairment had become apparent. Some affected family members reported that 
vestibular function tests had been performed in the past. However, official results 
of these tests could not be obtained. 
 
 
Figure 1. Simplified pedigree of the Australian DFNA9 family with an I109N mutation in 
COCH. Square, male; circle, female; open symbol, clinically unaffected; solid symbol, 
clinically affected; slash, deceased individual; plus, mutation carrier of which audiometric 
data was retrospectively analyzed. 
 
 
Audiometry 
Pure tone thresholds related to age 
The audiograms that were included in the cross-sectional analysis are shown in 
figure 2. In this figure, last-visit audiograms from the Australian I109N mutation 
carriers are ordered by age. High-frequency hearing impairment appeared to start 
before the age of 40 years, as evidenced by the down-sloping audiograms in 
figure 2. From the late 40s to the early 50s the low frequency threshold levels start 
to deteriorate resulting in flat audiograms with 90-120dB AC threshold levels.  
All threshold data measured for the Australian I109N mutation carriers are plotted 
against age in figure 3. Also, the last-visit measurement among the longitudinal 
data is represented as a single snapshot measurement (open circles), which was 
used in the cross-sectional analysis. 
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Figure 2. Individual audiograms of I109N mutation carriers from the Australian family, 
ordered by age at the last visit (from top left to bottom right). Shown are AC threshold 
levels for the right (open circles) and for the left (crosses) ear. Above each audiogram the 
age in years (y) is given. The dotted line represents the 95th percentile AC threshold 
levels of presbyacusis for a given age and sex according to ISO 7029.18 For the 
audiograms from individuals aged 74 and 91 years only data pertaining to the right ear 
were available. Bilateral hearing impairment was present in both of these individuals. 
V:3  F  42y
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
V:2  M  48y
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
V:1  F  53y
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
IV:6  F  68y
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
IV:3  M  74y
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
IV:5  M  77y
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
IV:1  F  78y
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
IV:2  F  91y
0
40
80
60
20
100
120
-10
dB
.25 .5 1 2 84 kHz
P95
 
Chapter 2.3 
 
114 
 
Figure 3. Mixed single-snapshot (open circles) and longitudinal individual measurements 
(small symbols with connection lines, different symbols for each I109N mutation carrier) 
are shown for each frequency separately. A dose-response curve with a variable slope 
could not be fitted to the data. Sigmoidal curves fitted to data pertaining to P51S (2 
dashed curves, one relating to an apparent congenital offset level) and G88E (dotted 
curve) mutation carriers are included for comparison. The number in the lower right-hand 
corner of each panel represents the average threshold deterioration (ATD) value in 
dB/year derived from cross-sectional linear regression analysis. ATD values in 
parentheses did not reach significance in cross-sectional linear regression analysis. 
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Neither the cross-sectional nor the individual longitudinal threshold data permitted 
reliable fitting of sigmoidal curves, for which reason no curves pertaining to these 
data are shown in figure 3. The dose-response curves fitted to audiometric data of 
several P51S families 4 and of a Dutch G88E family 21 were added to figure 3 for 
comparison with the Australian I109N family. Although the progression of hearing 
impairment with advancing age was fairly similar for all three mutations, I109N 
mutation carriers seemed more similar to P51S mutation carriers in terms of onset 
age and level of progression, especially in the high frequencies. For the lower and 
mid frequencies, hearing levels for the I109N mutation carriers seem worse than 
those for the P51S and G88E mutation carriers. In the higher frequencies (4 and 8 
kHz) hearing levels for the I09N family were similar to those for P51S mutation 
carriers. 
 
Table 1. Summary of available data on different DFNA9-causing mutations in the COCH 
gene. 
 
Mutation Origin Age of onset Genetic reference Phenotype reference 
P51S The Netherlands/ 
Belgium 
4th – 5th decade De Kok et al. (1999) 3 Fransen et al. (1999)9;  
Bom et al. (2003) 24;  
Bischoff et al. (2005) 4 
V66G USA 2nd – 3rd decade Manolis et al (1996) 7; 
Robertson et al. (1998) 8 
Manolis et al (1996) 7 
G87W The Netherlands 4th – 5th decade Collin et al. (2006) 14 Pauw et al. (2007) 22 
G88E USA 
The Netherlands 
5th decade 
5th decade 
Robertson et al. (1998) 8 
Kemperman et al (2005) 21 
Khetarpal et al (1991)16 
Kemperman et al (2005) 21 
V104del Hungaria 43 years * Nagy et al. (2004)11 Not available 
I109N Australia 4th – 5th decade Kamarinos et al. (2001)12 Present report 
I109T The Netherlands 4th – 5th decade Pauw et al. (2007) 23 Pauw et al. (2007) 23 
W117R USA 5th decade Robertson et al. (1998) 8 Not available 
A119T Japan 4th decade Usami et al. (2003) 13 Not available 
C542F USA 2nd decade Street et al. (2005) 10 Street et al. (2005) 10 
* Genotyping only performed in one individual. Onset age relates to subjective (reported) onset 
age 
 
Cross-sectional regression analyses performed on threshold-on-age data showed 
significant progression with advancing age only for 0.25, 0.5 and 1kHz, with ATD 
values ranging from 1.4 to 1.7 dB/year. In figure 3 ATD values are depicted in 
each threshold-against-age plot.  
Although cross-sectional analysis on last-visit audiometric data did not show 
significant progression with advancing age at the frequencies 2, 4 and 8 kHz it 
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was deemed appropriate to construct ARTA (Figure 4, top panel) based on 
apparent progression in the longitudinal data shown in figure 3. From figures 3 
and 4 (Figure 4, upper panel) it can be appreciated that at 40 years of age 
deterioration of threshold levels in the higher frequencies had already occurred 
and that after 40 years of age, progression mainly occurred in the lower 
frequencies. The audiometric data  from the Australian family were compared to 
those available for other DFNA9 families with different mutations in the COCH 
gene (Table 1). From 7 of the 10 known DFNA9/COCH mutations, including I109N 
in the Australian family, audiometric data have been presented (Table 1). Based 
on these data ARTA were constructed and shown in figure 4 for comparison. 
From the Dutch family harboring the G87W COCH mutation, audiometric data 
have been presented, but cross-sectional data did not allow for the construction of 
ARTA.22 
The ARTA for the I109N mutation carriers show more extensive deterioration in 
the fifth and sixth decades of life relative to those for the I109T mutation carriers 
and particularly so, relatively to those for the P51S and Dutch G88E mutation 
carriers. The audiometric profile for the Dutch G88E mutation carriers shows a 
more flat to gently down-sloping configuration with onset of hearing impairment 
occurring at a later age than in the I109N, I109T and P51S mutation carriers. The 
American G88E mutation carriers 8,16 show a similar audiometric pattern, but with 
a faster progression rate in the sixth decade leading to worse threshold levels at 
60 and 70 years of age. V66G mutation carriers 7,8 show an earlier onset of 
threshold deterioration that rapidly deteriorates to a (sub)residual hearing level at 
50 years of age. The C542F mutation is the only known mutation to occur outside 
the LCCL domain and is located in the vWFA2 domain of COCH.10 The 
audiometric phenotype shows an early onset age (before 20 years of age) of 
hearing impairment with a relatively slow progression rate. 
 
Speech recognition scores 
Figure 5 shows the single-snapshot measurements of the phoneme scores in the 
Australian I109N mutation carriers. 
The data available for the Australian family did not allow estimation of the onset 
age X90. The youngest age at which a measurement was performed was 48 
years. At this age maximum speech recognition score was 74% as estimated by 
non-linear regression analysis. The speech score deteriorated with 3% per year 
on average from this age onwards. A recognition score of 86% was found at a 
PTA1,2,4 level of 48dB and deteriorated by 1.3% per dB between the scores 86% 
and 40%. 
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Figure 4. Age-related typical audiograms (ARTA) derived from cross-sectional regression 
analysis of mean AC threshold levels for the Australian DFNA9 family with an I109N 
mutation in COCH (upper panel). For comparison the ARTA pertaining to the P51S 21 (2nd 
row, left panel), V66G 7 (2nd row, middle panel), G88E 16,21 (Two ARTA; Dutch family on 
2nd row right panel and American family 3rd row, left panel), I109T 23 (3rd row, middle 
panel) and C542F 10 (3rd row, right panel) mutation carriers are shown. Italic numerals 
indicate age in years. Downward arrows indicate either out-of-scale measurements, or 
underestimation of mean threshold due to exclusion of such measurements. 
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The dose-response curves fitted to speech audiometry data of several P51S 
families 4, a Dutch G88E family 21, a Dutch G87W family 22 and a Dutch I109T 
family 23 are included in figure 5 for comparison to the Australian I109N mutation 
carriers. The scores of I109N mutation carriers tended to be worse at given ages 
than those obtained for patients with a P51S, G87W, G88E or an I109T mutation 
(Figure 5). Probably, this observation reflects the finding of the poorest thresholds 
being present in the speech frequencies in the I109N mutation carriers in the sixth 
an seventh decades of life (Figure 4). The data pertaining to G88E and P51S 
mutation carriers were fitted with almost coinciding (dotted and dashed) curves 
(Figure 5). As related to the level of hearing impairment, the scores for patients 
with the I109N mutation appeared fairly similar to those with a P51S, G87W, 
G88E or I109T mutation. 
 
 
Figure 5. Single-snapshot measurements for the I109N mutation carriers (open circles) of 
binaural mean phoneme recognition scores against age (left panel) and against binaural 
mean pure-tone average at 1, 2 and 4 kHz (right panel). The solid line is a sigmoidal 
curve fitted to these measurements as previously described.20 The dotted and dashed 
curves are identical to similarly fitted curves previously established for G88E and P51S 
mutation carriers, respectively.21 The dotted-and-dashed curve was previously 
established for G87W mutation carriers 22 and the straight grey curve for I109T mutation 
carriers.23 
 
 
DISCUSSION 
The quantitative analyses of audiometric data from the Australian family with the 
I109N mutation in COCH confirm the conclusion by Kamarinos et al.12 that this 
family shows largely similar characteristics of hearing impairment as other families 
with different mutations in the COCH gene. A progressive high-frequency sensori-
neural type of hearing impairment is observed. Later on, progression also involves 
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the lower and mid frequencies. Onset age is before 40 years of age (Figures 2 to 
4) and probably before 30 years of age for the high frequencies (Figure 3). 
Interestingly, the only significant ATD values calculated from cross-sectional linear 
regression analysis occur in the lower frequencies. This is probably due to the fact 
that only threshold data for ages above 42 years were available for cross-
sectional analysis. Deterioration in the higher frequencies had presumably already 
started before this age. 
The available audiometric data did not permit fitting a sigmoidal curve to the 
threshold-on-age data for each frequency, as was previously performed for P51S 
and G88E mutation carriers.4,21 The steepest part of the sigmoidal curve 
corresponds to the most rapid progression of hearing impairment that has been 
shown to occur in mid-age P51S and G88E mutation carriers. This period of rapid 
progression probably applies to the present family as well, as judged by the last-
visit audiograms presented in figure 2, from which it can be appreciated that a 
large threshold increase occurs at ages between 48 and 53 years. It should be 
kept in mind, however, that such an apparent increase may also be caused by 
inter-individual variance in onset age and level of progression. The longitudinal 
data presented in figure 3 clearly show that the relatively greatest individual 
progression occurred in the fourth to sixth decades of life. In figure 3 the sigmoidal 
curves fitted to audiometric data of several P51S families 4,24 and of a Dutch G88E 
21 family are added for comparison to the Australian I109N family. Although the 
progression of hearing impairment with advancing age was fairly similar for all 
three mutations, I109N mutation carriers seemed to be more similar to P51S 
mutation carriers in terms of onset age and level of progression, especially in the 
high frequencies. However, the curves at these frequencies showed a downward 
bias consequential to the exclusion of out-of-scale thresholds.21 
The 7 ARTA from 7 families with 6 different DFNA9/COCH mutations allow for 
easy visual comparison of audiometric characteristics between the different 
mutations (Figure 4). The phenotype of the Australian I109N family is somewhat 
similar to the Dutch I109T family.23 This is not fully surprising, because in both 
families the same amino acid (isoleucine) at position 109 is replaced by a 
threonine (I109T) or an asparagine (I109N) residue. This, however, does not 
explain the fact that an intriguing difference seems to exist relating to the low and 
the speech frequencies (Figure 4). This observed difference of progression rate 
for the low and mid-frequency thresholds may be biased by the fact that the cross-
sectional data from the Australian I109N family mainly clustered around the more 
advanced ages, whereas those from the Dutch I109T family were spread more 
evenly across the different ages. Generally, the DFNA9 phenotype is fairly 
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comparable across the different COCH mutations. An adult onset hearing 
impairment applies and initially the high frequencies are mainly involved. As 
hearing deteriorates over time, the low and mid frequencies become involved as 
well. However, as judged by the 7 ARTA presented in figure 4, differences in 
terms of onset age, level of progression and degree of hearing impairment seem 
to exist between the different COCH mutations. This finding would imply that 
different COCH mutations exert different effects on the function of the inner ear. 
However, because these results are based on relatively small numbers of data, 
these conclusions should be treated with caution. 
Important insights into the function of cochlin in the inner ear and into the 
mechanism by which mutant cochlin causes the cochleovestibular disorder 
DFNA9 can be derived from fundamental studies. As cochlin is the most abundant 
protein in human, bovine and mice inner ears 17,25, it has previously been thought 
to play a critical role in the process of normal hearing. However, because mice 
deficient of Coch show a similar auditory phenotype compared to wild-type mice, it 
has been suggested that hearing impairment in DFNA9 is not a COCH 
haploinsufficiency disorder.17,26. Because both wild-type and mutant cochlin are 
secreted into the extracellular matrix in a similar fashion 27, it has been suggested 
that cochlin plays a role in the extracellular environment of the inner ear. Mutant 
cochlin presumably does not correctly integrate into the extracellular matrix 28, and 
possibly shows the tendency to slowly aggregate over a longer period of time, 
leading to hearing impairment through a dominant negative mechanism. This 
would provide an explanation for the late onset and progressive nature of DFNA9, 
and for the characteristic histopathological findings in the inner ear of DFNA9 
patients. The acidophilic acellular deposits found in temporal bones of DFNA9 
patients are localized to the spiral ligament, limbus, osseous spiral lamina, stria 
vascularis, and stroma of the maculae and cristae 16, and have recently been 
shown to contain cochlin.17  
In addition, neuronal and axonal degeneration has been observed as well.16 This 
degeneration is probably secondary because cochlin deposits occur in areas 
surrounding neurons and their processes, but not in the neuronal cell bodies or 
processes themselves. Presumably, cochlin deposits cause strangulation of these 
structures, which leads to secondary cell death, resulting in hearing impairment 
and vestibular dysfunction.  
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ABSTRACT 
This study reports on the audiometric characteristics of a large Dutch DFNA15 
family with a novel mutation in POU4F3, p.L289F. 
A large five-generation pedigree with sensorineural hearing impairment 
segregating as an autosomal dominant trait was studied. Pure tone and speech 
audiometry data from mutation carriers were cross-sectionally and longitudinally 
analyzed. Vestibular function was tested in two mutation carriers. 
Overall, a flat to gently downsloping audiometric configuration was observed with 
a progression rate of approximately 0.8 db/year across most frequencies. Speech 
recognition scores remained fairly good in relation to age and hearing level 
compared to a group of presbyacusis patients. Inter-individual variability was 
observed in terms of subjective onset age as well as in terms of audiometric 
configuration. Two mutation carriers, who reported vestibular symptoms, 
underwent vestibular examination and showed hypofunction of the vestibular 
labyrinth. 
The audiometric phenotype of the Dutch DFNA15 family with a novel mutation in 
POU4F3 is comparable to that observed in the original Israeli DFNA15 family. 
Relative good speech recognition scores suggest outer hair cell involvement. 
DFNA15 may represent a cochleovestibular disorder. 
Chapter 3.1 
 
128 
INTRODUCTION 
At present 54 loci for autosomal dominant non-syndromic hearing impairment 
(DFNA1-54) have been described. The causative genes have been identified in 21 
of these cases.1 A thorough phenotype description of each novel locus and 
mutation is necessary to identify the clinical significance of all the new findings 
and, for the purpose of counseling reasons, to gain insight into the natural course 
of the specific genetic disease. 
The autosomal dominant hearing impairment disorder DFNA15 is characterized 
by bilateral progressive, adult-onset sensorineural hearing impairment without 
concomitant vestibular features.2 It was described for an Israeli family, designated 
family H.2 Hearing impairment in this family appeared to be moderate to severe 
and audiometric configuration varied between flat and down sloping. Age of onset 
was between 18 and 30 years.2,3 The DFNA15 locus resides on human 
chromosome 5q31 and a mutation in the POU4F3 gene was shown to be 
responsible for the disorder.2 In affected members of family H an 8 base-pair (bp) 
deletion in POU4F3 (884del8) was identified resulting in a frame shift that causes 
premature termination of the POU4F3 protein.2 The annotation at protein level is 
I295fsX4. 
POU4F3 is a member of the POU family of transcription factors and is strongly 
expressed in mouse cochlear and vestibular hair cells. It is essential for the 
differentiation and survival of hair cells.4,5 Targeted deletion of Pou4f3 results in 
profound deafness and impaired balance due to complete loss of auditory and 
vestibular hair cells in mice homozygous for the deletion.6,7 
We report on the clinical characteristics of a large Dutch DFNA15 family with a 
novel mutation in POU4F3. The identification of this novel mutation, p.L289F, and 
its effect on protein function will be reported separately by Collin et al. (manuscript 
in preparation). Audiometric data were analyzed and compared to those obtained 
for the original DFNA15 family H. 
 
 
PATIENTS AND METHODS 
Patients 
After written informed consent had been obtained from all participating family 
members, a family investigation was performed and a pedigree of family W05-549 
was constructed (Figure 1). The study was approved by the local medical ethics 
committee. Medical history was taken from all participants, paying special 
attention to hearing impairment and vestibular symptoms. Furthermore, 
concommitant disease, the use of medication and any other possible cause of 
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acquired deafness were ruled out. After micro-otoscopic examination, pure tone 
audiometry was performed. Clinically affected individuals also underwent speech 
audiometry. Vestibular function was tested in 2 affected family members who 
reported vestibular symptoms. Blood samples were collected from 32 affected 
family members, 19 presumably unaffected family members and 10 spouses for 
the purpose of linkage analysis. Available previous medical records and 
audiograms were traced to enable individual longitudinal analysis. 
Analyses of audiometric data as described below, were performed on data 
pertaining to mutation carriers of the present family.  
 
Audiometry and data analysis 
Audiometric examination comprised conventional pure-tone audiometry in a 
sound-treated room. The individual 95th percentile threshold values of presby-
acusis in relation to the patient’s sex and age were derived for each frequency 
using the ISO 7029 method.8 Individuals were considered affected if the best 
hearing ear showed thresholds mainly or exclusively beyond the 95th percentile 
threshold values for presbyacusis. 
Cross-sectional binaurally averaged threshold data (air-conduction level in 
decibels hearing level) were plotted against age for each frequency and analyzed 
using linear regression analysis (threshold on age). The regression coefficient 
(slope) was called annual threshold deterioration (ATD), expressed in dB per year. 
Progression was significant if the 95% confidence interval of the ATD did not 
include zero. If significant progression was present, age-related typical 
audiograms (ARTA) were constructed following a method previously described 
elsewhere.9 Individual longitudinal regression analysis of binaural mean threshold 
values on age was only performed in clinically affected persons with three or more 
consecutive measurements and an overall follow-up period of at least 3 years. 
Individual progression was considered significant when significant progression 
was observed in at least 3 of 6 frequencies (p<0.05 in binomial distribution). The 
level of significance used in all tests was p=0.05.  
Speech audiometry was performed using phonetically balanced standard Dutch 
consonant-vowel-consonant word lists. The maximum phoneme recognition score 
(percentage correct, mean value for both ears) was obtained from monaural 
performance-intensity curves and was analyzed in relation to age and to pure-tone 
average (mean value for both ears) at the frequencies of 1, 2, and 4 kHz (PTA 1,2,4 
kHz). Nonlinear regression analysis was performed using a dose-response curve 
with variable slope to fit individual longitudinal scores for the p.L289F mutation 
carriers.10 The age of onset and the onset level (i.e. X90) were defined at a 
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recognition score of 90% in cross-sectional performance (Y-axis) versus age or 
performance versus impairment (X-axis) plots, respectively. Between the scores 
of 90% and 75%, a straight line was also fitted to simplify the results and to obtain 
an estimate of local average slope that was called deterioration rate in the score-
against-age plot and deterioration gradient in the score-against-PTA1,2,4 kHz plot.10  
A previously described group of subjects with only presbyacusis 11 was used as a 
reference group. 
 
Vestibulo-ocular examination and data analysis 
Two mutation carriers (IV:48 and IV:59) underwent vestibular and ocular motor 
tests. The tests included evaluation of the vestibulo-ocular reflex (velocity-step 
test), using electronystagmography with computer analysis and saccadic, smooth 
pursuit, and optokinetic nystagmus responses. Vestibular stimulation comprised 
rotatory tests. Details and normal values have been previously described.12  
 
 
RESULTS 
After written informed consent had been obtained from the proband and all 
participating family members, a pedigree was constructed (Figure 1). Forty 
persons were affected by history, 34 of which were alive. Blood samples were 
obtained from 60 individuals for genetic analysis. Audiometry was performed 
and/or audiograms could be retrieved from elsewhere in 60 individuals. This 
revealed that 32 individuals were affected. An autosomal dominant pattern of 
inheritance is apparent. The case histories and physical examinations excluded 
syndromic involvement. Most clinically affected individuals reported bilateral, 
slowly progressive hearing loss with mean subjective onset age of 35 years 
(range childhood - 60 years). Two individuals (IV:48 and IV:59) reported varying 
vestibular symptoms including instability, especially in the dark, vertigo, and a 
tendency to fall. Vestibular function tests in individual IV:59 revealed symmetrical 
hyporeflexia with timeconstants of 7 and 10 seconds for both nystagmus 
directions. Individual IV:48 showed asymmetrical velocity-step test responses with 
time constants of 11 seconds (marginally low) and 28 seconds (too long). 
Genetic analysis revealed the presence of a total of 30 POU4F3/p.L289F mutation 
carriers, all of whom were clinically affected. Two clinically affected individuals 
(IV:36 and IV:71) did not harbor the mutation in POU4F3 and may thus represent 
phenocopies (PC above symbols in figure 1). 
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Figure 1. Simplified pedigree of Family W05-549 with nonsyndromic autosomal dominant 
hearing loss, caused by a mutation (p.L289F) in POU4F3. Square, male; circle, female; 
open symbol, clinically unaffected; solid symbol, clinically affected; slash, deceased 
individual. PC, phenocopy. 
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Figure 2. Individual audiograms of p.L289F mutation carriers from the Dutch DFNA15 
family, ordered by age (from top left to bottom right) at last visit. Shown are AC threshold 
levels for the right (open circles) and for the left (crosses) ear. Above each audiogram, 
the pedigree number, sex (M: male, F: female) and age in years (y) is given. The dotted 
line represents the 95th percentile AC threshold levels of presbyacusis for a given age and 
sex according to ISO 7029.8 Asterisk indicates that data was excluded from cross-
sectional analysis (individuals VI:5, 45 years and III:33, 73 years) 
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Audiometry 
Pure tone thresholds related to age 
The last-visit audiograms pertaining to all mutation carriers are shown in figure 2. 
Overall, the threshold levels deteriorated with advancing age. However, some 
inter-individual variability in audiometric configuration as well as in the degree of 
hearing impairment was observed. A flat to gently downsloping audiometric 
configuration applies to most audiograms, but mid-frequency (V:39, age 16 years) 
as well as steeply downsloping (IV:48, age 44 years; VI:14, age 45 years; III:62, 
67 years) audiograms occured as well (Figure 2). It should be noted that patients 
IV:48 and VI:14 showed more steepness at the high frequencies at 44-45 years of 
age than predicted by presbyacusis, whereas steepness and thresholds at these 
frequencies conformed with presbyacusis in patient III:62 at age 67. Remarkably 
flat configurations were shown by individuals V:12 (18 years), V:6 (25 years), 
IV:19 (47 years), IV:10 (55 years) and III:18 (74 years). Audiogram data pertaining 
to individuals VI:5 (45 years) and III:33 (73 years) were excluded from cross-
sectional analyses because of outlier behaviour, i.e. threshold beyond 95% 
tolerance limits of linear regression line in cross-sectional analysis (asterisk in 
figure 2). 
The cross-sectional threshold-on-age data are plotted against age for each 
separate frequency in figure 3. Linear regression analysis was performed on these 
data and showed significant progression with advancing age for each frequency. 
ATD values ranged from 0.7 to 1.4 dB/year (Figure 3, italic numerals in upper 
right-hand corner).  
Individual longitudinal data were available for 12 mutation carriers. Linear 
regression analysis was performed on individual threshold-on-age data and 
showed significant progression only for individuals VI:5, III:33 and IV:59 at ages 
30-45, 30-73 and 32-75 years, respectively (data not shown). The data pertaining 
to the other 9 mutation carriers that did not show significant progression, covered 
relatively short time intervals and for some mutation carriers the available serial 
audiograms were obtained at relatively advanced ages. 
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Figure 3. Single-snapshot (open circles) thresholds are shown for each frequency 
separately. The line in each panel represents the result of the cross-sectional linear 
regression analysis for each frequency. The number in the upper right-hand corner of 
each panel represents the average threshold deterioration (ATD) value in dB/year derived 
from cross-sectional linear regression analysis. 
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Based on the results of cross-sectional linear regression analysis, ARTA were 
constructed as shown in figure 4 (left panel). The ARTA show a flat to gently 
downsloping configuration with a fairly similar ATD of 0.7 – 0.9 dB/year at the 
frequencies 0.25 to 2 kHz. The ARTA from the original Israeli DFNA15 family 3,13 
were added for comparison. At ages below 50 years, threshold levels from the 
present family are worse than those for family H, at 50 years of age threshold 
levels are similar and at 60 and 70 years family H shows worse threshold levels, 
mainly in the mid and high frequencies. Threshold levels deteriorated faster in the 
Israeli family H than in the Dutch family, mainly in the mid and high frequencies. 
 
 
 
Figure 4. Age-related typical audiograms (ARTA) derived from cross-sectional regression 
analysis of mean AC threshold levels for the Dutch DFNA15 family with a p.L289F 
mutation in POU4F3 (left panel). For comparison the ARTA pertaining to the original 
Israeli DFNA15 family are shown. 13 Italic numerals indicate age in years. 
 
 
Speech recognition scores 
Figure 5 shows the single-snapshot measurements of the phoneme scores in the 
p.L289F mutation carriers. 
Onset age X90 was 56 years, from which age onwards the recognition score 
deteriorated by 0.6% per year on average. The 90% recognition score was found 
at a PTA1,2,4 level of 59 dB and deteriorated by 0.8% per dB between the scores 
of 90% and 75%. 
The p.L289F mutation carriers showed better speech recognition scores than 
patients with only presbyacusis at matching ages (Figure 5, left panel). As related 
to the level of hearing impairment, the scores for patients with the p.L289F 
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mutation appeared to be better at similar levels of impairment than those for the 
presbyacusis patients (Figure 5, right panel). 
 
 
 
 
 
 
 
 
 
 
Figure 5. Single-snapshot measurements for the p.L289F mutation carriers (open circles) 
of binaural mean phoneme recognition scores against age (left panel) and against 
binaural mean pure-tone average at 1, 2 and 4 kHz (right panel). The solid line is a 
sigmoidal curve fitted to these measurements as previously described.10 The dotted curve 
represents data fitted to patients with only presbyacusis.11 
 
DISCUSSION 
This report presents a detailed audiometric analysis of a Dutch family linked to 
DFNA15 with a novel mutation in the POU4F3 gene (p.L289F). This is the second 
DFNA15 family that has been identified worldwide. The emerging clinical picture is 
consistent with the report on the original Israeli family H.2,3  
Based on the available clinical data an early adult to mid-life onset of hearing 
impairment applies to the present family. Most frequently, a high-frequency type of 
hearing impairment is observed with a downsloping audiometric configuration. 
However, mid-frequency as well as flat audiometric configurations also occurred 
(Figure 2). 
Linear regression analysis of cross-sectional audiometric data revealed significant 
progression for each frequency separately. The ARTA (Figure 4) showed a flat to 
gently downsloping audiometric configuration with a progression rate of 
approximately 0.8 dB/year across the frequencies 0.25-2 kHz. At 4-8 kHz the 
progression rate was slightly higher at 1 to 1.4 dB/year.  
Although all affected family members reported a slowly progressive type of 
hearing impairment, analysis detected significant progression to be present in 
three individuals with a sufficiently high number of suitable longitudinal data. This 
is most probably due to the fact that sequential audiograms were not available for 
each person or, when available, only covered a short time interval or were 
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obtained at relatively old ages at which time progression may have stopped 
already.  
A slowly progressive type of hearing impairment with a flat audiometric 
configuration may go unnoticed for a long period of time. In some cases this 
results in a discrepancy between the subjective onset age and the onset age 
estimated by backward extrapolation of hearing thresholds. This has been shown 
for other autosomal dominant types of hearing impairment with a flat to gently 
downsloping configuration, such as DFNA10 14, DFNA11 15, DFNA21 16 and 
DFNA31 17,18 (previously linked to DFNA13). So, the characteristics of hearing 
impairment in the present family may explain the fact that the subjective onset age 
varies to a great extent between the different mutation carriers.  
Speech recognition scores remained fairly good with advancing age and with 
progression of hearing impairment as measured with pure tone audiometry.  
DFNA2 10, DFNA5 19 and DFNA11 15,20 are other types of autosomal dominant 
hearing impairment disorders in which speech recognition scores remain relatively 
good. For these disorders the underlying defect is localized mainly in outer hair 
cells.19,21-26 Relative sparing of inner hair cell function may account for the 
preservation of speech recognition. This suggests outer hair cell involvement in 
DFNA15 and would confirm findings in Pou4f3 null mice.6,7 Speech recognition 
scores for DFNA2, DFNA5 and DFNA11 are comparable to those obtained for the 
Dutch as well as for the Israeli DFNA15 families.3,10,15,19 
In mice Pou4f3 (also known as Brn 3.1 or Brn-3c) is expressed in both inner and 
outer hair cells of the cochlea and hair cells in the vestibular labyrinth.6,7 Targeted 
deletion of the gene results in deafness and vestibular dysfunction.6, 7 In the Israeli 
DFNA15 family H, no vestibular involvement was reported.2,3 In the present Dutch 
DFNA15 family two mutation carriers reported vestibular symptoms and 
underwent vestibular function tests. These tests showed a hypofunction of the 
vestibular labyrinth in one of them and problematic results in the other. It may be 
interesting to subject an additional subset of mutation carriers of the present 
DFNA15 family to vestibular function tests to assess whether DFNA15 represents 
a cochleovestibular disorder such as DFNA9 27-29 and DFNA11 15 and as 
demonstrated in mice with a targeted deletion of Pou4f3.6,7 
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ABSTRACT 
This study reports on the audiometric and radiological findings in the first 
otosclerosis family linked to OTSC5. Cross-sectional analyses on presurgery pure 
tone audiometric data were performed. Additionally, high-resolution computed 
tomography (CT) images of temporal bones from genetically affected family 
members were obtained. On these CT images otosclerotic foci were categorized 
by size and location within the temporal bone. 
Audiometric data showed a considerable degree of phenotypic variability. Cross-
sectional regression analysis did not disclose any clear age dependence of 
threshold-related data. Systematic differences between mean parameter values 
relating to the thresholds in the best or the worst ear were found. High-resolution 
CT images revealed a fenestral otosclerotic focus in 7 of 9 (78%) clinically 
affected individuals and cochlear foci in 1 of these 7 patients. 
The phenotype of OTSC5 seems to be variable. Additional long-term audiometric 
data are needed to construct age-related typical audiograms, which may also 
facilitate the comparison between phenotypes of the different otosclerosis loci. 
The detection rate of otospongiotic foci in our study group is similar or lower 
compared to previous reports on CT data in consecutive otosclerosis patients who 
had stapes replacing surgery. 
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INTRODUCTION 
Otosclerosis is a primary disorder of bone metabolism which is known to only 
occur in the human temporal bone.1 It is characterized by focal inappropriate 
resorption and formation of otic capsular endochondral bone, leading to the 
development of newly formed bone of greater density, cellularity and vascularity 
and eventually to the inactive end-stage of thick sclerotic bone. The term 
otosclerosis was coined by Politzer in 1894 2 and refers to the final inactive stage 
of the disease process. Otospongiosis, a term introduced by Siebenmann in 1912 
3, is considered to describe more adequately the active stage of the disease 
process from a pathological point of view, as it refers to the well-vascularized 
bone, characteristic of the active stage. 
A predilection site for otosclerotic foci is a region anterior to the oval window, 
referred to as the fissula ante fenestram. Otosclerotic foci in this region may cause 
fixation of the stapedial footplate, thus leading to conductive hearing loss due to 
reduced mobility of the ossicular chain. Sensorineural hearing loss, which occurs 
in about 10% of patients, is thought to be caused by the development of cochlear 
otosclerosis.4   
Otosclerosis can be divided into a histological and clinical type. In histological 
otosclerosis clinical symptoms or manifestations are absent and it can only be 
discovered in histological temporal bone sections. Early reports on the prevalence 
of histological otosclerosis specify figures ranging from 8.3% 5 to 11.4% 6, 
whereas a more recent report estimates the prevalence to be 3.4% in the white 
population.7 In approximately 70-80% of patients the disease is bilateral.8 Clinical 
otosclerosis has a lower prevalence (0.3-0.4%) than the histological type and 
leads to conductive and/or sensorineural hearing loss.4,8 
The prevalence of otosclerosis varies greatly between various ethnic populations; 
it is rare in African blacks, Asians and American Indians and more common in 
whites.9 
Despite extensive research, the etiology of otosclerosis is poorly understood and 
environmental as well as genetic factors have been implicated. Epidemiologic 
studies suggest autosomal dominant inheritance with reduced (25-40%) 
penetrance.10 Strong support for a genetic cause of otosclerosis is provided by 
studies on monozygotic twins in which concordance for clinical otosclerosis has 
been found in nearly all cases.11 In addition, other factors, such as measles viral 
infection 12 or autoimmunity may also play contributing roles.13  
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Table 1. Loci for otosclerosis derived from the Hereditary Hearing Loss Homepage *  
 
Locus Location Gene Reference 
OTSC 1 15q26.1-qter Unknown Tomek et al., 199814 
OTSC 2 7q34-q36 Unknown Van Den Bogaert et al., 200116 
OTSC 3 6p21.3-22.3 Unknown Chen et al., 200217 
OTSC 4 Unknown Unknown Brownstein et al., 200618 
OTSC 5 3q22-q24 Unknown Van Den Bogaert et al., 200419 
OTSC 6 Reserved 
OTSC 7 Reserved 
* accessed may 2005 (http://webhost.ua.ac.be/hhh/).15 
 
 
In 1998 Tomek et al.14 were the first to report a locus for otosclerosis on 
chromosome 15q25-26. At present 7 different loci for otosclerosis have been 
identified (Table 1) 15, 5 of which have been publicly reported.14,16-19 None of the 
corresponding genes have yet been cloned. The number of different loci reflects 
the genetic heterogeneity of this disorder. Given this heterogeneity, a thorough 
genotype-phenotype correlation study on each otosclerotic locus could be in place 
to help distinguishing possible differences in clinical behavior. Insight into the 
clinical characteristics may contribute to understanding gene function once the 
corresponding genes have been cloned. In this paper we will present the clinical 
characteristics of the OTSC5 family 19, including audiometric data and high-
resolution spiral computed tomography (CT) imaging data of genetically affected 
individuals. 
 
 
PATIENTS AND METHODS 
Patients 
After informed consent had been obtained from the proband and other 
participating family members, a family investigation was performed and a pedigree 
was constructed (Figure 1). Medical history was taken from all participants, paying 
special attention to concomitant disease, use of medication and any possible 
cause of acquired deafness. After micro-otoscopic examination, audiometry was 
performed. Tympanic membrane compliance and ipsilateral and contralateral 
stapedial reflex decay were also evaluated. Previous medical records and 
audiograms, where available, were traced to allow for individual longitudinal 
analysis. 
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At the start of the genetic linkage study, family members who had had stapes 
replacing surgery for otosclerosis were considered to be affected. In non-operated 
family members, the clinical diagnosis of otosclerosis was considered most likely 
when several of the following criteria were met: presence of conductive or mixed 
hearing loss, air-bone gap (ABG) ≥ 20 decibels (dB) averaged across 0.5-2 kHz, 
absent stapedial reflexes and normal otoscopy. Peripheral blood samples were 
taken from 19 relatives and 1 spouse for linkage analysis. The genetic linkage 
study revealed a new locus for otosclerosis, OTSC5, as previously reported by 
Van Den Bogaert et al. in 2004.19 For the present genotype-phenotype correlation 
study, the pedigree underlying the OTSC5 linkage report was extended with five 
family members (III:12, III:13, III:15, III:17, III:23). After genotyping these 
additional persons for the OTSC5 markers, audiometric analyses were based on 
presurgery audiometric data of all genetically affected family members. High-
resolution spiral computed tomography images of the temporal bones of 
genetically affected family members were obtained to study the prevalence and 
extent of otospongiotic foci in these individuals. 
 
Audiometry and data analysis 
Audiometric examination comprised conventional pure-tone audiometry in a 
sound-treated room according to the International Organization for 
Standardization standards 389 and 8253-1.20,21 Air conduction (AC) thresholds 
were measured in dB hearing level (HL) at 0.25, 0.5, 1, 2, 4 and 8 kHz. The bone 
conduction (BC) threshold was also measured and the ABG was derived at each 
frequency. 
 
High-resolution spiral Computed Tomography (CT) imaging 
High-resolution spiral CT images of the temporal bone on both sides were 
obtained (CT aura, Philips Medical Systems, Best, The Netherlands). Images with 
a slice thickness of 1 mm were obtained in the axial as well as the direct coronal 
plane. Images were analyzed on a dedicated workstation enabling reformatted 
images in any direction (Easy Vision Workstation, Philips Medical Systems, Best, 
The Netherlands). All images were analyzed by an experienced Head and Neck 
radiologist (F.B.J.). 
Otospongiotic lesions were defined as areas of decreased bone density in the otic 
capsule and were divided in fenestral (oval window region) and cochlear foci. Both 
groups were classified into three groups according to the criteria suggested by 
Naumann et al. (Table 2).22 
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Table 2. Suggested criteria for classification of otospongiosis based on CT imaging *  
 
Group 1 Otospongiosis limited to the fissula ante fenestram 
Group 2 Otospongiosis extends to at least half the diameter 
of the oval window niche and/or the cochleariform 
process 
Fenestral 
otospongiosis 
Group 3 Otospongiosis extending over the entire diameter of 
the oval window niche 
Group 1 Otospongiosis not exceeding the diameter of one 
cochlear turn 
Group 2 Between Group 1 and 3 
Cochlear 
otospongiosis 
Group 3 Spongiotic involvement of the entire otic capsule 
* based on work by Naumann et al.22 
 
Statistical analysis 
Only the threshold data of unoperated ears were included in the analyses. Linear 
cross-sectional regression analysis was performed of AC threshold, BC threshold 
and ABG data on age. Individual longitudinal analysis was attempted, but there 
was a general lack of sufficient numbers of data. 
 
 
 
Figure 1. Pedigree of the Dutch OTSC5 family. Square, male; circle, female; open 
symbol, clinically unaffected; solid symbol, clinically affected; slash, deceased individual; 
plus, genetically affected, clinically unaffected; PC, phenocopy. 
 
 
RESULTS 
Pedigree and general findings 
The pedigree (Figure 1) comprises 32 relatives, 25 of which are alive, and spans 2 
branches and 4 generations. Medical history was taken from 25 relatives and did 
not reveal any type of acquired hearing impairment. Audiograms from 25 family 
members were obtained. Based on the diagnostic criteria, 10 affected family 
members (III:1, III:2, III:4, III:7, III:10, III:11, III:14, III:16, IV:2 and IV:3) were 
identified. According to history, three deceased family members had been affected 
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(I:2, II:2 and II:4). Genetic linkage analysis revealed a new locus for otosclerosis, 
OTSC5, localized to chromosome 3q22-24.19 Out of the 10 clinically affected 
family members, 9 had the linked OTSC5 haplotype (III:1, III:4, III:7, III:10, III:11, 
III:14, III:16, IV:2 and IV:3) and 1 did not have the disease haplotype (III:2).  
Individual III:2 did not carry the haplotype segregating with the disease in the 
other patients, and must be considered a phenocopy given the fact that he 
underwent bilateral stapes replacing surgery. He lives outside of Europe and we 
did not succeed in obtaining high-resolution CT images of his temporal bones. In 
addition, 2 clinically unaffected individuals, diagnosed and genotyped after the 
initial linkage analysis, had the disease haplotype (III:12, age 49 y and III:23, age 
41 y), adding up to a total of 11 genetically affected family members. 
 
 
Figure 2a. Individual (presurgery) audiograms of evaluable patients who were considered 
clinically affected and showed positive linkage to OTSC5. AC threshold, open circles and 
solid line; BC threshold (not always measured), dots and dashed line. Age in years (y) of 
the individual is shown above each audiogram. 
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Figure 2b. Same as Figure 2a., but audiometric data from these individuals are also 
included in longitudinal analysis. 
 
 
The male:female ratio was 6:4 for clinically affected individuals and 7:4 for 
individuals with the disease haplotype. 
 
Audiometric analysis 
The presurgery audiograms of the clinically affected family members, on which 
analyses were based, are shown in figure 2. In individual III:1 no presurgery 
audiograms could be obtained. 
Although individuals III:12 and III:23 showed the linked haplotype, based on the 
diagnostic criteria, they were considered clinically unaffected and their audiometric 
data were therefore excluded from the analyses. For the sake of completeness we 
present their audiograms in figure 3a. 
Individual III:11 is considered to be an example of cochlear otosclerosis. She did 
not undergo stapes replacing surgery as stapedial reflexes were present on both 
sides and no ABG was present. Pure tone thresholds are beyond the 95th 
percentile threshold value for presbyacusis at most frequencies in relation to age 
and sex (16, 17, 18, 23, 30 and 46 dB at 0.25, 0.5, 1, 2, 4 and 8 kHz).23 
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Figure 3. Audiograms of family members excluded from the analyses. Same symbols as 
in Figure 2. A. Individuals III:12 and III:23 were genetically affected, but they did not meet 
the criteria for clinical otosclerosis and their audiograms were therefore excluded from the 
analyses. B. The presurgery audiogram for individual IV:2 was excluded from the 
analyses because of outlier behavior. 
 
Based on plots of threshold against age (data not shown), the data from individual 
IV:2 (Figure 3b) were labelled as outliers  and were therefore excluded from 
further analyses. Interestingly, this individual appeared to be the only one with 
cochlear otospongiotic foci on CT images. 
Cross-sectional regression analyses did not reveal any significant increase in AC 
or BC thresholds, or ABG level with increasing age. For this reason, age was 
ignored and mean values were calculated.  
A systematic difference in AC threshold level appeared to exist between the best 
and the worst ear, which resulted in significant differences in most of the output 
parameters (data not shown). For this reason, the categories of best and worst 
ear are distinguished in the mean audiograms as shown in figure 4. The 
presurgery data pertaining to the R ear of patient III:4 (Figure 2b) were eliminated 
from the cross-sectional analysis because it could not be decided whether this 
was the best or the worst ear (for the other ear there were no presurgery threshold 
data available). Given the special status of individual III:11, mean values were 
calculated with and without audiometric data from this individual. This did not yield 
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a substantial difference in the results and conclusions. Because individual III:11 is 
considered having a cochlear otosclerosis, audiometric data from this individual 
were excluded from the calculation of the mean audiograms as presented in 
Figure 4. Figure 4a shows that the AC thresholds clearly reflect the systematic 
differences between best and worst ear, whereas this is not so clear for the BC 
thresholds.  
The only evaluable individual pre-surgery longitudinal data related to the R ear of 
patient III-10 (age 28-44 years) and the L ear of patient III-4 (age 59-65 years) and 
is presented in Figure 2b. The AC threshold did not change in the latter patient, 
but the former, younger, patient showed increases in AC threshold of between 
approximately 25 dB at the low and 50 dB at the high frequencies, thus reflecting 
an annual threshold deterioration of 1.5 dB and 2.9 dB, respectively. 
 
 
Figure 4. Average threshold data based on audiometry results from individuals III:7, III:10, 
III:14, III:16 and IV:3 (aged 28-46 years).  
A. AC and BC thresholds with same symbols as in Figure 2. Error bar is 1 SD. 
B. ABG, solid squares and line. 
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High-resolution spiral CT imaging 
Results of the classification of the high-resolution spiral CT images of temporal 
bones of 11 genetically affected family members are shown in table 3. In 7 out of 
9 (78%) clinically affected family members otospongiosis was detected. In 6 of 
these 7 (86%) a bilateral focus was detected. Fenestral otospongiosis was 
apparent in 12 of 14 ears (see Figure 5 for examples of fenestral otospongiosis 
group 1 and 2). Cochlear otospongiosis was present in both ears of one patient 
(IV:2), i.e. the patient that was excluded from audiometric analyses. 
 
 
Figure 5 Illustrative CT images showing fenestral otospongiotic foci (arrow). 
A. Fenestral otosclerosis group 1, left ear of individual IV:3. 
B. Fenestral otosclerosis group 2, right ear of individual III:1. 
 
In 4 individuals (2 clinically affected (III:11 and III:16) and 2 clinically unaffected 
(III:12 and III:23)) no otospongiotic plaques were detected with CT imaging. 
However, in one of them (III:16) ossification of the oval window was detected on 
both sides which was considered to be the sclerotic endstage of the disease 
A
 
B
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process and was therefore classified as fenestral otosclerosis group 3*. An 
asterisk was added to indicate that fenestral otospongiosis (group 3) had 
progressed to fenestral otosclerosis. 
 
 
Table 3. Results of radiological evaluation of 11 genetically affected individuals of the 
Dutch OTSC5 family * 
 
Fenestral otospongiosis Cochlear otospongiosis Years postsurgery 
Patient 
R L R L R L 
III:1 2 0 0 0 19 39 
III:4 0 0 0 0 30 NS 
III:7 1 2 0 0 32 30 
III:10 1 1 0 0 13 26 
III:14 1 1 0 0 NS NS 
III:16 3** 3** 0 0 23 NS 
IV:2 0 1 2 2 NS 3 
IV:3 2 1 0 0 3 NS 
III:11 0 0 0 0 NS NS 
III:12 0 0 0 0 NS NS 
III:23 0 0 0 0 NS NS 
*uses the classification suggested by Naumann et al.22 (table 2). The right most column 
shows the time in years between stapes replacing surgery and CT imaging of the 
temporal bone. NS: no surgery; 0: no otospongiosis detected,  
**: sclerotic end stage. 
 
 
DISCUSSION 
This paper is the first to outline phenotype findings in an OTSC5 family. Given the 
small number of evaluable patients, additional data from new OTSC5 families are 
needed for a more elaborate study on the phenotype of this particular disorder.  
Similar studies are needed for the other genetic otosclerosis types (Table 1) 14,16-
19 to distinguish possible phenotypic differences. Clinical data from two OTSC2 
families (n=34) have already been collected and presented at the GENDEAF 
meeting in 2005.24 
Cross-sectional analysis of the presurgery threshold data in the present family did 
not disclose any clear dependence of threshold on the patient’s age. We therefore 
focused on mean across-subjects thresholds and found a systematic difference 
between best and worst ear. Probably, the ages of the present patients included in 
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the cross-sectional analysis do not sufficiently cover the presumed age window in 
which progression of clinical otosclerosis can be detected. More data obtained at 
suitable ages are needed to derive age-related typical audiograms (ARTA) 25, 
which might aid in comparing the clinical characteristics including the natural 
course of the different otosclerotic loci. ARTA have proven useful in comparing 
clinical characteristics of genetic non-syndromic hearing impairment disorders. 
They give way to a classification of these disorders based on audioprofiles, which 
can be used for the differential diagnosis of these disorders, for counseling 
purposes and for guiding phenotyping efforts involving newly identified non-
syndromic hearing impairment traits.  ARTA are about to appear in communicated 
clinical descriptions bearing on otosclerosis foci.24,26 
Given the presumed natural history of otosclerosis, the present clinical picture 
must include progression during at least a number of years prior to surgery. This 
is confirmed by the longitudinal audiometric data from the right ear of individual 
III:10, whose age range (28-44 years) covers the reported age of onset as 
described for clinical otosclerosis.1  
The mean audiograms for best and worst presurgery ears (Figure 4) show a fairly 
flat configuration. The AC threshold (Figure 4a) and the ABG level (Figure 4b) 
showed a slight tendency towards gently upsloping configurations in both the best 
and the worst ear. A Carhart notch can be discerned in figure 4a; the configuration 
of the ABG level reflects this notch (Figure 4b).  
Individual III:11, is considered to be a case presenting with cochlear otosclerosis. 
This might explain both the sensorineural threshold beyond P95 presbyacusis at 
most frequencies and the CT findings negative for otospongiosis. Individual III:11 
was considered to be affected, although the diagnosis was not based on the 
clinical criteria outlined above. 
In most cases of otosclerosis the diagnosis is based on clinical findings combined 
with the results of audiometry. The use of imaging in the detection of otosclerosis, 
however, has increased with the development of spiral CT scanners with high-
resolution images, which is at present the imaging modality of choice for the 
assessment of the osseous labyrinth, labyrinthine windows, and cochlear capsule. 
In otosclerosis, high-resolution CT gives the opportunity to assess the extent of 
the disease and to confirm non-penetrance and/or cochlear involvement. In most 
cases, CT only detects the otospongiotic stage of the disease process, 
characterized by a hypodense lesion in the otic capsule, while the otosclerotic 
stage may go unnoticed as it has the same density as normal otic capsule bone 
tissue. Thus, 100% sensitivity of CT in the detection of otosclerosis may be 
impossible. Many reports on the validity of CT in otosclerosis have appeared. The 
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methods used, however, show much variation.27-29 Reported slice thickness 
ranges from 0.5 mm to 2 mm; analyses were done on printed images or directly 
on a workstation. It has been stated that the best method for the detection of 
otosclerotic foci on CT is to use sub-millimeter slice thickness and assess the 
images directly on a workstation. In literature, detection rates of surgically 
confirmed otosclerosis with presurgery CT of up to 91% have been reported.28,29 
Furthermore, Shin et al.27 conducted a study in which they distinguished familial 
(positive family history) from sporadic otosclerosis and correlated evidence for 
otosclerosis on axial CT scans with clinical findings. CT imaging was positive in 50 
out of 51 (98%) patients with familial otosclerosis compared to 89 out of 102 
(87.3%) patients with sporadic otosclerosis. In our study we used 1 mm slice 
thickness. We therefore may have missed sub-millimeter otospongiotic foci. 
Furthermore, CT scans were performed years after surgery (table 3) at which 
point in some cases the disease might already be in the sclerotic endstage. This is 
nicely illustrated by the finding in one individual (III:16, 23 years after stapes 
replacing surgery of the right ear) of ossification of the oval window niche on both 
sides, which was classified as the sclerotic endstage of fenestral otosclerosis 
group 3 and therefore designated group 3* to indicate the difference between 
otospongiosis and otosclerosis (Table 2). 
The classification for the radiological presence and extent of otospongiotic lesions 
by Naumann et al.22 is very clear and useful for descriptive purposes and may aid 
in the standardized evaluation of the clinical characteristics of otosclerotic loci. 
Penetrance in autosomal dominantly inherited otosclerosis has been reported to 
be 25-40%.10 Of our 25 analyzed individuals 11 are genetically affected, 2 of 
whom are clinically unaffected. Based on these figures, a penetrance of 82% 
would apply to our study sample. Clinical assessment of additional OTSC5 
families and of the other otosclerotic loci may provide an explanation for this 
difference between the level of penetrance in our study sample and previously 
reported levels of penetrance. It seems not unlikely that the apparent level of 
penetrance will be increased anyway by the recently improved imaging methods. 
Given the general prevalence of otosclerosis in the white population, the presence 
of a phenocopy in our study sample is not completely unexpected. 
A hope for the future will be to provide a good outcome in the medical treatment of 
otosclerosis, especially to prevent the start of a cochlear component. Elucidating 
the genes involved in the etiology of otosclerosis may serve this purpose, because 
the nature of the causative genes might influence outcome and effect of medical 
treatment on the progression of this disorder. At present, the genetic classification 
of otosclerosis is only based on the results of linkage analysis. The identification 
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of the involved genes will help to elucidate the pathophysiology of otosclerosis at 
a molecular level and provide possible targets for therapy. Furthermore, insight 
into the natural course of the various types of otosclerosis may contribute to a 
proper evaluation of the efficacy of current and future pharmacological therapies. 
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ABSTRACT 
This study reports on a clinical investigation of a Dutch family that shows 
suggestive linkage to OTSC7. Cross-sectional as well as longitudinal analyses of 
audiometric data were performed. Also, high-resolution computed tomography 
(CT) images of the temporal bones from genetically affected family members were 
obtained to study the incidence and extent of otospongiotic foci.  
Audiometric data showed a considerable degree of phenotypic variability. Cross-
sectional regression analysis did not show age-dependent progression of bone 
conduction, air conduction and air-bone gap levels. Longitudinal analysis of audio-
metric follow-up data of one family member showed age-dependent progression 
of air conduction, bone conduction and air-bone gap levels. High-resolution CT 
images revealed an otospongiotic focus in 6 of 6 (100%) clinically affected 
individuals that carried the disease haplotype. In none of the clinically unaffected 
family members that showed linkage to OTSC7 an otospongiotic focus was 
detected by CT.  
In conclusion, hearing impairment in the present otosclerosis family seems to be 
variable in terms of onset age and level of progression. Long-term audiometric 
data of one patient proved to be valuable in understanding progression of hearing 
impairment in this individual. The detection rate of otospongiotic foci in our study 
group is similar compared to previous reports on CT data in consecutive 
otosclerosis patients who had stapes replacing surgery. 
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INTRODUCTION 
Otosclerosis is a primary disorder of bone metabolism, which is known to occur 
only in the human temporal bone.1 It is characterized by focal inappropriate 
resorption and formation of otic capsular endochondral bone, leading to the 
development of newly formed bone of greater density, cellularity and vascularity 
and eventually to the inactive end-stage of thick sclerotic bone. A predilection site 
for otosclerotic foci is a region anterior to the oval window, referred to as the 
fissula ante fenestram. Otosclerotic foci in the fenestral region may cause fixation 
of the stapedial footplate, thus leading to conductive hearing loss, in association 
with an air-bone gap (ABG). Sensorineural hearing loss, which occurs in about 
10% of otosclerosis patients, is thought to be caused by the development of 
cochlear otosclerosis.2  
A recent report estimates the prevalence of histological otosclerosis, i.e. 
otosclerosis found in temporal bone sections without clinical evidence of hearing 
impairment, to be 3.4% in the white population.3 Clinical otosclerosis has a lower 
general prevalence (0.3-0.4%) than the histological type.2,4 In approximately 70-
80% of patients the disease is bilateral.4 
Despite extensive research, the etiology of otosclerosis is poorly understood and 
environmental as well as genetic factors have been implicated. Epidemiologic 
studies suggest autosomal dominant inheritance with reduced (25-40%) 
penetrance.5 Strong support for a genetic cause of otosclerosis is provided by 
studies on monozygotic twins in which concordance for clinical otosclerosis has 
been found in nearly all cases.6 In addition, other factors, such as measles viral 
infection 7 or autoimmunity may also play contributing roles.8  
Recently, Iliadou et al. 9 reported on the clinical characteristics of a large Greek 
family segregating autosomal dominant otosclerosis. Genome-wide linkage 
analysis revealed a new locus, designated OTSC7, on chromosome 6q13-
q16.1.10 In the present Dutch family with 6 otosclerosis patients, suggestive 
linkage to the same region was found. When linkage results from both families 
were combined, an overlapping candidate region of 1.06 Mb large was found, 
containing 8 genes, 5 gene predictions and 2 pseudogenes.10 However, DNA 
sequencing of all the exons and the intron-exon boundaries of the 8 known genes 
and the 5 gene predictions did not result in the identification of a disease-causing 
mutation.10 To date, 7 different loci for otosclerosis, including OTSC7, have been 
identified (Table 1) 11, 6 of which have been publicly reported.10, 12-16 None of the 
corresponding genes has yet been cloned. 
The number of different loci reflects the genetic heterogeneity of this disorder. 
Given this heterogeneity, a thorough phenotype study on each otosclerotic locus 
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could be in place to help distinguishing possible differences in clinical behavior. 
Insight into the clinical characteristics may contribute to understanding gene 
function once the corresponding genes have been cloned. In this paper we will 
present the clinical characteristics of the Dutch family that showed suggestive 
linkage to OTSC7 10, including audiometric data and high-resolution multidetector 
computed tomography (CT) imaging data of genetically affected individuals. 
 
Table 1. Loci for otosclerosis derived from the Hereditary Hearing Loss Homepage, 
(http://webhost.ua.ac.be/hhh/).11 
 
Locus Location Gene Clinical reference Genetic reference 
OTSC 1 15q26.1-qter Unknown Not available Tomek et al., 1998 
12 
OTSC 2 7q34-q36 Unknown Declau et al., 200717 Van den Bogaert et al., 200113 
OTSC 3 6p21.3-22.3 Unknown Not available Chen et al., 2002 
14 
OTSC 4 Unknown Unknown Brownstein et al., 2006 15 Brownstein et al., 2006 15 
OTSC 5 3q22-q24 Unknown Pauw et al., 200618 Van den Bogaert et al., 2004 16 
OTSC 6 Reserved 
OTSC 7 6q13-16.1 Unknown 
Iliadou et al., 2005 9 
Present report Thys et al., 2007 
10 
 
 
PATIENTS AND METHODS 
Patients 
After informed consent had been obtained from the proband and other 
participating family members, a family investigation was performed in the year 
2000 and a pedigree was constructed (Figure 1). The study was approved by the 
local medical ethics committee. Medical history was taken from all participants. All 
were at least 18 years old. Special attention was paid to concomitant disease, use 
of medication and any possible cause of acquired deafness. After micro-otoscopic 
examination, audiometry was performed. Tympanic membrane compliance and 
ipsilateral and contralateral stapedial reflexes were also evaluated. Previous 
medical records and audiograms, where available, were traced to allow for 
individual longitudinal analysis. 
Family members who had had stapes-replacing surgery for otosclerosis were 
considered to be affected. In non-operated family members, the clinical diagnosis 
of otosclerosis was made when several of the following criteria were met: 
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presence of conductive or mixed hearing loss, ABG ≥ 20 decibels (dB) averaged 
across the frequencies 0.5-2 kHz, absent stapedial reflexes and normal otoscopy. 
Peripheral blood samples were taken from 18 relatives and 5 spouses for linkage 
analysis. The genetic linkage study revealed suggestive linkage to a new locus for 
otosclerosis, OTSC7, as previously reported.10 
For the present phenotype study, descendants of clinically affected family 
members, who were all clinically unaffected at the beginning of the study in 2000, 
were invited to undergo audiometry again in 2006. In addition, the pedigree 
underlying the OTSC7 linkage report was extended with 2 family members (IV:10 
and IV:11) who were under 18 years of age at the time of the family investigation 
in 2000. The descendants of clinically affected family members were all 
genotyped for the OTSC7 markers. Audiometric analyses were based on 
(presurgery) audiometric data of clinically affected family members. High-
resolution multidetector CT images of the temporal bones were performed on all 
genetically affected family members to study the prevalence and extent of 
otospongiotic foci in these individuals. 
 
Audiometry 
Audiometric examination comprised conventional pure-tone audiometry in a 
sound-treated room according to common clinical standards. Air conduction (AC) 
thresholds were measured in dB hearing level (HL) at 0.25, 0.5, 1, 2, 4 and 8 kHz. 
The bone conduction (BC) threshold was also measured and the ABG level was 
derived at each frequency. 
 
High-resolution multidetector CT imaging 
High-resolution CT images of the temporal bone on both sides were performed 
using a 40-channel multidetector CT scanner (CT brilliance, Philips Medical 
Systems, Best, The Netherlands). Volume scanning was performed with a voxel 
size of 0.5 mm3. Images were analyzed on a dedicated workstation enabling 
reformatted images in any direction (Brilliance workstation, Philips Medical 
Systems, Best, The Netherlands). All images were analyzed by an experienced 
Head and Neck radiologist (F.B.J.). 
Otospongiotic lesions were defined as areas of decreased bone density in the otic 
capsule and were divided in fenestral (oval window region) and cochlear foci. 
Following our previous report on the phenotype of OTSC5 18, both groups were 
classified into three groups according to the criteria suggested by Naumann et al. 
19 (Table 2 and 3).  
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Table 2. Classification of otospongiosis based on CT imaging as proposed by Naumann 
et al. 19 
 
Group 1 Otospongiosis limited to the fissula ante fenestram 
Group 2 
Otospongiosis extends to at least half the diameter 
of the oval window niche and/or the cochleariform 
process 
Fenestral 
otospongiosis 
Group 3 Otospongiosis extending over the entire diameter of the oval window niche 
Group 1 Otospongiosis not exceeding the diameter of one cochlear turn 
Group 2 Between Group 1 and 3 
Cochlear 
otospongiosis 
Group 3 Spongiotic involvement of the entire otic capsule 
 
 
Statistical analysis 
The threshold data pertaining to the unoperated ears of clinically affected family 
members with the disease haplotype were included in this study. Linear cross-
sectional regression analysis was performed of AC threshold, BC threshold and 
ABG data on age and pertained to only one entry (ear) per individual. The 
regression coefficient (slope) was called annual threshold deterioration (ATD), 
expressed in dB per year. Progression was significant if the 95% confidence 
interval of the ATD did not include zero. If significant progression was present, 
age-related typical audiograms (ARTA) were constructed following a method 
previously described elsewhere.20 If significant progression was not present, 
mean audiograms were calculated. 
Individual longitudinal analysis was only performed of AC, BC and ABG threshold 
values on age in clinically affected persons with three or more consecutive 
measurements and an overall follow-up period of at least 3 years. The level of 
significance used in all tests was p=0.05. 
 
RESULTS 
Pedigree and general findings 
The pedigree (Figure 1) comprises 31 relatives, 25 of whom alive, and spans 4 
generations. Medical history was taken from all 25 relatives alive at the time of the 
study, and did not reveal any type of acquired hearing impairment other than 
hearing impairment developed by otosclerosis and audiograms were obtained 
from all of them. Based on the diagnostic criteria, 6 clinically affected family 
members (III:1, III:6, III:9, III:10, III:12 and IV:1) were identified. Mean subjective 
onset age of hearing impairment was 28.8 years (range 18-45, SD ± 9.1 years), 
Chapter 4.2 
 
168 
mean age at first surgery was 32.2 years (range 21-38, SD ± 6.6 years). The t-test 
showed no difference between man and women regarding subjective onset age 
as well as age at first surgery (data not shown). According to history, two 
deceased family members had been affected (II:1 and II:4), however no previous 
audiograms were obtained, so they were given an uncertain diagnosis (Fig. 1) and 
excluded from further analyses. Results of genetic linkage analysis were reported 
previously by Thys et al. 10 In brief, we included all affected (n = 6) subjects, and 
unaffecteds above age 50 into the linkage analysis. A LOD score of 1.96 was 
found for a locus on chromosome 6q, overlapping the region that had been found 
for a large Greek otosclerosis family, designated OTSC7.9, 10 All clinically affected 
family members had the linked haplotype.10  
 
 
Figure 1. Pedigree of the Dutch OTSC7 family. 
Square, male; Circle, female; Open symbol, clinically unaffected; solid symbol, clinically 
affected; +, genetically affected; ?, uncertain diagnosis;  slash, deceased individuals. 
 
 
After suggestive linkage to OTSC7 had been found, clinically unaffected 
descendants of the affected family members were included in both the genetic 
and clinical analyses. Marker analysis was performed in the descendants of 
affected individuals. Five of them have the disease haplotype (IV:2, age 33y, IV:4, 
age 35y, IV:7, age 31y, IV:10, age 19y and IV:11, age 18y), producing a total 
number of 11 putative mutation carriers within this family. None of these 5 
mutation carriers form generation IV met the diagnostic criteria for otosclerosis. 
The male:female ratio was 3:3 for clinically affected individuals and 6:5 for 
individuals with the disease haplotype. 
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Audiometric analysis 
The available presurgery audiograms of the clinically affected mutation carriers 
are shown in figure 2a. The audiogram panels in this figure show the familiar 
audiogram configuration typical for clinical otosclerosis in most cases, except for 
persons III:10 and perhaps also person III:9. The typical audiogram configuration 
comprises a downsloping AC threshold and a largely through-shaped BC 
threshold, establishing a typical Carhart notch together with the AC threshold. The 
ABG is greatest at the lower frequencies and generally decreases with increasing 
frequency, but may be minimal in association with the Carhart notch. An atypical 
feature of person III:10 is that the left ear showed an extremely wide ABG (≥ 
60dB) already at the age of 21 years (Figure 2a). This ear was therefore excluded 
from further regression analysis. This feature of a wide ABG was also shown, 
although to a lesser extent, by person III:9 at age 36 years in the left ear (data not 
excluded). For person IV:1, the right ear at age 30 years was arbitrarily elected for 
regression analyses.  
 
 
Figure 2a. Individual (presurgery) audiograms of evaluable patients who were clinically 
diagnosed to have otosclerosis and showed positive linkage to OTSC7. AC threshold, 
open circles and solid line; BC threshold, dots and dashed line. Age in years (y) of the 
individual is shown above each audiogram. R, right ear; L, left ear. 
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Figure 2b. Individual audiograms of family members who showed positive linkage to 
OTSC7, but were clinically unaffected. Same symbols as used in figure 2a. 
 
Figure 2b shows the audiograms of the 5 clinically non-affected family members 
carrying the disease haplotype. Although none of these disease haplotype carriers 
met the criteria for clinical otosclerosis (Methods), some of them did show hearing 
impairment that was clinically relevant for their age. These included person IV:7 at 
higher frequencies in the left ear, person IV:10 in both ears at the low frequencies 
and person IV:11 in both ears at the low and high frequencies. 
Cross-sectional regression analyses on threshold data of clinically affected 
mutation carriers (n=6) did not reveal significant progression of BC, AC and ABG 
levels with increasing age at any frequency. Therefore, any (non-significant) 
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progression was ignored and mean audiograms were calculated for BC, AC and 
ABG levels (Figure 3). 
 
 
Figure 3. Average threshold data based on audiometry results from individuals III:1, III:6, 
III:9, III:10, III:12 and IV:1 (aged 21 – 55 years). AC threshold, open circles and solid line; 
BC threshold, dots and dashed line; ABG levels, solid squares and line. Error bar is 1 SD. 
 
 
The only evaluable individual pre-surgery longitudinal data related to the right and 
left ear of patient III-10 and covered 37 years (range 18-54 years) and 3 years 
(range 18-21 years), respectively. Linear regression analysis revealed a 
significant increase in BC threshold, AC threshold and ABG levels with advancing 
age for each frequency in the right ear. ATD values for BC were 0.9-2.1 dB/year, 
1.7-2.6 dB/year for AC and 0.4-1.2 dB/year for ABG levels. BC threshold levels 
were greater than P95 AC threshold values corrected for sex and age according 
to the ISO 7029 standard.21 For the left ear, linear regression analysis revealed a 
significant increase of AC and ABG levels with advancing age, with extremely high 
ATD values ranging from 17.1-24.5 for AC levels and from 14.7-24.7 dB/year for 
ABG levels, whereas BC levels did not show progression within the given age 
frame. Examples of longitudinal AC, BC and ABG data on age for 1 kHz pertaining 
to the right (open circles) and the left (crosses) ear of patient III-10, including the 
linear regression line with ATD values, are shown in the upper panels of figure 4. 
Note that for the BC threshold data pertaining to the left ear no ATD value is 
shown because linear regression analysis of these data did not show significant 
progression with advancing age. 
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Figure 4. Longitudinal BC, AC and ABG levels pertaining to the right (open circles) and 
left (crosses) ear of patient III:10. Upper panels show illustrative level-against-age plots 
for 1kHz. Linear regression lines and their slopes, indicating annual threshold 
deterioration (ATD) in decibels per year, are included. Sigmoidal dose-response curves 
(dotted) were fitted to the data pertaining to the right ear. Five representative audiograms 
were selected to illustrate progression in BC, AC and ABG levels (lower panels). Italic 
numbers represent the ages at which the different audiograms were obtained. 
 
 
From the large number of serial audiograms pertaining to the right ear of patient 
III:10, 5 representative audiograms that covered the entire age range were 
selected to illustrate the progression in BC, AC and ABG levels (Figure 4, lower 
panels). These data provide a clear overview of the deterioration in AC, BC and 
ABG levels and seem to present a more realistic pattern of progression than the 
cross-sectional analysis in this family. However, the longitudinal results cannot be 
extrapolated to the entire Dutch OTSC7 family because they are based on only 
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progression, an arbitrary sigmoidal dose-response curve with variable slope was 
fitted to the threshold data pertaining to the right ear of patient III-10, as shown in 
figure 4 (upper panels) for illustrative purposes. These curves suggest that 
hearing impairment initially mainly consisted of a conductive component that 
attained a plateau level at around 32 years of age. A progressive sensorineural 
component developed later on and started from around 36 years of age. The data 
pertaining to the left ear of patient III-10 did not permit fitting of a sigmoidal dose-
response curve, probably due to the limited time span of 3 years that is covered 
by these data.  
 
High-resolution multidetector CT imaging 
Results of the classification of the high-resolution multidetector CT images of 
temporal bones of 11 genetically affected family members are shown in table 3. In 
6 out of 6 (100%) clinically affected family members at least 1 otospongiotic focus 
was detected. In 3 of these 6 (50%) a bilateral focus was found. Fenestral oto-
spongiosis was apparent in 6 of 6 patients (9 of 12 ears). Cochlear otospongiosis 
was present in 4 of 6 patients (7 of 12 ears). All ears that underwent stapes-
replacing surgery (n=7) showed fenestral otospongiosis and in 5 of these ears 
otospongiotic foci were graded group 3. Figure 5 shows an illustrative CT image 
with a group 3 fenestral and a group 3 cochlear otospongiotic focus in the right ear 
of patient IV:1. No otospongiotic foci were detected in any of the clinically 
unaffected family members carrying the disease haplotype.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Illustrative CT image. Multidetector CT scan of the right temporal bone of patient 
IV :1. Dashed arrow shows fenestral otospongiosis group 3 according to Naumann et al. 
19 Straight arrow points to cochlear otospongiosis group 3 around middle and apical turn 
of cochlea. 
There was no clear correlation found between the imaging and the audiometrical 
findings. It was remarkable, for example, that no imaging abnormalities were 
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found in the right ear of person III:6, who showed considerable hearing 
impairment (Figure 2). Also, the scores for both fenestral and cochlear oto-
spongiosis for person III:10 were fairly similar for the right and the left ear, whilst 
the audiograms differed considerably (Figure 2).  
 
 
Table 3. Results of radiological evaluation of 11 mutation carriers from the Dutch OTSC7 
family using the classification suggested by Naumann et al. 19 (table 2). The right most 
column shows the time in years between stapes replacing surgery and CT imaging of the 
temporal bone. ns: no surgery. 
 
Fenestral 
otospongiosis 
Cochlear 
otospongiosis Post-surgery (years) 
 
Patient 
R L R L R L 
III:1 3 3 2 1 34 22 
III:6 0 3 0 1 ns 22 
III:9 0 3 0 0 ns 22 
III:10 2 2-3 3 3 ns 36 
III:12 1 0 0 0 ns ns 
C
lin
ic
al
ly
 a
ffe
ct
ed
 
IV:1 3 2 3 3 6 5 
IV:2 0 0 0 0 ns ns 
IV:4 0 0 0 0 ns ns 
IV:7 0 0 0 0 ns ns 
IV:10 0 0 0 0 ns ns C
lin
ic
al
ly
 
IV:11 0 0 0 0 ns ns 
 
 
 
DISCUSSION 
This report presents the clinical description of an otosclerosis family with 
suggestive linkage to OTSC7. The original family was a large Greek family 9, in 
which Thys et al. recently found linkage to chromosome 6q13-16.1.10 In the latter 
publication, suggestive linkage to the same locus was found for the present Dutch 
otosclerosis family (LOD-score 1.96). In case of a whole genome scan, a LOD-
score of at least 3.3 (p-value 4.9 x 10-5) is considered to represent significant 
linkage. The reason for this stringent level of significance is that when 500 
markers or more are tested, a multiple testing correction must be taken into 
account to keep the type I error under control. In the Dutch otosclerosis family, 
however, only the known otosclerosis loci were tested and in one of these, e.g. 
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OTSC7, a LOD-score of 1.96 was reached.10 Linkage simulation using FastSLINK 
showed that this LOD-score corresponds to the theoretical maximum LOD-score 
for the present family.10 Given the limited number of loci tested, such a result is 
highly unlikely to occur by chance. So, according to the widely accepted criteria by 
Lander and Kruglyak 22 a LOD-score of 1.96 represents suggestive linkage in the 
present family. 
Combining the results from the linkage study in both families (Greek and Dutch) 
reduced the size of the candidate region from 13.47 cM to 1.06 Mb.10 A detailed 
phenotype study of the Dutch OTSC7 family was subsequently conducted. 
The present family harbors 6 patients with clinically confirmed otosclerosis, all of 
whom carry the disease haplotype. An additional 5 family members who did not 
meet the diagnostic criteria for clinical otosclerosis were found to carry the 
disease haplotype. This would imply 54,5% penetrance. Reduced penetrance is 
not uncommon in otosclerosis.5 However, given the fact that 90% of new cases of 
otosclerosis are diagnosed before 50 years of age 2, penetrance in otosclerosis is 
presumed to be age-dependent, so no definite diagnosis of clinically unaffected is 
given to individuals below this age. All 5 clinically unaffected family members that 
showed linkage to OTSC7, were all still below 50 years of age, so they may 
develop clinical otosclerosis in the future. This means that penetrance within this 
family may turn out to be higher than 54,5%. 
Within the group of clinically affected family members, the mean reported onset 
age of hearing impairment was 29 years, which is within the reported age of onset 
range as described for clinical otosclerosis (20-40 years).1 The type and extent of 
hearing impairment seem to vary between the patients with both the conductive 
and mixed type of hearing impairment occurring to varying extents. 
Cross-sectional linear regression analysis of audiometric data pertaining to all 6 
clinically affected mutation carriers on age was performed. This revealed that BC 
levels, representing the sensorineural component of hearing impairment, as well 
as AC and ABG levels, representing the conductive component of hearing 
impairment, did not show significant progression. These findings should be treated 
with caution and may be due to the limited numbers of observations. Given the 
natural course of otosclerosis, one would expect a period in which progression of 
conductive or mixed hearing impairment occurs. This is confirmed by longitudinal 
analysis of patient III-10 (right ear). First, progressive conductive hearing 
impairment developed and stabilised around the third decade of life with ABG 
levels of 50dB, which accords with previous reports on the natural course of 
otosclerosis.23 Later on, a progressive sensorineural component also developed 
with BC threshold levels greater than the P95 AC threshold values corrected for 
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sex and age according to the ISO 7029 standard.21 Serial audiometry data that 
relate to the right ear of patient III-10 (Figure 4, lower panels) may better reflect 
the natural course of progression of hearing impairment in otosclerosis than the 
results from the cross-sectional analysis. This is most likely due to the variability in 
onset age and rate of progression of hearing impairment in otosclerosis, which 
may hamper a reliable cross-sectional analysis. This is nicely illustrated by the 
large difference in ATD values for AC values between the right and left ear of 
patient III-10. It is worth of note that large series of consecutive longitudinal pre-
surgery audiometric data are rarely seen in otosclerosis. Patient III-10 underwent 
stapes-replacing surgery of the left ear at the age of 21 years and developed a 
completely deaf left ear afterwards. ABG levels in the right ear progressed to 
levels that would normally justify otosclerosis surgery, but the risk of losing his 
only hearing ear caused his physician to advise against surgery. 
The findings in the present family are not fully consistent with the clinical 
description of the Greek OTSC7 family that was reported previously by Iliadou et 
al. 9 Using multi-linear regression analysis of the audiometric data pertaining to 
the Greek family they showed that BC threshold levels increase significantly with 
advancing age, whereas AC and ABG levels did not show significant progression. 
Also, hearing impairment in the Greek family started much earlier at the age of 10 
years.9 It must be kept in mind that, although the candidate regions in the Greek 
and the Dutch OTSC7 families overlap, they do not necessarily harbor the same 
mutation, and also mutations in different genes may be responsible for the 
development of otosclerosis. In addition, no genome scan was performed on the 
Dutch family, so the possibility that other regions show suggestive linkage cannot 
entirely be excluded. 
High-resolution CT imaging revealed at least 1 otospongiotic focus in 6 out of 6 
(100%) clinically confirmed otosclerosis patients of the present family. Detection 
rates of surgically confirmed otosclerosis with presurgery CT of up to 91% have 
been reported.24 Furthermore, Shin et al. 25 conducted a study in which they 
distinguished familial (positive family history) from sporadic otosclerosis and 
correlated evidence for otosclerosis on axial CT scans with clinical findings. CT 
imaging was positive in 50 out of 51 (98%) patients with familial otosclerosis 
compared to 89 out of 102 (87.3%) patients with sporadic otosclerosis.25 In the 
present OTSC7 family a cochlear otospongiotic focus was detected in 4 of 6 
(67%) clinically confirmed otosclerosis patients. In our previous report on the 
clinical characteristics of OTSC5, a cochlear otospongiotic focus was detected in 
only 1 out of 11 (9,1%) mutation carriers.18 So, across the different otosclerosis 
loci, variability regarding the extent of radiological cochlear otosclerosis may exist. 
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On the other hand, in the report on OTSC5 1 mm slice thickness was used, so 
sub-millimeter foci may have been missed. Furthermore, in most cases CT only 
detects the otospongiotic stage of the disease process, which is characterized by 
a hypodense lesion in the otic capsule, while the otosclerotic stage may go 
unnoticed as it has the same density as normal bone tissue of the otic capsule. 
This may explain why no clear correlation was found between CT and audiometry 
results. Thus, 100% sensitivity of CT in the detection of otosclerosis may be 
impossible. High-resolution CT imaging is a valuable tool in the evaluation of 
(hereditary) otosclerosis. In combination with the classification proposed by 
Naumann et al. 19 it provides the opportunity to assess the extent of the disease 
and to confirm non-penetrance and/or cochlear involvement.  
A hope for the future is that based on a genetic diagnosis, a more specific medical 
treatment for otosclerosis will become available, especially to prevent the start of 
otospongiosis. Elucidating the genes involved in the etiology of otosclerosis may 
serve that purpose, because the nature of the causative genes and their 
presumed relation to bone metabolism might influence outcome and effect of 
medical treatment on the progression of this disorder. At present, the genetic 
classification of otosclerosis is only based on the results of linkage analysis. The 
identification of the involved genes will help to elucidate the pathophysiology of 
otosclerosis at a molecular level and provide possible targets for therapy. 
Furthermore, insight into the natural course of the various types of otosclerosis 
may provide the opportunity for a proper evaluation of the efficacy of current and 
future pharmacological therapies. 
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The aim of this thesis was to provide further insight into the phenotype of 
autosomal dominant non-syndromic types of hearing impairment with a special 
focus on DFNA9 (chapter 2), DFNA15 (chapter 3) and otosclerosis (chapter 4). 
 
Following the general introduction in chapter 1.1, a review on audiometric profiles 
associated with genetic non-syndromic hearing impairment is presented in chapter 
1.2. This review provides a detailed overview of genetic non-syndromic hearing 
impairment disorders that, at the time of writing, had already been linked to human 
chromosomal loci. The autosomal dominant loci for hearing impairment include 
DFNA1-5, DFNA6/14/38, DFNA7, DFNA8/12, DFNA9-11,DFNA13, DFNA15-18, 
DFNA20/26, DFNA21-25, DFNA28, DFNA30-31, DFNA36, DFNA41-44 and 
DFNA47-50. The autosomal recessive loci include DFNB1-6, DFNB7/11, 
DFNB8/10, DFNB9, DFNB12-18, DFNB20-23, DFNB26-27, DFNB29-33, 
DFNB35-40, DFNB42, DFNB44, DFNB46 and DFNB48-49. The loci linked to the 
X-chromosome include DFN2-4 and DFN6. In addition, a recently identified locus 
on the Y-chromosome, AUNA1 is also included. 
Based on their characteristic audioprofile, hearing impairment loci were classified 
into one of the following types of audiometric configuration: residual hearing, high-
frequency downsloping, flat-to-gently downsloping, mid-frequency or U-shaped 
and low-frequency audiometric configuration. Audioprofiles can be used for the 
differential diagnosis of non-syndromic hearing impairment disorders, for 
counselling purposes, especially for focusing on treatment options, and for guiding 
genotyping efforts involving newly identified non-syndromic hearing impairment 
traits. 
 
DFNA9 
The autosomal dominant cochleovestibular disorder DFNA9 is the subject of 
chapter 2. Phenotype descriptions for 3 different COCH mutations are presented 
in chapters 2.1 to 2.3. 
Chapters 2.1 and 2.2 describe the clinical characteristics of 2 Dutch DFNA9 
families with novel COCH mutations, G87W and I09T. Pure-tone thresholds, 
phoneme recognition scores, and vestibular responses of the mutation carriers 
were analyzed and compared to those previously established for P51S and G88E 
mutation carriers. In case of the I109T mutation carriers (chapter 2.2), data were 
also compared to those obtained for G87W mutation carriers. The observed 
phenotype was largely comparable across the different mutations. Hearing 
impairment started in the high frequencies with subjective onset age between the 
4th and 5th decades for both mutations (G87W and I109T). Hearing levels at the 
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high frequencies (4 and 8 kHz) may have started to deteriorate well before this 
age, as suggested by figure 2 in chapter 2.1 and figures 4 and 5 in chapter 2.2. 
In the G87W family (chapter 2.1), vestibular symptoms were reported by 15 of 28 
mutation carriers (54%). When only hearing impaired individuals were included, 
this figure increased to 88% (15 out of 17). Vestibular function was tested in 12 
G87W mutation carriers. In 10 of these 12 (83%) vestibular function tests showed 
a hypofunction of the vestibular labyrinth. All individuals that underwent vestibular 
tests and were older than 40 years of age, showed vestibular dysfunction. Similar 
to G88E mutation carriers, the proportion of patients over 40 years of age who 
had developed complete vestibular areflexia was significantly lower for the G87W 
mutation carriers than for the P51S mutation carriers. 
Five of 11 I109T mutation carriers (chapter 2.2) reported vestibular symptoms. 
Seven I109T mutation carriers, aged 45 years or older, underwent vestibular 
function tests. These tests showed vestibular dysfunction in 4 of them (57%). 
 
For the Australian DFNA9 family with the I109N COCH mutation (chapter 2.3) 
audiometric data were retrieved and presented. Kamarinos et al. reported on the 
I109N COCH mutation in this family in 2001.1 A detailed description of the 
phenotype of the Australian DFNA9 family had not been given yet, so we retrieved 
serial audiograms from 8 mutation carriers and subjected these audiograms to 
cross-sectional and longitudinal analyses. Hearing impairment started before the 
age of 40 as judged from figures 2-4, and probably before 30 years of age in the 
high frequencies (figure 3, chapter 2.3). 
An overview of ARTA from 7 different DFNA9 families with 6 different mutations: 
P51S, V66G, G88E (1 Dutch and 1 American family), I109T, I109N and C542F is 
given in chapter 2.3 (figure 4). 
 
Across the known DFNA9/COCH mutations, complete penetrance of cochlear 
involvement is observed in mutation carriers over 40 years of age with a 
comparable pattern of hearing impairment. However, detailed analysis of 
audiometric data revealed subtle differences in terms of onset age, level of 
progression and extent of hearing impairment between families with different 
mutations. Remarkably, a difference in frequency and extent of vestibular 
involvement appears to exist. In addition, the vertical corneal striae that were 
observed in two DFNA9 P51S families and in one DFNA9 G88E family 2, were not 
apparent in I109T and only in one G87W mutation carrier. These findings may 
lead to the conclusion that different mutations within the same gene lead to 
(subtle) differences in the phenotype. This conclusion should, however, be treated 
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with caution because they are based on small amounts of data. The clinical 
descriptions of the families harboring the G87W, I109T and I109N COCH mutation 
were based on 28, 11 and 8 mutation carriers, respectively. Although the amount 
of 28 G87W mutation carriers in one family is quite large for phenotype 
descriptions in hereditary hearing impairment pedigrees, the data did not allow for 
reliable cross-sectional analysis because they were clustered around relatively 
young and relatively old age groups (chapter 2.2). In the Netherlands and 
Belgium, the P51S COCH mutation is relatively frequently encountered.3,4 
Phenotype descriptions are available for different families and the mutation is 
considered a founder mutation.5 Because of the large amount of clinical data on 
P51S mutation carriers, a reliable phenotype description based on different 
families is available for this mutation.3 
Possibly, penetrance and extent of both cochlear and vestibular involvement are 
comparable between the different COCH mutations if large amounts of clinical 
data of all mutations would be available. This would assume a common pathway 
in which different mutations in COCH lead to changes in cochlin that equally affect 
its function. On the other hand, based on the current data it cannot be excluded 
that different mutations in COCH lead to different DFNA9 phenotypes in terms of 
cochlear and vestibular involvement. Fundamental studies are necessary in order 
to gain more insight into the pathophysiology of DFNA9. 
 
The function of cochlin and its role in the development of the cochleovestibular 
disorder DFNA9 is not yet entirely understood. Cochlin is the most abundant 
protein in human, bovine and mice inner ears.6,7 As such, it has previously been 
thought to play a critical role in the process of normal hearing. However, mice 
deficient of Coch show a similar auditory phenotype compared to wild-type mice, 
which led to the conclusion that hearing impairment in DFNA9 is not a COCH 
haploinsufficiency disorder.7,8 Further support for this conclusion is provided by 
the finding that mutant cochlin (P51S, V66G and G88E) is transported through the 
cells and secreted in a similar fashion as the wild type protein when transiently 
transfected in several mammalian cell lines.9 In addition, mutant cochlin also 
undergoes glycosylation and (extracellular) proteolytic processing and appears to 
be a stable protein.9 
These results point towards a function for cochlin in the extracellular matrix. 
Cochlin, with its LCCL and vWFA-domains, is likely to bind to or interact with 
several components of the extracellular matrix. In other proteins with the same 
domains these interactions have been demonstrated.10-12 
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Possibly, mutations in cochlin impair proper function of the protein in the 
extracellular matrix and result in cumulative deleterious effects over time through 
a dominant negative mechanism. This would explain the late-onset progressive 
hearing impairment in DFNA9. The characteristic histopathological findings in 
temporal bones of DFNA9 patients are the accumulation of large amounts of 
eosinophilic acellular material in the cochlear and vestibular labyrinths, co-
localizing with areas that express cochlin mRNA and protein.13-15 Electron 
microscopic examination of these deposits revealed a marked excess of a 
branched microfibrillar structure that fills up the extracellular spaces in 
combination with an absence of major fibrillar type II collagen bundles.13 Recently, 
it was shown that these deposits contain cochlin.7 Mutated cochlin has been 
suggested to not correctly integrate into the extracellular matrix of the cochlea and 
vestibular system, which leads to structural changes.16 It is possible that mutant 
cochlin shows the tendency to slowly aggregate over a longer period of time, 
which is particularly relevant in light of the late onset and progressive nature of 
DFNA9, and the characteristic histopathological findings in the inner ear of DFNA9 
patients. In addition, the mutant protein, once secreted into the extracellular 
environment, may manifest pathology through its impaired function or altered 
interaction with other extracellular components of the cochlear and vestibular 
labyrinths, where cochlin is expressed abundantly. 
Another interesting histopathological observation in DFNA9 temporal bone 
sections is the degeneration of neuroepithelial and neural tissue. Cochlin is not 
expressed in these neuroectodermal structures, so it is likely that these changes 
are secondary to those in mesodermal tissues. Cochlin is expressed in areas 
surrounding neuronal processes in the cochlea and vestibulum, so it has been 
proposed that strangulation of these structures by cochlin deposits results in 
secondary degeneration, which, in turn, leads to hearing impairment. In spite of 
the observed degeneration of neural tissue, cochlear implantation in DFNA9 
patients leads to good speech perception and quality of life.17 
Additionally, disruption of inner ear ionic balance possibly plays a role in DFNA9, 
because a lack of fibrocytes as well as the presence of cochlin deposits were 
observed in areas critical for K+ recycling.7 
Several studies have implicated cochlin as a target antigen for autoimmune 
sensorineural hearing loss via both T-cell and antibody-mediated mechanisms. In 
a number of patients with autoimmune hearing loss elevated serum levels of anti-
cochlin immunoglobulins have been detected.18,19 In addition, significantly higher 
levels of cochlin-specific circulating T-cells as well as elevated cochlin-specific 
serum antibody titers were detected in individuals with autoimmune sensorineural 
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hearing loss compared to unaffected age-matched controls.20 Based on these 
data, autoimmunity may play a role in the development the cochleovestibular 
impairment disorder DFNA9. It would be interesting to assess levels of cochlin-
specific circulating T-cells and cochlin-specific serum antibody in DFNA9 patients 
to test this hypothesis.  
Interestingly, recent studies have revealed cochlin as the most abundant protein in 
the trabecular meshwork of glaucomatous human eyes, but absent in normal age-
matched control donor eyes.21 It is hypothesized that the altered architecture of 
trabecular meshwork tissue by cochlin may cause obstruction of the aqueous flow 
in the eye.21,22 This is particularly interesting in the light of the presence of a 
peculiar pattern of vertical corneal striae in several DFNA9 patients harbouring the 
P51S and the G88E COCH mutation, but not in those carrying the G87W and 
I109T COCH mutation.2,23 
Future studies will further outline the role of cochlin in hearing and provide 
additional insights into the mechanisms by which mutations in cochlin result in 
hearing impairment. 
 
DFNA15 
Chapter 3 reports on the clinical characteristics of a large Dutch DFNA15 family 
with a novel mutation in the POU4F3 gene. Results of the analyses of audiometric 
data were compared to those obtained in the original DFNA15 family.24,25 
In the Dutch DFNA15 family a flat to down-sloping audiometric configuration was 
observed. Significant progression of threshold levels was detected with 
progression rates ranging from 0.7 to 1.4 decibels/year across the frequencies. 
Speech recognition scores remained fairly good in relation to age and hearing 
level compared to a group of presbyacusis patients.  
The autosomal dominant hearing impairment disorders DFNA2 26, DFNA5 27 and 
DFNA11 28,29 also show relatively good speech recognition scores. The underlying 
defect in these disorders is mainly localized in outer hair cells.28,30-35 It has been 
postulated that relative sparing of inner hair cell function accounts for the 
preservation of speech recognition. Speech recognition scores for DFNA2, 
DFNA5 and DFNA11 are comparable to those obtained for the Dutch as well as 
for the Israeli DFNA15 families.25-28 
Furthermore, inter-individual variability in terms of subjective onset age was 
observed in the Dutch as well as in the Israeli DFNA15 family. For some other 
autosomal dominant hearing impairment disorders with a comparable audioprofile, 
like DFNA10 36, DFNA11 28, DFNA21 37 and DFNA31 38,39 it has been shown that 
in some of these cases a discrepancy between the subjective onset age and the 
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onset age estimated by backward extrapolation of hearing thresholds exists. This 
suggests that this slowly progressive flat type of hearing impairment may go 
unnoticed for a long period of time, providing a possible explanation for the inter-
individual variability in terms of subjective onset age that was reported by the 
family members of the Dutch DFNA15 family. 
 
In mice Pou4f3 (also known as Brn 3.1 or Brn-3c) is expressed in both inner and 
outer hair cells of the cochlea and hair cells in the vestibular labyrinth.40,41 
Targeted deletion of the gene results in deafness and vestibular dysfunction.40,41 
No vestibular symptoms were reported to occur in the Israeli DFNA15 family 
H.24,25 In the present Dutch DFNA15 family two mutation carriers reported 
vestibular symptoms and underwent vestibular function tests. These tests showed 
a hypofunction of the vestibular labyrinth in both of them. An additional subset of 
mutation carriers of the present DFNA15 family takes part in vestibular function 
tests to assess whether DFNA15 represents a cochleovestibular disorder such as 
DFNA9 3,4,42 and DFNA11 28 and as demonstrated in mice with a targeted deletion 
of Pou4f3.40,41  
 
The function of POU4F3 in hearing and the mechanisms by which mutations in 
POU4F3 cause hearing impairment is not entirely understood. POU4F3 is a 
transcription factor that is localized to the nucleus of hair cells in the cochlea and 
vestibular labyrinth.43 In the mouse, hair cells initially differentiate in the absence 
of Pou4f3, but begin to undergo apoptosis at embryonic day 17, leading to a 
complete depletion of hair cells from all inner ear sensory epithelia by early 
postnatal stages.44,45 These data indicate that genes regulated by Pou4f3 are 
necessary for hair cell survival and differentiation but not for determination of cell 
fate. Therefore, it has been suggested that haploinsufficiency of POU4F3 
downregulates genes responsible for hair cell survival, causing a progressive loss 
of hair cells eventually resulting in hearing impairment. However, hearing in 
heterozygote Pou4f3 knockout mice up to 24 months of age is indistinguishable 
from that of wild-type animals, which does not support the assumption that 
haploinsufficiency of POU4F3 is the most probable explanation for the deafness 
phenotype.46 
 
In the nucleus POU4F3 binds to DNA, where it forms a specific DNA-protein 
complex. Mutant POU4F3 hardly shows any binding to the POU4F consensus 
DNA-binding site, in part because a significant amount of the transcription factor 
localizes to the cytoplasm, resulting in a greatly reduced amount of protein in the 
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nucleus.47 Importantly, transcriptional activity of mutant POU4F3 is greatly 
reduced compared to that of the wild-type protein.47,48 
Mutant POU4F3 does not appear to form complexes with normal POU4F3 or 
POU4F2. In addition, it does not interfere with binding of the normal proteins to 
the consensus site, nor does it influence transcriptional activity of wild type 
POU4F3.47 These data suggest that DFNA15 is not caused by a dominant-
negative mutation in POU4F3. Because haploinsufficiency is probably not the 
explanation for the observed phenotype either, the mechanism by which mutant 
POU4F3 leads to hearing impairment remains unclear. However, these 
conclusions are based on results obtained in animal studies and in studies 
performed in vitro, so extrapolation to the situation in humans should be treated 
with caution. It therefore cannot be entirely excluded that mutations in POU4F3 
lead to the DFNA15 phenotype through either haploinsufficiency or a dominant-
negative mechanism. 
 
An important step towards the elucidation of the function of POU4F3 in hearing, is 
the identification of downstream targets of the transcription factor. Hertzano et al. 
identified the transcription factor Gfi1 (growth factor independence 1) as  an 
important downstream target gene of Pou4f3.49 Gfi1 is downregulated in Pou4f3 
mutant mice. Gfi1 mutant mice show a pattern of outer hair cell morphology and 
degeneration that is essentially similar to that observed in Pou4f3 mutant mice, 
suggesting that the phenotype of the outer hair cells in the Pou4f3 mutants largely 
results from the loss of expression of Gfi1.49 In contrast, the inner hair cell 
phenotypes of these two mutants were different; Gfi1 mutants showed relative 
sparing of inner hair cells. This would confirm the theory that speech recognition 
scores in DFNA15 patients remain relatively good due to sparing of inner hair cells 
(chapter 3). However, Pou4f3 mutant mice show degeneration of both inner and 
outer hair cells, so this remains an issue that is to be further investigated in future 
studies. 
Mice lacking Pou4f3 show loss of sensory neurons and hair cell innervation, 
thought to be secondary to loss of hair cells. However, it has been demonstrated 
that Pou4f3 plays a more direct role in the development and maintenance of inner 
ear innervation by playing a role in the regulation of the neurotrophins brain 
derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3).48 BDNF and NT-3 
are required for normal innervation of hair cells of the inner ear.50,51 Mutant Pou4f3 
may thus directly result in the loss of sensory neurons and hair cell innervation. 
Recently, the LIM domain transcription factor Lhx3 was identified as an in vivo 
target gene of Pou4f3.52 Lhx3 is a hair cell-specific protein that in the cochlear hair 
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cells is regulated either directly or indirectly by Pou4f3.52 Lhx3 mRNA levels are 
decreased in the ears of Pou4f3 mutant mice. Although Lhx3 is expressed in both 
cochlear and vestibular hair cells, it is only regulated by Pou4f3 in cochlear hair 
cells.52 Further research into this interesting aspect could provide insight into 
vestibular involvement observed in some of the Dutch DFNA15 patients. 
 
Otosclerosis 
The audiometric characteristics and radiological findings of two Dutch otosclerosis 
families are described in chapter 4. 
In chapter 4.1 the phenotype of a Dutch otosclerosis family linked to OTSC5 is 
presented. Results of linkage analysis in this family have been previously 
described by Van Den Bogaert and colleagues.53 Cross-sectional as well as 
longitudinal analyses were performed on pre-surgery audiometric data pertaining 
to affected family members. These analyses showed a large degree of phenotypic 
variability and no age-dependent progression of threshold levels were detected. 
From all family members that carried the disease haplotype, high-resolution CT 
images of temporal bones were obtained to study the prevalence and extent of 
otospongiotic foci. Otospongiotic foci were classified according to size and 
location following a classification scheme proposed by Naumann et al. (chapter 
4.1, table 2).54 The detection rate of otospongiotic foci in the present study group 
is similar or lower compared to that in previous reports on CT data in consecutive 
otosclerosis patients who had stapes replacing surgery. 
 
Chapter 4.2 reports on a Dutch otosclerosis family with suggestive linkage to 
OTSC7. Thys et al. reported linkage to OTSC7 on chromosome 6q13.1-16.1 in a 
Greek otosclerosis family.55,56 In a Dutch otosclerosis family suggestive linkage 
(LOD-score 1.96) to the same chromosomal region was found, so we extended 
the family study and investigated the phenotype of this family following the 
methods as described above for OTSC5. This extension did not result in a higher 
LOD-score. Therefore, it cannot be entirely excluded that in the future a different 
causative gene will be identified for the Dutch otosclerosis family with suggestive 
linkage to OTSC7 than for the Greek otosclerosis family linked to OTSC7. 
Hearing impairment in the Dutch otosclerosis family with suggestive linkage to 
OTSC7 was variable in terms of onset age and level of progression. Long-term 
audiometric data of one patient proved to be valuable in understanding 
progression of hearing impairment in this individual. High-resolution CT imaging 
detected an otospongiotic focus in 6 out of 6  (100%) clinically affected individuals. 
We did not detect otospongiotic foci in clinically unaffected family members who 
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carried the disease haplotype. No clear correlation was found between 
radiological findings and audiometric data. 
 
Otosclerosis is a primary disorder of bone metabolism that only occurs in the 
human temporal bone. The otic capsule, which contains and protects the delicate 
structures of the inner ear, normally displays a very low level of bone remodelling 
compared to other bones in the body.57 To appreciate the significance of this fact 
in relation to otosclerosis an understanding of bone remodelling is necessary. 
The past decades saw rapid advances in understanding the mechanisms of bone 
biology. Bone is a dynamic tissue controlled by various biochemical, hormonal, 
and biomechanical stimuli. 
The process of bone turnover is characterised by activation of osteoclasts, 
subsequent resorption of bone by these cells followed by a reversal phase in 
which the osteoclasts undergo apoptosis. This is closely followed by the formation 
of new bone by osteoblasts. In order to maintain skeletal integrity, the process of 
bone resorption and formation must be tightly coupled and as such, the initiating 
step, osteoclastogenesis, is controlled by (pre)osteoblasts.  
Recently, the system that primarily regulates bone remodelling has been resolved. 
The balance between osteoprotegerin (OPG), receptor activator of nuclear factor 
kappa B (RANK) and RANK ligand (RANKL) has been shown to be crucial in 
determining the kinetics of bone turnover at the local level.58 
RANKL is expressed by osteoblasts and promotes the activation, and survival of 
osteoclasts by activation of its specific receptor RANK, which is located on 
osteoclasts.59,60 
In bone, OPG is a soluble factor that competes with RANKL for the RANK 
receptor on osteoblasts, thereby acting as a neutralizing agent.61 OPG inhibits the 
differentiation, survival, and fusion of osteoclastic precursor cells, suppresses the 
activation of osteoclasts, and promotes their apoptosis.62 Thus, OPG is a powerful 
inhibitor of bone remodeling. 
Although the process of bone remodeling and turnover is influenced by multiple 
factors, including mechanical stimuli, hormones, and several cytokines, the effects 
of such factors are predominantly mediated by the RANK, RANKL, and OPG 
system.63 
As stated before, the otic capsule displays a very low level of bone remodelling. 
The overall rate of bone turnover in the otic capsule of dogs is 2.1% per year 
compared with 7.4% in the humerus.57 Other species showed a similar pattern.57 
Interestingly, within the otic capsule, bone turnover varies from practically full 
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inhibition (0.13%/y) in the innermost perilymphatic zone to a gradually increasing, 
yet still reduced, level at the periphery. 
Recently, it has been shown that OPG is expressed at extremely high levels within 
the soft tissue of the cochlea and that perilymph contains a high concentration of 
this bone turnover inhibitor.64 It may diffuse into the otic capsule by means of an 
extensive system of interconnected canaliculi that directly connects the inner ear 
to the surrounding bone.64 The high ratio of OPG to RANKL in the inner ear may 
be responsible for the nearly complete absence of bone turnover within the 
surrounding otic capsule. Further away from the perilymph this ratio may be 
decreased, explaining the gradient of bone remodelling activity observed in the 
otic capsule.64 
Otosclerotic foci most frequently occur around the oval and round windows and in 
the cochlear capsule, i.e. locations where inhibition of bone remodelling normally 
is most prominent. So, a crucial step in the pathogenesis of otosclerosis may be a 
change in the OPG/RANKL ratio. This hypothesis is corroborated by findings in 
OPG knockout mice. These mice demonstrated abnormal remodelling of bone 
within the otic capsule with multiple foci showing osteoclastic bone resorption and 
formation of new bone.65 These foci showed many similarities to those observed 
in human otosclerosis specimens.65 In addition, progressive hearing impairment 
was observed in these mice lacking OPG, but stapes ankylosis did not occur in 
this animal model.65 
 
The hypothesis that OPG and RANKL can be the mediators of the stimulatory or 
inhibitory effects on bone remodelling of a variety of systemic hormones, growth 
factors, cytokines and factors yet to be identified, may help to explain the 
characteristics of otosclerosis. For example, it may explain why otosclerosis 
generally displays a predictable audiometric phenotype in spite of the fact that 
different etiologic factors lead to the disease. 
To date, eight different loci for otosclerosis have been identified.66 The phenotype 
is largely comparable across the different loci. None of the genes have yet been 
cloned. It may well be that the responsible genes influence the OPG/RANKL ratio 
through different pathways, but result in a common clinical phenotype. 
Furthermore, measles virus infection has been implicated in the development of 
otosclerosis. Measles virus RNA has been detected in stapedial footplates of 
otosclerosis patients.67 In addition, measles virus positive otosclerotic footplates 
showed increased levels of TNF-alpha in combination with reduced levels of 
OPG.68 
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The fact that otosclerosis appears to be more frequent in women than in man 
implicates a role for estrogens in the development of otosclerosis. It has been 
shown that estrogens influence osteoclast and osteoblast formation and 
differentiation through an effect on the OPG/RANKL/RANK system.69,70 
 
Further understanding of the OPG/RANKL/RANK system may provide new 
insights into the pathogenesis of otosclerosis. The search for genes that influence 
bone metabolism in the otic capsule may be guided by up- and downstream 
targets of the OPG/RANKL/RANK pathway. Identification of these genes will 
provide further insight into the pathogenesis of otosclerosis. 
 
 
General considerations 
This thesis comprises phenotype descriptions of autosomal dominant non-
syndromic hearing impairment disorders. Two types of sensorineural hearing 
impairment (DFNA9 and DFNA15) and the hearing impairment disorder 
otosclerosis are outlined and discussed. 
Advances in genomics have given way to a tremendous progress in the discovery 
of the molecular mechanisms of auditory function. Since the first report of a locus 
involved in non-syndromic genetic hearing impairment by Leon et al. in 1992 
(DFNA1) 71, the number of deafness loci has grown exponentially. At present, 54 
autosomal dominant loci (DFNA1-54), 67 autosomal recessive loci (DFNB1-67), 7 
X-linked loci (DFN1-6 and DFN8), 1 Y-linked locus (DFNY1) and 1 auditory 
neuropathy locus (AUNA1) have been identified.66 Additionally, 8 loci involved in 
the development of otosclerosis have been found (OTSC1-8).66 
From these deafness loci many causative genes have been identified. Based on 
their function in the inner ear, the proteins encoded by these genes can be divided 
into different classes including cytoskeletal components, extracellular matrix 
components (cochlin), molecules involved in maintaining ion homeostasis, 
transcription factors (POU3F4), molecules belonging to the cadherin superfamily 
and proteins of which the function is not known yet. Through the identification of 
genes involved in hearing impairment we have been able to gain knowledge of the 
molecular mechanisms involved in hearing and of those involved in the 
development of hearing impairment. 
The vast amount of deafness loci and genes reflects the genetic heterogeneity of 
hearing impairment. Although a lot has been accomplished, there are still 
numerous unidentified hearing impairment genes and the exact physiological 
function of many deafness genes has yet to be determined. For example, the first 
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otosclerosis gene has yet to be uncovered. In addition, growing evidence exists 
that modifier genes, i.e. genes that affect the phenotypic expression of other 
genes, also play an important role in hearing impairment. 
Given the genetic heterogeneity, detailed phenotype studies are of utmost 
importance to be able to detect variation in clinical presentation between different 
loci or even between different mutations within the same gene. The establishment 
of genotype-phenotype correlations may facilitate the differential diagnosis of 
genetic hearing impairment traits. Furthermore, knowledge of the natural course of 
a specific genetic hearing impairment disorder enables proper genetic counseling.  
In the future, novel treatment strategies like hair cell regeneration or gene therapy 
may be implemented in clinical practice. For accurate evaluation of their effects on 
restoration of hearing or prevention of hearing impairment, knowledge of the 
specific phenotype of a given genetic hearing impairment trait is crucial. 
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SUMMARY 
Following the general introduction in chapter 1.1, a review on audiometric profiles 
associated with genetic non-syndromic hearing impairment is presented in chapter 
1.2. This review provides a detailed overview of genetic non-syndromic hearing 
impairment disorders that, at the time of writing, had already been linked to human 
chromosomal loci. Based on their characteristic audioprofile, hearing impairment 
loci were classified into different types of audiometric configuration. Audioprofiles 
can be used for the differential diagnosis of non-syndromic hearing impairment 
disorders, for counseling purposes, especially for focusing on treatment options, 
and for guiding genotyping efforts involving newly identified non-syndromic 
hearing impairment traits. 
 
The autosomal dominant cochleovestibular disorder DFNA9 is the subject of 
chapter 2. Chapter 2.1 describes the clinical characteristics of a Dutch DFNA9 
family with a novel COCH mutation, G87W (28 mutation carriers). Hearing 
impairment started in the high frequencies with subjective onset age between the 
4th and 5th decades. Hearing levels at the high frequencies (4 and 8 kHz) may 
have started to deteriorate well before this age. Vestibular function was tested in 
12 G87W mutation carriers and showed a hypofunction of the vestibular labyrinth 
10 of them. The proportion of patients over 40 years of age who had developed 
complete vestibular areflexia was significantly lower for the G87W mutation 
carriers than for the P51S mutation carriers. 
Chapter 2.2 reports on a Dutch family with a novel COCH mutation, I109T (11 
mutation carriers). Pure-tone thresholds, phoneme recognition scores, and 
vestibular responses of the I109T mutation carriers were essentially similar to 
those previously established in the P51S, G87W and G88E mutation carriers. 
Deterioration of hearing in the I109T mutation carriers started between the 4th and 
5th decades. Five of 11 I109T mutation carriers reported vestibular symptoms. 
Seven I109T mutation carriers, aged 45 years or older, underwent vestibular 
function tests. These tests showed vestibular dysfunction in 4 of them (57%). 
Chapter 2.3 reports on the audiometric data from an Australian DFNA9 family with 
the I109N COCH mutation. Serial audiograms from 8 mutation carriers were 
retrieved and subjected to cross-sectional and longitudinal analyses. A 
progressive high-frequency sensorineural type of hearing impairment was 
observed with onset before 40 years age and probably before 30 years of age in 
the high frequencies. ARTA from 7 different DFNA9 families with 6 different 
COCH mutations (P51S, V66G, G88E (1 Dutch and 1 American family), I109T, 
I109N and C542F) were compared. The auditory phenotype is generally 
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comparable across the different COCH mutations. An adult onset high frequency 
hearing impairment applies and, as hearing deteriorates over time, the low and 
mid frequencies become involved as well. However, differences in terms of onset 
age, level of progression and degree of hearing impairment seem to exist between 
the different COCH mutations. 
 
Chapter 3 reports on the clinical characteristics of a large Dutch DFNA15 family 
with a novel mutation in the POU4F3 gene. A flat to down-sloping audiometric 
configuration was observed. Significant progression of threshold levels was 
detected with progression rates ranging from 0.7 to 1.4 decibels/year across the 
frequencies. Speech recognition scores remained fairly good in relation to age 
and hearing level compared to a group of presbyacusis patients. Furthermore, 
inter-individual variability in terms of subjective onset age was observed. Two 
mutation carriers reported vestibular symptoms and underwent vestibular function 
tests. These tests showed a hypofunction of the vestibular labyrinth in both of 
them. 
 
The audiometric characteristics and radiological findings of two Dutch otosclerosis 
families are described in chapter 4. 
In chapter 4.1 the phenotype of a Dutch otosclerosis family linked to OTSC5 is 
presented. Cross-sectional as well as longitudinal analyses on pre-surgery 
audiometric data pertaining to affected family members showed a large degree of 
phenotypic variability and no age-dependent progression of threshold levels. High-
resolution CT images of temporal bones were obtained to study the prevalence 
and extent of otospongiotic foci. The detection rate of otospongiotic foci in the 
present study group is similar or lower compared to that in previous reports on CT 
data in consecutive otosclerosis patients who had stapes replacing surgery. 
Chapter 4.2 reports on a Dutch otosclerosis family with suggestive linkage to 
OTSC7. (LOD-score 1.96). Hearing impairment in this otosclerosis family was 
variable in terms of onset age and level of progression. Long-term audiometric 
data of one patient proved to be valuable in understanding progression of hearing 
impairment in this individual. High-resolution CT imaging detected an oto-
spongiotic focus in 6 out of 6 (100%) clinically affected individuals. We did not 
detect otospongiotic foci in clinically unaffected family members who carried the 
disease haplotype. No clear correlation was found between radiological findings 
and audiometric data. 
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SAMENVATTING 
Na een algemene introductie in hoofdstuk 1.1, wordt in hoofdstuk 1.2 een 
gedetailleerd overzicht gegeven van de bekende genetische niet-syndromale 
vormen van slechthorendheid, die reeds gekoppeld zijn aan een humaan 
chromosomaal locus. Deze verschillende loci hebben een karakteristiek audio-
profiel, op basis waarvan ze geclassificeerd kunnen worden in verschillende typen 
audiometrische configuraties. Deze audioprofielen kunnen worden gebruikt voor 
differentiaal diagnoses van niet-syndromale slechthorendheid, voor counseling 
doeleinden, met name gericht op behandelingsmogelijkheden en voor het geven 
van richting aan de genotypering van nieuwe vormen van niet-syndromale 
slechthorendheid. 
 
In hoofdstuk 2 wordt de autosomaal dominante cochleovestibulaire afwijking 
DFNA9 besproken. Hoofdstuk 2.1 gaat in op de klinische kenmerken van een 
Nederlandse DFNA9 familie met een nieuwe COCH mutatie, G87W (28 mutatie-
dragers). Verslechtering van het gehoor in deze familie begint in de hoge 
frequenties met een subjectieve beginleeftijd tussen het 40e en 50e levensjaar. 
Gehoordrempels in de hoge frequenties (4 en 8 kHz) zijn mogelijk al aangedaan 
voor deze subjectieve leeftijdsgrens. Vestibulaire functie werd getest in 12 G87W 
mutatie dragers. Bij 10 van deze 12 mutatiedragers werd een hypofunctie van het 
evenwichtsorgaan gevonden. Het percentage DFNA9 patiënten boven de 40 jaar, 
dat een complete vestibulaire areflexie ontwikkelt, is significant lager bij G87W 
mutatiedragers dan bij P51S mutatiedragers.  
In hoofdstuk 2.2 wordt een Nederlandse familie met een nieuwe COCH mutatie, 
I109T (11 mutatiedragers) besproken. De gehoordrempels, het spraakverstaan en 
de vestibulaire functie bij de I109T mutatiedragers, blijken grotendeels gelijk te 
zijn aan de waarden die hiervoor gevonden werden bij de P51S, G87W en G88E 
mutatiedragers. Gehoorverslechtering bij de dragers van de I109T mutatiedragers 
begon tussen het 40e en 50e levensjaar. Vijf I109T mutatiedragers hadden 
evenwichtsklachten. Zeven I109T mutatiedragers ondergingen evenwichts-
onderzoek. Bij vier van hen werd een vestibulaire hypofunctie aangetoond (57%). 
Hoofdstuk 2.3 beschrijft de audiometrische data van een Australische DFNA9 
familie met de bekende  I109N mutatie in het COCH gen (8 mutatiedragers). Uit 
cross-sectionele en longitudinale analyses van audiometrische data kwam het 
beeld naar voren van een progressief, hoge tonen cochleair gehoorverlies, 
beginnend vóór het 40e  levensjaar. ARTA van 7 verschillende DFNA9 families 
met 6 verschillende COCH mutaties (P51S, V66G, G88E (1 Nederlandse en 1 
Amerikaanse familie) I109T, I109N en C542F) werden vergeleken. Het 
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audiometrische fenotype lijkt in het algemeen vergelijkbaar te zijn tussen de 
verschillende COCH mutaties; het gehoorverlies begint op volwassen leeftijd in de 
hoge frequenties. In de loop van de tijd verergert het gehoorverlies waarbij dan 
ook het gehoor in de lage en midden frequenties verslechtert. Tussen de 
verschillende COCH mutaties lijken echter wel verschillen te bestaan in de 
beginleeftijd, de mate van progressie en de mate van gehoorverlies.  
 
Hoofdstuk 3 beschrijft de klinische kenmerken van een grote Nederlandse 
DFNA15 familie met een nieuwe mutatie in het POU4F3 gen. Het gehoorverlies in 
deze familie is progressief voor alle frequenties en wordt gekarakteriseerd door 
een vlakke tot aflopende audiometrische configuratie. Vergeleken met een groep 
presbyacusis patiënten bleek de spraakherkenning relatief goed in relatie tot de 
leeftijd en de mate van gehoorverlies. Overigens was er sprake van 
interindividuele variabiliteit in de subjectieve beleving van de beginleeftijd van het 
gehoorverlies. Twee mutatiedragers hadden klachten passend bij vestibulaire 
disfunctie. Middels evenwichtsonderzoek werd bij beiden hypofunctie van het 
vestibulaire labyrint vastgesteld.  
 
Klinische beschrijvingen van twee Nederlandse families met otosclerose worden 
gegeven in hoofdstuk 4. In hoofdstuk 4.1 wordt het fenotype gepresenteerd van 
een otosclerose familie gekoppeld aan het OTSC5 locus. Zowel cross-sectionele 
als longitudinale analyse van pre-operatieve audiometrische data vertonen grote 
variabiliteit waardoor significante leeftijdsafhankelijke progressie van gehoor-
drempels niet aangetoond kon worden. Om de prevalentie en uitgebreidheid van 
otospongiose haarden te beoordelen, werden hoge resolutie CT scans van het os 
temporale vervaardigd. Het detectiepercentage van otospongiotische haarden in 
deze studie populatie was gelijk of kleiner vergeleken met resultaten van series 
patiënten die een stapedotomie ondergingen. 
Hoofdstuk 4.2 beschrijft een Nederlandse otosclerose familie, waarschijnlijk 
gekoppeld aan het OTSC7 locus (LOD-score 1.96). Bij deze familie werd een 
variabele begin leeftijd en mate van progressie van het gehoorverlies gezien. Van 
één patiënt waren veel longitudinale data beschikbaar, hetgeen de mogelijkheid 
bood om het verloop van het gehoorverlies over de tijd in deze patiënt nader te 
analyseren. Hoge resolutie CT scans toonden minstens één otospongiotische 
haard in alle klinisch aangedane patiënten. Er werden geen otospongiotische 
haarden gezien bij de klinisch niet-aangedane familieleden, die wel drager waren 
van het haplotype. Er werd geen duidelijke correlatie gevonden tussen de 
radiologische afwijkingen en de audiometrische data. 
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DANKWOORD 
En dan het dankwoord… het meest gelezen hoofdstuk van dit proefschrift en in 
die zin dus het hoofdstuk met de hoogste impact factor. Terugdenkend aan de 
onderzoeksperiode, besef ik dat dit proefschrift nooit tot stand zou zijn gekomen 
zonder de hulp en de steun van velen die al dan niet zijdelings bij het onderzoek 
betrokken zijn geweest. 
 
De familieleden van de verschillende families die de basis van de belangrijkste 
hoofdstukken van dit proefschrift vormen, wil ik hartelijk danken voor hun 
vrijwillige en vaak enthousiaste deelname aan de verschillende onderzoeken. 
Zonder uw deelname had dit boekje nooit in deze vorm het levenslicht gezien. 
 
Prof. dr. C.W.R.J. Cremers. Hooggeleerde heer, het gesprek dat wij in november 
2004 bij u thuis hadden, bevestigde mijn enthousiasme voor de KNO  en is 
achteraf gezien het begin geweest van onze samenwerking. Ik bewonder de wijze 
waarop u uw onderzoekslijn heeft georganiseerd en het ongekend hoge aantal 
promovendi dat u dit jaar naar de doctor titel leidt is het bewijs van het succes van 
uw aanpak. Van uw promovendi verwacht u een doel- en resultaatgerichte 
efficiënte werkwijze, waarbij doorlooptijd the keyword is. Zelf zult u zich te allen 
tijde maximaal inzetten om de doorlooptijd van het project te waarborgen. Overleg 
tijdens een volle poli? Geen probleem, loop maar binnen. Overdag geen tijd? Kom 
’s avonds maar langs, in het weekend mag trouwens ook. Vakantie? We hebben 
toch fax en e-mail! Voor de gemiddelde promovendus luidt het inleveren van een 
stuk bij zijn promotor een relaxte periode in waarin even achterover geleund kan 
worden. Zo niet voor de Cremeriaan: het stuk wordt binnen 24 uur van hand tot 
hand, gecorrigeerd en wel terugbezorgd. Ik begrijp nog steeds niet waar u de tijd 
vandaan haalt. 
 
Dr. P.L.M. Huygen. Beste Patrick, de term homo universalis komt bij mij op 
wanneer ik aan jou denk. Intelligent, creatief, artistiek en muzikaal. De man die 
sneller denkt dan zijn schaduw. Jouw oog voor detail aangaande de precieze 
weergave van referenties heeft mij tijdens het schrijven van het overzichtsartikel in 
hoofdstuk 1.2 van dit proefschrift bijna tot wanhoop gedreven. Het mooie is dat ik 
tijdens het voltooien van dit proefschrift heb gemerkt dat ik dit volledig van je heb 
overgenomen! 
 
Dr. H. Kremer. Beste Hannie, via jou heb ik de wondere wereld van de genetica 
leren kennen en waarderen. Je bent kritisch en recht door zee. Je kritiek op de 
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eerste versie van hoofdstuk 5 was natuurlijk terecht. Ik waardeer het (achteraf) dat 
je je niet hebt laten overhalen van je standpunt af te wijken. Het stuk is er 
minimaal 100% beter op geworden. Bedankt. 
 
Dr. R.W.J. Collin. Beste Rob, in zekere zin waren wij afhankelijk van elkaars data. 
Zonder klinische gegevens en bloedmonsters geen genetische data en zonder 
genetische data geen klinische beschrijving. Ik heb onze samenwerking altijd als 
zeer goed en gezellig ervaren. 
 
Prof. dr. G. Van Camp. Beste Guy, bij 9 van de 10 artikelen die geciteerd worden 
in tabel 4 van het introductie hoofdstuk, ben jij betrokken geweest. Dit geeft aan 
wat voor belangrijke rol je speelt in het onderzoek naar erfelijke otosclerose. 
Bedankt voor de samenwerking die heeft geleid tot hoofdstuk 4.1 en 4.2 van dit 
proefschrift. 
 
Prof. dr. J.R.M. Cruysberg. Hooggeleerde heer, de samenwerking tussen KNO en 
Oogheelkunde is op het gebied van DFNA9 zeer vruchtbaar gebleken. Ik 
waardeer het zeer dat u zitting heeft willen nemen in de manuscriptcommissie. 
 
Drs. F.J.W. van Drunen. Beste Wendy, hartelijk dank voor je hulp bij het tot stand 
komen van hoofdstuk 3. 
 
Leden van de manuscriptcommissie, prof. dr. H.G. Brunner, prof. dr. J.R.M. 
Cruysberg en prof. dr. F.E. Offeciers, hartelijk dank dat u het manuscript heeft 
willen beoordelen.  
 
Prof. dr. K. Graamans, overige stafleden van de afdeling KNO van het UMC St 
Radboud. Hooggeleerde en weledelzeergeleerde heren, hartelijk dank voor het in 
mij gestelde vertrouwen. 
 
Dames van het audiologisch centrum. Pieta, Donneke, Mieki, Henriette, Teja, 
Mariska en Esther, hartelijk dank voor jullie bereidheid om op zaterdagen en soms 
tussendoor op de poli metingen te verrichten. Het behoeft weinig uitleg dat deze 
data vrij essentieel geweest zijn voor dit proefschrift. 
 
Drs. S. van de Velde-Visser. Beste Saskia, bedankt voor de strakke en uiterst 
professionele organisatie met betrekking tot de logistiek van de bloedmonsters. 
 
Dankwoord 
208 
Diny Helsper. Hartelijk dank voor je essentiële hulp bij de lay-out en voor de 
gastvrije ontvangst bij jullie thuis.   
 
Maarten ter Stege. Maître, je kaftontwerp is briljant! Het is nog mooier geworden 
dan ik gehoopt had. Als we volgend jaar met de leeden van fietsclub St. Remy de 
Provence (waar zijn de shirts eigenlijk!?) op het buitenblad de Mont Ventoux op 
stoempen, zal ik je als dank voor laten gaan… 
 
(Oud-)assistenten KNO. Karien, Martijn, Savitri, Erik, Niels, Brechtje, Ronald, 
Anne, Myrthe, Liselotte, Stijn, Rutger, Olivier, Bart, Godelieve, Sylvia, Ferdinand, 
Ilse, Jan-Willem, Anne-Martine, Veronique en Louise, bedankt voor de overvloed 
aan gezelligheid, borrels, feestjes en diners die er vanaf het eerste moment voor 
gezorgd hebben dat ik het enorm naar mijn zin heb in het soms zo pluizige 
Nijmegen! 
 
Jaarclub Fortes. Heeren, ook al hebben jullie inhoudelijk misschien niet zo heel 
veel bijgedragen aan dit proefschrift, in dit dankwoord mogen jullie zeker niet 
ontbreken. Al was het maar vanwege het feit dat het aantal bakkies dat we samen 
gedronken hebben sinds ‘96 het aantal woorden in dit proefschrift ruimschoots 
overstijgt! Dank voor jullie vriendschap! 
 
Paranimfen Victor Baas en Bart Kuus. Vic en Kuus, de hechte vriendschap die ik 
met jullie heb, is moeilijk onder woorden te brengen. Dat jullie mijn paranimfen 
zouden worden, stond al vast voordat ik überhaupt wist wat wetenschappelijk 
onderzoek in hield. Supermooi dat jullie op 2 oktober naast me staan.  
 
Ruud en Aleid Kammeraad, hartelijk dank voor jullie warmte en gezelligheid die er 
vanaf het begin voor hebben gezorgd dat ik dat ik me, ondanks het omgeslagen 
bootje, altijd welkom heb gevoeld in Reeuwijk. 
Emilie en Quirijn, Ruud en Stefanie, bedankt voor de gezelligheid en de mooie 
borrels met vuisten chips en ongelimiteerde hoeveelheden Hongaarse salami. 
 
Monique en Maarten, lieve zus en broer, ik ben trots op onze hechte familieband! 
De Pauwtjes vormen een drie-eenheid waar met geen speld tussen te komen is.  
Lieve Monk, de manier waarop jij een drukke baan met een mogelijk nog drukker 
sociaal leven weet te combineren, zou voor mij fysiek niet haalbaar zijn. Op beide 
gebieden zal je nooit concessies doen en ik vind het knap dat het dan ook nog 
lukt om op beide gebieden zo succesvol te zijn!  
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Lieve Map, als jij ergens voor gaat, is dat voor de volle 100% en zal je altijd 
bereiken wat je voor ogen hebt. Met sportieve prestaties ben je me op die manier 
helaas altijd net een stapje voor. Nu je de Marmotte gefietst hebt, ben ik bang dat 
ik niet kan achterblijven…  
 
Lieve papa en mama, jullie hebben me altijd gestimuleerd mijn mogelijkheden ten 
volle te benutten en jullie zorgden ook altijd dat dit mogelijk was. Zonder jullie 
onvoorwaardelijke steun was het me nooit gelukt te komen waar ik nu ben.  
Pap, de manier waarop jij alles nuchter en rationeel bekijkt en hoe je vervolgens je 
gedachten onder woorden weet te brengen is voor mij een voorbeeld. Ik ben er 
trots op ‘de zoon van..’ te zijn en ik mag hopen ooit zover te komen als jij. 
Mam, ik hou van je spraakwaterval en je heerlijk bevestigende enthousiasme! Het 
is fantastisch hoe jij een klein succesje tot een wereldprestatie kan opwaarderen. 
Lieve pap en mam, dank voor alles en ik hou van jullie. 
 
Allerliefste Jane, zonder jouw hulp, steun en luisterend oor was het afronden van 
dit proefschrift een stuk minder vlot verlopen. Dank je wel voor alle leuke, 
bijzondere, spannende en bijzonder spannende momenten die we samen beleefd 
hebben en in de toekomst nog veel meer zullen gaan beleven. Het leven is mooi, 
véél mooier, met jou! …want zonder jouw liefde…. Love u veel. 
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CURRICULUM VITAE 
Robert Jan Pauw werd op 16 juni 1978 geboren te Rotterdam. In 1996 behaalde 
hij het eindexamen aan het Erasmiaans Gymnasium te Rotterdam. In datzelfde 
jaar begon hij met de studie Geneeskunde aan de Universiteit van Utrecht. In ’t 
Sticht beleefde hij een mooie studententijd en werd het doctoraal examen 
Geneeskunde gehaald in 2001. In het kader van een wetenschappelijke stage 
deed hij onderzoek bij de afdeling Experimentele in vivo NMR van het Image 
Sciences Institute, Universiteit Utrecht, naar de pathofysiologie en behandelings-
opties van cerebrale ischemie. Alvorens te starten met zijn co-schappen, deed hij 
gedurende 8 maanden onderzoek op hetzelfde gebied in het Neuroprotection 
Research Lab, Massachusetts General Hospital, Harvard Medical School in 
Boston. Na het behalen van het artsexamen in 2004 werkte hij als ANIOS op de 
afdeling Neurochirurgie van het UMC Utrecht. In 2005 werd hij aangesteld als 
arts-onderzoeker bij de afdeling Keel-, Neus- en Oorheelkunde van het UMC St 
Radboud. Onder leiding van prof. dr. C.W.R.J. Cremers deed hij onderzoek op het 
gebied van de erfelijke slechthorendheid, hetgeen heeft geleid tot de tot het tot 
stand komen van dit proefschrift. Sinds november 2006 is hij in opleiding tot Keel-, 
Neus- en Oorarts in het UMC St Radboud (opleider prof. dr. K. Graamans). 
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